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Abstract	  	  The	   first	   end	   point	   of	   this	   study	   was	   to	   identify	   specific	   pro-­‐apoptotic	   or	   anti-­‐proliferative	  factors	  in	  the	  breast	  cancer	  cell	  secretome.	  To	  this	  end,	  we	  designed	  an	  
in	   vitro	   screen	   that	   effectively	   cross-­‐cultured	   20	   breast	   cancer	   cell	   lines	   in	   each	  other’s	   conditioned	   media.	   We	   selected	   the	   strongest	   pro-­‐apoptotic	   hits	   and	  performed	  further	  proteomic	  and	  biochemical	  characterization	   in	  order	  to	  analyze	  their	   composition.	   We	   determined	   that	   the	   pro-­‐apoptotic	   activity	   resided	   in	   the	  soluble,	   exosome-­‐free	   secreted	   fraction	   of	   triple	   negative	   breast	   cancer	   cell	  conditioned	  medium	  and	  used	  proteomic	  insights	  in	  order	  to	  narrow	  down	  the	  list	  of	   possible	   candidate	   molecules	   responsible	   for	   the	   apoptotic	   effect.	   The	   second	  endpoint	  of	  this	  study	  was	  to	  evaluate	  the	  particulate	  fraction	  found	  in	  breast	  cancer	  cell	   conditioned	  media	   for	  diagnostically	   significant	  molecules.	  We	   isolated	  cancer	  exosomes,	   employing	   a	   serial	   ultracentrifugation	   protocol,	   and	   were	   able	   to	  establish	   that	   the	   exosome	   cell	   surface	   receptors	   identically	   reflect	   the	  molecular	  identity	   of	   their	   cell	   lines	   of	   origin.	   However,	   downstream	  protein	   kinases	  within	  exosomes	   display	   patterns	   of	   depletion	   or	   enrichment	   in	   comparison	   to	   the	  corresponding	  cell	  lines.	  Overall,	  we	  found	  that	  the	  exosome	  protein	  composition	  in	  breast	   cancer	   is	   informative	   enough	   to	   guide	   the	   choice	   of	   specific	   inhibitor	  treatment	  in	  a	  clinical	  setting.	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Abstract	  In	   this	   chapter	   we	   provide	   the	   context	   within	   which	   the	   present	   study	   and	   its’	  scientific	  aims	  were	  set.	   	  We	  begin	  with	  a	  description	  of	  how	  our	  understanding	  of	  cancer	   has	   changed	   in	   the	   last	   two	   decades,	   and	   in	   particular	   the	   role	   of	   tumor	  heterogeneity.	  Once	  considered	  a	  disease	  of	  sequentially	  acquired	  genetic	  mutations	  leading	   to	   clonally	   identical	   tumor	   cells,	   we	   now	   know	   that	   cues	   from	   the	   tumor	  microenvironment	   strongly	   contribute	   to	   disease	   onset	   and	   progression.	   In	  addition,	   it	   is	   now	   recognized	   that	   a	   significant	   amount	   of	   epigenetic	   plasticity	  drives	   disease	   progression.	   It	   is	   also	   recognized	   that	   a	   significant	   amount	   of	  phenotypic	  plasticity	  allows	  cancer	  cells	  to	  adapt	  to	  different	  environments	  during	  the	  metastatic	  process.	  As	  a	   result	  of	   all	   these	  processes	  –	  mutation,	   environment	  and	  epigenetics	  –	  acting	  differentially	  on	  cells	  within	  a	  tumor,	  strong	  heterogeneity	  is	   observed	  within	   primary	   tumors	   as	  well	   as	   between	   primary	   tumors	   and	   their	  metastatic	  sites.	  	  	  After	  discussing	  recent	  advances	  in	  cancer	  understanding	  we	  turn	  our	  attention	  to	  novel	   therapeutics.	   As	   our	   understanding	   of	   the	   molecular	   pathways	   governing	  cancer	  deepens,	   the	   list	  of	   tyrosine-­‐kinase	   inhibitors	  rationally	  designed	  as	  cancer	  treatments	   expands.	  We	  discuss	   the	  most	   important	   of	   these	   inhibitors	   as	  well	   as	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their	   performance	   in	   the	   clinic.	   Due	   to	   the	   development	   of	   this	   highly	   specialized	  artillery	  against	  cancer,	  the	  need	  for	  diagnostic	  tools	  that	  will	  connect	  the	  molecular	  makeup	   of	   specific	   tumors	   to	   the	   adequate	   therapeutic	   compound	   is	   now	   more	  pressing	   than	   ever.	   We	   relate	   a	   selection	   of	   studies	   that	   use	   cancer	   cell	   line	  collections	   in	   order	   to	   extract	   ‘biomarker	   signatures’	   that	   will	   predict	   clinical	  sensitivity	  to	  inhibitors.	  ‘Biomarker’,	  in	  this	  context,	  means	  a	  measurement	  made	  of	  a	   human	   tumor,	   or	   a	  measurement	  made	   in	   cell	   culture	   that	   could	   potentially	   be	  extended	  to	  a	  human	  tumor.	  Beyond	  that,	  we	  also	  discuss	  ‘liquid	  biopsy’	  diagnostic	  technologies	   that	   are	   currently	   under	   development.	   These	   technologies	   aim	   to	  establish	  molecular	   typing	   of	   cancer	   from	   patient	   blood	   samples	   and	   obviate	   the	  risks	  and	  limitations	  inherent	  to	  tumor	  biopsies.	  We	  close	  this	  chapter	  by	  presenting	  our	   list	   of	   specific	   aims	   and	   the	   order	   in	   which	   these	   will	   be	   addressed	   in	   the	  chapters	  that	  follow.	  
	  
1.1	  Phenotypic	  plasticity	  and	  clonal	  evolution	  of	  cancer	  cells	  In	  the	  first	  part	  of	  my	  PhD	  I	  analyzed	  interactions	  between	  many	  breast	  cancer	  cell	  lines	   chosen	   for	   their	   genetic	   diversity.	   The	   goal	   of	   this	   undertaking	   was	   to	  understand	   the	   functional	   consequences	   of	   cancer	   heterogeneity	   in	   terms	   of	   how	  factors	  secreted	  by	  one	  cancer	  clone	  might	  affect	  another.	  To	  set	  up	  this	  part	  of	  my	  work	   I	  will	   introduce	   the	   concept	   of	   heterogeneity	   in	   tumors	   –	   how	   it	   arises	   and	  what	  its	  functional	  consequences	  might	  be.	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Cancer	   is	  known	  to	  arise	   in	  accordance	  with	  the	  modern	  dogma	  of	  cancer	  genesis,	  which	   stipulates	   that	   a	   tumor	   evolves	   from	   a	   single	   cell	   that	   undergoes	   gradual	  malignant	   transformation1.	   In	   their	   seminal	   review	   publication,	   Hanahan	   and	  Weinberg	  describe	  the	  six	  hallmarks	  of	  cancer,	  a	  set	  of	  genetic	  mutations	  gradually	  acquired	   by	   cancer	   cells	   and	   driving	   disease	   progression	   and	   metastasis.	   In	   the	  ensuing	   decade	   however,	   it	   became	   exceedingly	   clear	   that	   a	   tumor	   is	  much	  more	  than	  a	  collection	  of	  identical	  genetically	  mutated	  cells.	  Beyond	  genetic	  mutation,	  the	  tumor	   microenvironment	   plays	   a	   paramount	   role	   in	   cancer	   development	   and	  progression2.	   In	   the	   last	  decade	  cancer	  research	  has	  brought	   forth	  deeper	   insights	  regarding	   the	  varied	  cellular	  composition	  of	   solid	   tumors,	   the	   transient	  epigenetic	  plasticity	  of	  cancer	  cells,	  as	  well	  as	  the	  role	  of	  ambient	  mechanical	  and	  biochemical	  signals,	  all	  major	  contributors	  to	  malignant	  progression.	  
	  
Non-­soluble	  cues	  in	  the	  tumor	  microenvironment	  Cell	  fate	  within	  a	  tumor	  is	  regulated	  by	  a	  variety	  of	  signals	  the	  cell	  receives	  from	  its	  environment.	  These	  cues	  can	  be	  of	  a	  chemical	  or	  mechanical	  nature,	  but	  what	  they	  have	   in	  common	   is	   that	   they	  both	   initiate	  molecular	  programs	  within	   the	  cell	   that	  lead	  to	  proliferation,	  differentiation,	  senescence,	  apoptosis	  and	  migration3.	  In	  recent	  years	  cell	  substrate	  stiffness	  has	  been	  increasingly	  recognized	  as	  a	  regulator	  of	  cell	  fate	  and	  a	  significant	  contributor	  in	  cancer	  progression.	  	  Ulrich	  et	  al.	  confirm	  this	  by	  culturing	  glioblastoma	  cells	  on	  fibronectin	  substrates	  of	  defined	  mechanical	  rigidity	  and	  show	  that	  both	  proliferation	  and	  the	  development	  of	  a	  migratory	  phenotype	  in	  this	  highly	  malignant	  cell	  type	  is	  dependent	  on	  substrate	  stiffness4.	  In	  the	  same	  vein,	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the	   actual	   tissue	   architecture	   in	  which	   a	   cancer	   cell	   is	   embedded	   is	   of	   paramount	  importance	   in	  determining	  whether	  a	   tumor	  will	  develop.	  Weaver	  et	  al.	   show	  that	  mammary	   epithelial	   cells	   incorporated	   in	   polarized	   3D	   structures,	   biomimetic	   of	  physiological	   mammary	   gland	   architecture,	   are	   resistant	   to	   death	   cues	   such	   as	  chemotherapeutic	  agents,	   tumor	  necrosis	   factor	   (TNF)	  and	  TNF-­‐related	  apoptosis-­‐inducing	   ligand	   (TRAIL).	   The	   same	   cells,	   when	   grown	   in	   2D	   monolayers	   are	  supremely	  sensitive	  to	  cell	  death	  induced	  by	  these	  stimuli5.	  	  Another	   informative	   experiment	   regarding	   the	   interplay	   between	   environmental	  cues	  and	  genetic	  mutations	  on	  breast	  tumorigenesis	  was	  performed	  by	  Debnath	  et	  al.	  who	  developed	  a	  protocol	  for	  culturing	  MCF-­‐10A,	  a	  non-­‐transformed	  mammary	  epithelial	   cell	   line,	   in	   Matrigel	   basement	  membrane	  matrix.	   This	  method	   allowed	  them	   to	   reconstitute	   in	   vitro	   acinar	   luminal	   structures	   reminiscent	   of	   normal	  mammary	  ducts	  over	  a	  period	  of	  15	  days.	  They	  experimented	  with	  transformation	  of	  MCF-­‐10A	  cells	  by	  a	  variety	  of	  oncogenes	  and	  found	  that	  certain	  oncogenes	  (such	  as	  Erbb2)	  were	  successful	  at	  generating	  solid	  filled	  structures	  resembling	  carcinoma	  
in	   situ	   histopathology,	   while	   others	   (such	   as	   CyclinD1	   and	   HPV16)	   were	   not	  sufficient	  to	  disturb	  luminal	  architecture	  of	  the	  spheroids6.	  	  
Reversal	   of	   the	   cancerous	   phenotype	   in	   response	   to	   environmental	   cues	  Perhaps	  the	  most	  telling	  experiments	  of	  phenotypic	  plasticity	  of	  cancer	  cells	  and	  by	  consequence	  the	  importance	  of	  environmental	  cues	  to	  tumor	  formation	  are	  the	  ones	  reprogramming	   cancer	   cells	   by	   injecting	   them	   in	   embryonic	  milieus.	   In	   one	   such	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experiment	   Lee	   et	   al.	   implanted	   the	   metastatic	   melanoma	   cell	   line	   C8161	   in	  zebrafish	  embryos.	  They	  found	  that	  melanoma	  cells	  did	  not	  proliferate	  but	  instead	  remained	  dormant	   in	  adult	   fish	  for	  up	  to	  3	  months.	  However,	  when	  the	  same	  cells	  were	  transplanted	  into	  zebrafish	  eggs	  2	  days	  post	  fertilization,	  after	  the	  completion	  of	  morphogenesis	  and	  organogenesis,	  the	  cells	  not	  only	  divided	  but	  also	  developed	  into	  vascularized	  tumors7.	  In	  a	  similar	  experiment	  Kulesa	  et	  al.	  implanted	  metastatic	  melanoma	   cells	   in	   chick	   embryos	   adjacent	   to	   the	   embryo’s	   premigratory	   neural	  crest	   cells.	   Surprisingly,	   the	   melanoma	   cells	   did	   not	   form	   tumors.	   Instead	   they	  populated	  host	  neuronal	  structures	  and	  co-­‐expressed	  neuronal	  markers	  along	  with	  melanocyte-­‐specific	  markers8.	  A	  similar	  study	  was	  performed	  in	  1973	  using	  murine	  mammary	  tumor	  cells	  by	  DeCosse	  et	  al..	  The	  authors	  employed	  a	  precursor	  of	  what	  is	  known	  today	  as	  transwell	  culture	  to	  co-­‐culture	  murine	  mammary	  tumor	  cells	   in	  the	   presence	   of	   soluble	   signals	   from	   embryonic	  mouse	  mammary.	   They	   observed	  that	   in	   response	   to	   embryonic	   cues	   the	   tumor	   cells	   proliferated	   less	   and	   formed	  tubules	  characteristic	  of	  normal	  mammary	  gland	  histology9.	  These	  findings	  suggest	  that	   the	   developmental	   signaling	   taking	   place	   in	   embryonic	   environments	   has	   an	  inhibitory	   effect	   on	   cancer	   cells.	   More	   broadly,	   these	   studies	   demonstrate	   the	  important	  role	  of	  environmental	  cues	  in	  cancer	  development.	  	  
Heterogeneity	  and	  clonal	  evolution	  in	  breast	  cancer	  	  So	   far	  we	  discussed	   the	  phenotypic	  plasticity	  of	  cancer	  cells	   in	  response	   to	  micro-­‐environmental	   cues,	   both	   of	   mechanical	   and	   soluble	   nature.	   We	   now	   turn	   our	  attention	   to	   the	   heterogeneity	   of	   solid	   tumors	   and	   the	   local	   competition	   arising	  
	   6	  
between	   cancer	   cells	   in	   an	   environment	   of	   limited	   oxygen	   and	   nutrient	   supply.	  Multiple	  studies	  have	  documented	  that	  breast	  tumors	  are	  heterogeneous,	  composed	  of	   a	   variety	   of	   cell	   types	   that	   differ	   in	   features	   such	   as	   size,	   proliferation	   rate,	  metastatic	   potential,	   drug	   response	   and	  phenotype10–12.	   In	   one	  of	   these	   studies,	  H	  Fuji	  et	  al.13	  performed	  PCR	  analysis	  on	  microsatellite	  markers	  of	  23	  breast	  tumors,	  and	  recorded	  patterns	  of	  allelic	  loss.	  It	  emerged	  that	  individual	  tumor	  foci	  exhibited	  genetically	  divergent	  populations	  with	  respect	  to	  some	  allelic	  changes,	  a	  divergence	  that	  was	  more	   common	   in	   the	   in	   situ	   tumors	  with	   synchronous	   invasive	   cancers,	  rather	   than	   in	   tumors	   of	   in	   situ	   cancer	   only.	   They	   concluded	   that	   this	   genetic	  divergence	   is	   a	   form	   of	   clonal	   evolution	   within	   the	   tumor	   site,	   driven	   by	   the	  progression	  of	  in	  situ	  to	  invasive	  carcinoma.	  	  Most	   research	   converges	   in	   observing	   that	   indeed	  metastases	   and	   primary	   tumor	  are	   clonaly	   related14,15.	   Yet,	   there	   are	   conflicting	   reports	   within	   the	   literature	  regarding	   the	   dominance	   of	   the	   metastatic	   clone	   within	   the	   primary	   tumor	   site.	  What	   invariably	   complicates	   tracing	   a	   clonal	   relationship	   between	  primary	   tumor	  and	   metastatic	   lesions	   is	   the	   fact	   that	   genetic	   instability	   and	   clonal	   evolution	   is	  ongoing	  at	  metastatic	  sites.	  Kukarsjavi	  et	  al.14	  performed	  CGH	  cytogenetic	  analysis	  as	  well	   as	   X-­‐chromosome	   inactivation	   tests	   on	  29	  primary	  breast	   carcinomas	   and	  their	  various	  metastases.	  They	  found	  that	  synchronous	  lymph	  node	  metastases	  are	  much	   more	   closely	   related	   to	   the	   primary	   tumor	   than	   asynchronous	   soft-­‐tissue	  metastases,	  the	  latter	  having	  more	  time	  to	  genetically	  drift	  further	  from	  the	  original	  clone.	   A	   study	   by	   Symmans	   et	   al.15	   looked	   at	  DNA	  ploidy	   by	   image	   analysis	   of	   17	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invasive	  breast	  cancers	  and	  their	  82	  corresponding	  metastases.	   It	  emerged	  that	   in	  90%	  of	  metastatic	  samples,	   the	  corresponding	  clone	  was	   identified	   in	   the	  primary	  tumor	  sample	  representing	  a	  quarter	  or	  more	  of	   the	   tumor	  cell	  population	  (hence	  deemed	  a	  dominant	  clone).	  They	  were	  able	  to	  identify	  a	  majority	  DNA	  clone	  in	  60%	  of	  primary	   tumors	   and	   in	  70%	  of	  metastatic	   tumors.	  However,	   there	   clearly	  were	  tumors	   where	   the	   identification	   of	   a	   major,	   dominant	   clone	   was	   not	   possible.	  Furthermore,	   in	   approximately	   half	   of	   the	   metastatic	   samples	   an	   'unexpected	  majority'	   clone	  was	   identified	   -­‐that	   is,	   a	   clone	   that	  was	   deemed	   a	  minority	   in	   the	  primary	  tumor	  site	  and	  by	  consequence	  was	  not	  expected	  to	  metastasize.	  	  
1.2	  Advances	  in	  Cancer	  Treatment	  In	  my	  PhD,	  I	   investigated	  potential	  biomarkers	  that	  could	  in	  theory	  predict,	  on	  the	  basis	   of	   blood	  measurements	   alone,	   response	  of	   tumors	   to	   certain	   types	  of	   drugs.	  The	  drugs	  that	  interested	  me	  were	  not	  the	  classic	  cytotoxic	  treatments	  that	  so	  many	  patients	  have	  to	  endure,	  but	  rather	  the	  more	  modern	  ‘targeted	  therapies’.	  These	  are	  drugs	   designed	   to	   block	   the	   pathways	   that	   drive	   the	   cancer,	   and	   the	   hope	   is	   for	  much	  more	   selective	   treatment,	   and	  much	   less	   toxicity.	   To	   set	   up	   this	   part	   of	  my	  work	  I	  will	  briefly	  review	  this	  type	  of	  treatment	  as	  it	  is	  starting	  to	  emerge	  in	  breast	  cancer.	  	  
Clinical	  snapshot:	  emerging	  targeted	  therapies	  for	  breast	  cancer	  	  Breast	  cancer	  treatment	  primarily	  involves	  surgical	  resection	  of	  the	  diseased	  tissue	  followed	   by	   adjuvant	   drug	   treatment,	  which	   is	   dependent	   on	   the	   histology	   of	   the	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resected	  lesion	  and	  its	  ensuing	  molecular	  subtype16.	  In	  terms	  of	  molecular	  identity,	  breast	   tumors	   are	   binned	   in	   three	   categories	   according	   to	   the	   presence	   of	   three	  receptors.	  The	  overexpression	  of	  the	  estrogen	  (ER)	  and/or	  progesterone	  receptors	  (PR)	   defines	   a	   hormone	   receptor	   positive	   tumor	   (HR+)	   and	   patients	   with	   this	  disease	  are	  treated	  with	  HR	  antagonists	  such	  as	  tamoxifen17,18.	  The	  amplification	  of	  the	   receptor	   tyrosine	   kinase	   ErbB2,	   also	   known	   as	   HER2,	   defines	   HER2	   positive	  lesions,	  which	  are	  treated	  with	  targeted	  antibody-­‐therapy	  such	  as	  Trastuzumab	  or	  Pertuzumab19–21.	  All	   other	  breast	   tumors	   are	   categorized	   as	   triple	  negative	  breast	  cancer	  (TNBC)	  since	  they	  lack	  the	  presence	  of	  all	  three	  receptors	  mentioned	  above.	  Due	   to	   the	   lack	   of	   specific	   molecular	   therapy,	   TNBC	   is	   often	   treated	   with	   a	  combination	  of	  aggressive	  chemotherapy	  and	  radiation.	  TNBC	  tumors	  show	  a	  more	  aggressive	  phenotype	   than	  other	  breast	   tumors22	   and	  patients	  with	   this	  diagnosis	  have	  poor	  prognosis23.	  Both	  the	  absence	  of	  molecular	  therapeutics	  for	  TNBC	  tumors	  as	  well	   as	   the	  development	  of	  Trastuzumab	  resistance24	   in	  HER2-­‐amplified	  breast	  tumors,	   underscores	   the	   need	   for	   better	   biomarkers	   and	   diagnostic	   specificity	   in	  breast	  cancer	  classification	  and	  treatment.	  	  
	  Tyrosine	  kinase	  receptors	   localize	  on	  the	  plasma	  membrane.	  Before	  binding	  of	  the	  signaling	   molecule,	   the	   receptors	   act	   as	   monomers.	   Each	   of	   these	   individual	  monomer	   units	   have	   an	   extracellular	   ligand-­‐binding	   site,	   an	   alpha-­‐helix	   in	   the	  membrane,	  a	   ligand	  binding	  site,	  and	  an	   intracellular	   tail	   featuring	   tyrosine	  amino	  acids.	  Upon	  ligand	  binding	  the	  two	  monomers	  dimerize.	  The	  process	  of	  dimerization	  activates	   the	   tyrosine	   kinase	   region	   of	   each	   individual	   monomer.	   Both	   of	   these	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tyrosine	  kinases	  add	  a	  phosphate	  from	  an	  ATP	  molecule	  to	  a	  tyrosine	  on	  the	  tail	  of	  the	   other	   monomer.	   Once	   the	   receptor	   gets	   activated,	   it	   becomes	   recognized	   by	  specific	   relay	   proteins	   located	   within	   the	   cell.	   Each	   protein	   binds	   to	   a	   specific	  phosphorylated	   tyrosine,	   leading	   to	   a	   structural	   alteration	   which	   activates	   the	  bound	   protein.	   Each	   of	   these	   activated	   proteins	   trigger	   a	   transduction	   pathway,	  culminating	  to	  a	  change	   in	  gene	  expression	  and	  resulting	   in	  cellular	  response.	  The	  main	   two	   pathways	   downstream	   of	   receptor	   tyrosine	   kinases	   are	   the	  PI3K/AKT/mTOR	  pathway	  and	  the	  Ras/Raf/MEK/Erk	  pathway,	  as	  shown	  in	  figure	  1.1.	  
In	   recognition	   of	   the	   differences	   in	   pathway	   activity,	   disease	   progression	   and	  response	  to	  therapy	  in	  cancer,	  over	  800	  small	  molecule	  and	  biological	  inhibitors	  are	  now	  under	  development	  for	  the	  treatment	  of	  human	  malignancies.	  These	  inhibitors	  vary	   in	   strength	   and	   specificity.	   Some,	   like	   rapamycin,	   are	   pharmaceutical	   agents	  whose	  molecular	  target	  was	  identified	  years	  after	  they	  were	  introduced	  in	  the	  clinic.	  Most	  often	  however,	   these	   inhibitors	   are	   the	  product	  of	   rational	  design	  exhibiting	  high	   target	   specificity.	   Below	   we	   summarize	   the	   main	   molecular	   pathways	  implicated	   in	   cancer	   and	   the	   multiple	   opportunities	   they	   present	   for	  pharmacological	  inhibition.	  	  
	   10	  
	  
Figure	   1.1:	   Targeted	   pharmacological	   inhibition	   of	   protein	   tyrosine	   kinase	   receptor	   pathways	   in	  cancer.	  Image	  adapted	  from	  Faivre	  et	  al.55	  	  
Pharmacological	  inhibition	  of	  the	  PI3K/AKT/mTOR	  pathway	  Rapamycin	  (Sirolimus),	  originally	  an	  antifungal	  agent,	  was	  identified	  as	  an	  mTOR	  C1	  allosteric	  inhibitor	  in	  1991.	  Rapamycin’s	  commercial	  semi-­‐synthetic	  successors,	  the	  rapalogues	  Everolimus25	  and	  Temsirolimus26,	  conserved	  the	  selectivity	  of	  the	  parent	  molecule	  while	  boasting	  an	  improved	  pharmacokinetic	  profile.	  However,	  instead	  of	  the	   expected	   wide-­‐spectrum	   anti-­‐cancer	   sensitivity,	   favorable	   results	   with	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rapalogues	  have	  been	  seen	  in	  only	  a	  small	  handful	  of	  cancers.	  Specifically,	  rapalogue	  treatment	   prolonged	   progression-­‐free	   survival	   in	   patients	   with	   renal	   cell	  carcinoma27.	  Similarly,	   temsirolimus	  was	  efficacious	   in	   the	   treatment	  of	   refractory	  mantle	   cell	   lymphoma28	   and	   everolimus	   was	   successful	   in	   treating	   pancreatic	  neuroendocrine	   tumors29.	   Beyond	   this	   limited	   list	   of	   applications	   rapamycin,	   and	  the	   ensuing	   rapalogues,	   have	   fallen	   short	   of	   expectations	   as	   cancer	   treatment.	   A	  study	   of	   breast	   cancer	   tissue	   samples,	   after	   four	   weeks	   of	   everolimus	   treatment	  showed	   increased	   levels	   of	   activated	   AKT	   when	   compared	   to	   untreated	   tissue30.	  This	   suggests	   that	   mTORC1	   inhibition	   by	   rapalogues	   stimulates	   the	   PI3K-­‐AKT	  pathway	   and	  may	   actually	   increase	   the	   survival	   and	   proliferation	   of	   cancer	   cells.	  Another	   explanation	   of	   rapamycin	   failure	   is	   that	   cancer	   cells	   that	   have	   acquired	  sufficiently	   high	   levels	   of	   constitutive	   mTORC1	   activation	   are	   able	   to	   evade	  pharmacological	   inhibition	   of	   proliferation31.	   To	   remedy	   these	   inefficiencies,	   dual	  inhibitors	  of	  mTOR	  with	  either	  downstream	  or	  upstream	  regulators	  are	  currently	  in	  clinical	   trials.	   Notably,	   Novartis	   has	   generated	   the	   dual	   PI3K/mTOR	   inhibitor	  NVPBEZ235	  that	  was	  effective	  in	  preclinical	  testing32,33	  	  and	  is	  currently	  in	  Phase	  II	  trials	  of	  advanced	  solid	  tumors	  in	  metastatic	  breast	  cancer34.	  A	  similar	  PI3K/mTOR	  dual	   inhibitor	   introduced	   by	   Sanofi-­‐Aventis,	   was	   tested	   in	   Phase	   I	   trials.	   Results	  showed	   downregulation	   of	   PI3K-­‐mTORC2	   dependent	   AKT	   phosphorylation	   and	  reduced	   tumor	  growth35.	  Moreover,	   combining	   IGF1R	  antagonists	  with	  rapalogues	  has	   been	   shown	   to	   yield	   anti-­‐proliferative	   effects	   in	   breast	   and	   prostate	   cancer36.	  This	  approach	  has	  also	  been	  extended	  to	  the	  EGFR	  receptor37.	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Pharmacological	  inhibition	  of	  the	  Ras/Raf/MEK/Erk	  pathway	  The	   mitogen-­‐activated	   protein	   kinase	   (MAPK)	   cascade	   is	   a	   key	   intracellular	  signaling	  pathway	  that	  regulates	  diverse	  cellular	  functions.	  The	  cascade	  is	  initiated	  by	   receptor	   tyrosine	   kinases	   at	   the	   cell	   surface.	   The	   pivotal	   role	   of	   the	  Ras/Raf/MEK/Erk	   pathway	   in	   a	   multitude	   of	   cellular	   functions	   underlies	   the	  importance	   of	   the	   cascade	   in	   oncogenesis	   and	   growth	   of	   transformed	   cells.	  Therefore,	   therapeutic	   targeting	   of	   these	   kinases	   cascade	   has	   been	   extensively	  investigated	  in	  cancer.	  	  	  RAS	  activation	  is	  the	  first	  step	  in	  activation	  of	  the	  MAPK	  signaling	  cascade.	  Human	  tumors	  frequently	  feature	  point	  mutations	  in	  the	  RAS	  gene,	  a	  notable	  example	  being	  KRAS	  mutation	  in	  colorectal	  carcinoma,	  the	  detection	  of	  which	  is	  established	  as	  an	  independent	   prognostic	   marker	   in	   response	   to	   EGFR	   inhibitor	   treatment	  (cetuximab)	  in	  these	  tumors38,39.	  The	  covalent	  attachment	  of	  the	  farnesyl	  isoprenoid	  group	  to	  the	  HRAS,	  KRAS	  and	  NRAS	  proteins	   is	  the	  post-­‐translational	  modification	  responsible	   for	   the	   stable	   localization	   of	   RAS	   to	   the	   plasma	   membrane	   and	  subsequent	  RAS	  activation.	  Therefore	  this	  was	  an	  obvious	  early	  target	  for	  the	  design	  of	  rational	  therapies	  in	  this	  pathway.	  Indeed,	  farnesyltransferase	  inhibitors	  showed	  promise	  in	  early	  murine	  models	  of	  mammary	  carcinomas,	  where	  tumors	  regressed	  impressively	  in	  response	  to	  treatment40.	  In	  addition,	  the	  drug	  was	  well	  tolerated	  by	  the	  animals.	  Unfortunately	   similar	   results	  have	  not	  been	  achieved	   in	   clinical	   trials	  with	   human	  patients,	  where	   farnesyltransferase	   inhibitors	   have	   been	   surprisingly	  ineffective.	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  The	  next	  step	  in	  the	  MAPK	  signaling	  cascade	  is	  RAF	  activation.	  Mutations	  of	  the	  RAF	  gene	  are	  not	  as	  ubiquitous	  as	  RAS	  mutations.	  However,	  they	  are	  prevalent	  in	  a	  few	  specific	  malignancies.	   	   B-­‐RAF	  mutations	   can	   be	   found	   in	   approximately	   63%41	   of	  melanomas,	   45%	   of	   papillary	   thyroid	   cancers42	   and	   36%	   of	   ovarian	   cancers43.	  Mutations	   on	   the	   BRAF	   gene	   occur	   almost	   invariably	   at	   the	   V600E	   position	   and	  result	  in	  a	  ‘gain	  of	  function’	  constitutively	  active	  BRAF.	  The	  first	  RAF	  inhibitor	  to	  be	  investigated	   in	   clinical	   trials	   of	   melanoma	   was	   sorafenib,	   designed	   to	   block	   the	  downstream	  CRAF,	   rather	   than	  BRAF,	  which	  demonstrated	  modest	   response	  rates	  as	   an	   adjuvant	   treatment	   in	   patients	   receiving	   chemotherapy44.	   Sorafenib	   may	  therefore	   be	   valuable	   in	   combination	   therapy	   with	   V600E	   BRAF	   inhibitors.	  Vemurafenib	  was	  a	  newer	  and	  selective	  inhibitor	  of	  active	  V600E	  BRAF	  approved	  in	  2011	  by	  the	  FDA	  for	  the	  treatment	  of	  late-­‐stage	  melanoma.	  Vemurafenib	  displayed	  marked	   selectivity	   in	   both	   cell-­‐based	   assays	   and	   animal	   models.	   Potent	   cytotoxic	  effects	   were	   limited	   to	   BRAF-­‐mutated	   cells	   and	   led	   to	   tumor	   regression	   without	  significant	   generalized	   toxicity45.	   Vemurafenib	   has	   fared	   well	   in	   the	   clinic.	   Most	  patients	   respond	   to	   the	   drug	   leading	   to	   longer	   progression-­‐free	   survival	   rates46.	  Here	   too	   however	   resistance	   inevitably	   sets	   in	   which	   indicates	   the	   need	   for	  combination	  therapy	  with	  upstream/downstream	  inhibitors.	  	  	  	  Further	   down	   the	   MAPK	   cascade	   are	   the	   MEK	   and	   Erk	   protein	   kinases.	   Blocking	  MAPK	  via	   small-­‐molecule	  MEK	   inhibitors	  has	   come	   to	   the	   forefront	   as	   an	   exciting	  approach	  in	  cancer	  therapeutics.	  Initial	  MEK	  inhibitors	  were	  effective	  in	  preclinical	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studies	   but	   lacked	   the	   desirable	   pharmacokinetic	   profile	   for	   human	   testing.	  Optimization	  led	  to	  the	  design	  of	  	  the	  second-­‐generation	  MEK	  inhibitor	  Selumetinib	  (AZD6244)	   that	   proceeded	   to	   clinical	   trials.	   Pre-­‐treatment	   and	   post-­‐treatment	  tumor	  biopsies	  obtained	  from	  17	  patients	  showed	  a	  mean	  83%	  reduction	  in	  nuclear	  Erk	  phosphorylation,	   an	   indication	   that	   Selumetinib	   achieved	   target	  modulation47.	  However,	   in	   terms	   of	   efficacy	   endpoints	   no	   objective	   response	   to	   treatment	   was	  identified	   in	   these	   patients	   other	   than	   stable	   disease	   lasting	   over	   5	   months.	  PD0325901,	  another	  MEK	  inhibitor	  that	  was	  evaluated	  in	  the	  clinic,	  demonstrated	  a	  similar	  result	  of	  84%	  suppression	  in	  Erk	  phosphorylation	  as	  compared	  to	  baseline	  expression48.	   Development	   of	   this	   compound	   however	   was	   stopped	   due	   to	   high	  toxicity	  associated	  with	  treatment.	  	  	  
Molecular	  Signatures	  Predict	  Drug	  Response	  in	  Breast	  Cancer	  Cell	  Lines	  As	  the	  list	  of	  experimental	  tyrosine	  kinase	  inhibitors	  grows,	  the	  need	  for	  tools	  that	  will	  successfully	  predict	  patient	  response	  on	  the	  basis	  of	  the	  molecular	  make-­‐up	  of	  the	  particular	   tumor	  becomes	  ever	  more	  pressing.	  Specifically	   in	  breast	  cancer,	  an	  initiative	   across	   academic	   institutions	   was	   spurred	   in	   order	   to	   study	   the	   varied	  genomic	   profiles	   across	   a	   large	   collection	   of	   breast	   cancer	   cell	   lines	   and	   extract	  signatures	   that	   will	   predict	   breast	   tumor	   response	   to	   particular	   inhibitors.	   In	   a	  pioneering	   research	   paper	   Neve	   et	   al.49	   confirm	   that	   cell	   lines	   display	   the	   same	  heterogeneity	   in	   copy	   number	   and	   expression	   abnormalities	   as	   primary	   breast	  tumors.	  The	  51	  cell	  lines	  employed	  in	  this	  study	  carried	  almost	  all	  of	  the	  recurrent	  genomic	   abnormalities	   associated	   with	   clinical	   outcome	   in	   primary	   tumors.	   In	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addition	  the	  breast	  cancer	  cell	  lines	  clustered	  into	  basal-­‐like	  and	  luminal	  expression	  subsets,	  much	  like	  primary	  tumors	  do.	  In	  regards	  to	  molecular	  signatures	  indicative	  of	  response	  to	  Trastuzumab,	  they	  found	  that	  increased	  protein	  levels	  of	  MEK,	  ESR1,	  TYK2,	   FASN,	   GRB7	   and	   MAPK1/3	   most	   strongly	   correlated	   with	   response	   to	  treatment.	   Conversely	   protein	   levels	   associated	   with	   Trastuzumab	   resistance	  included	   high	   levels	   of	   SFN,	   CAV2,	   GRB2,	   RB1	   and	   FLNA.	   Gene	   ontology	   analysis	  suggests	  that	  the	  upregulation	  of	  genes	  involved	  in	  insulin/MAPK	  signaling	  predicts	  response	  to	  Herceptin,	  whereas	  the	  mTOR	  pathway,	  Toll-­‐like	  receptor	  pathway,	  N-­‐glycan	   biosynthesis	   and	   inositol-­‐phosphate	   signaling	   are	   associated	   with	  resistance49.	  	  In	  a	  subsequent	  study	  this	  approach	  was	  expanded	  to	  a	  screen	  of	  49	  breast	  cancer	  cell	  lines	  for	  response	  to	  77	  therapeutic	  compounds,	  including	  hormonal	  inhibitors,	  kinase	   inhibitors	   and	   conventional	   chemotherapeutic	   agents	   (taxanes,	   platinum	  compounds	  and	  anthracyclins)50	  .	  The	  authors	  found	  that	  overall	  responses	  to	  drugs	  with	   similar	  mechanisms	   and	   targets	  were	   highly	   correlated	   across	   the	   cell	   lines.	  Namely	   HER2-­‐amplified	   cell	   lines	   were	   preferentially	   sensitive	   to	   compounds	  targeting	   EGFR	   and/or	   HER2,	   like	   AG1478,	   BIBW2992	   and	   Gefitinib.	   	   The	  chemotherapeutics	  Etoposide,	  Docetaxel	  and	  cisplatin	  showed	  preferential	  activity	  in	   basal	   or	   claudin-­‐low	   cell	   lines,	   which	   was	   in	   accordance	   with	   clinical	  observations51,52.	   Moreover,	   some	   compounds	   targeting	   the	   mitotic	   apparatus,	  Ispinisib	   and	   GSK913195,	   showed	   no	   significant	   subtype	   specificity.	   The	   authors	  concluded	  by	  noting	  that	  additional	  work	  remains	  before	  the	  signatures	  reported	  in	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their	   study	   could	   be	   used	   to	   select	   patients	   for	   clinical	   trials.	   Robust	   and	   reliable	  molecular	  assays	  to	  evaluate	  clinical	  samples	  are	  currently	  lacking.	  	  Another	   study	   further	   expanded	   this	   approach	   by	   screening	   a	   total	   of	   479	   cancer	  cell	   lines	  with	   24	   anti-­‐cancer	   drugs53.	   Their	   findings	   echoed	   those	   of	  Heiser	   et	   al.	  regarding	   EGFR	  mutations	   and	   HER2	   amplifications	   being	   predictors	   of	   Erlotinib	  and	   Lapatinib	   response	   respectively.	   Moreover,	   and	   not	   surprisingly,	   they	   found	  that	  BRAF	  and	  NRAS	  mutations	  were	  among	  the	  top	  four	  predictors	  of	  sensitivity	  to	  the	  MEK	   inhibitor	   PD-­‐0325901.	   Additional	   predictive	   features	   for	  MEK	   inhibition	  included	   expression	   of	   PTEN,	   PTPN5	   and	   SPRY2.	   Because	   this	   study	   was	   done	  across	  cancer	  cell	  lines	  derived	  from	  a	  variety	  of	  solid	  tumors	  as	  well	  as	  leukemias	  and	  lymphomas,	  predictions	  connecting	  the	  cell	  line	  lineage	  to	  drug	  response	  were	  made	  possible.	  Namely,	  the	  haematological	  lineage	  of	  the	  cancer	  was	  a	  predictor	  of	  HDAC	  inhibitor	  (Panobinoblast)	  sensitivity.	  Similarly,	  most	  myeloma	  cell	  lines	  were	  sensitive	  to	  IGF1	  receptor	  inhibitor	  AEW541.	  	  	  Finally,	   a	   study	  carried	  out	  by	  Niepel	  et	  al.54	  offered	  an	   insightful	  variation	   in	   this	  line	  of	  research.	  Here	  the	  authors	  profiled	  signaling	  pathway	  activity	  in	  a	  collection	  of	   37	   breast	   cancer	   cell	   lines	   before	   and	   after	   stimulation	   with	   physiologically	  relevant	   ligands.	   Based	   on	   their	   measurements	   they	   constructed	   models	   that	  significantly	  predicted	  sensitivity	   to	  23	   targeted	   therapeutics.	  They	   found	   that	   the	  response	   to	   the	   growth	   factor	   receptor	   ligand	   heregulin	   effectively	   predicted	   the	  sensitivity	  of	  cells	  to	  drugs	  targeting	  the	  PI3K	  and	  Akt	  pathway,	  whereas	  in	  contrast	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the	  abundance	  of	  Akt	  or	   the	  mutational	   status	  of	   the	  enzymes	   in	   the	  pathway	  did	  not.	  They	  observed	  that	  unsupervised	  clustering	  divided	  the	  cell	   lines	  into	  clusters	  primarily	  on	  the	  basis	  of	  the	  abundance	  of	  ligand	  responsiveness	  of	  receptors	  such	  as	  c-­‐MET,	  FGFR4	  and	  IL-­‐6R.	  TNBC	  cells	  were	  more	  responsive	  to	  EGF	  and	  the	  c-­‐Met	  ligand	  HGF,	  whereas	  HR+	  cells	   responded	   robustly	   to	  FGF-­‐2	  and	  HRG	   (heregulin).	  HER2-­‐amplified	  cell	  lines	  responded	  weakly	  to	  most	  growth	  factors,	  but	  a	  subset	  of	  them	  responded	  to	  IL-­‐6.	  	  
1.3	  Novel	  diagnostic	  tools	  in	  breast	  cancer	  The	  last	  part	  of	  my	  PhD	  involved	  analysis	  of	  exosomes,	  small	  vesicles	  derived	  from	  breast	   cancer	   cells,	   in	   the	   hope	   of	   identifying	   biomarkers	   that	   predict	   drug	  responsiveness.	  To	  set	  up	  this	  part	  of	  my	  work	  I	  will	  review	  novel	  approaches	  aimed	  to	   develop	   predictive	   biomarkers,	   with	   a	   focus	   on	   methods	   that	   do	   not	   require	  inserting	  a	  needle	  or	  biopsy	  gun	  into	  the	  primary	  tumor.	  	  	  	  As	   discussed	   previously,	   molecular	   profiling	   of	   cancer	   is	   a	   preferred	   method	   of	  classifying	   tumors	   and	   matching	   patients	   with	   targeted	   therapeutics.	   Still,	   the	  clinical	  tools	  that	  will	  facilitate	  this	  matching	  process	  are	  not	  yet	  in	  place.	  Currently,	  physicians	   rely	   on	   serial	   surgical	   biopsies	   in	   order	   to	   characterize	   the	   molecular	  subtype	  of	  a	  cancerous	  lesion.	  However,	  biopsies	  are	  invasive	  procedures	  that	  carry	  morbidity	  risk	  due	  to	  seeding,	  the	  spread	  of	  cancer	  cells	  along	  the	  path	  of	  the	  needle	  track	   at	   the	   biopsy	   site56.	   Another	   clinical	   practice	   is	   the	   immuno-­‐histological	  staining	  of	  archival	  resected	  tissue	  in	  order	  to	  drive	  clinical	  decisions	  at	  later	  stages	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of	  the	  disease.	  This	  method	  discounts	  the	  previously	  discussed	  clonal	  and	  molecular	  drift	  that	  a	  cancer	  undergoes	  during	  the	  metastatic	  process.	  Treatment	  decisions	  are	  often	  made	  according	   to	   the	  molecular	  subtype	  of	   the	  primary	   tumor,	  but	   it	   is	   the	  metastatic	  disease	  that	  invariably	  proves	  fatal	  to	  patients.	  	  	  Another	  shortcoming	  of	  current	  diagnostic	  practices	  is	  that	  once	  a	  primary	  lesion	  has	  been	  resected	  there	  is	  no	   clinical	   method	   to	   diagnose	   micrometastatic	   disease	   before	   it	   becomes	  radiographically	   detectable	   and/or	   symptomatic.	   Moreover,	   despite	   some	  impressive	  clinical	  successes	  with	  kinase-­‐targeting	  therapies,	  treatment-­‐responsive	  patients	  ultimately	  relapse	  as	  a	  result	  of	  acquired	  resistance.	  This	  too	  underlines	  the	  dire	   need	   for	   biodynamic	   diagnostic	   tools	   that	   closely	  monitor	   treatment	   efficacy.	  Below	  we	  will	  discuss	  some	  recent	  advances	  in	  the	  development	  of	  liquid	  biopsies,	  a	  novel	   term	   describing	   the	   variety	   of	   new	   technologies	   aiming	   to	   identify	   cancer	  biomarkers	  present	  in	  the	  bloodstream	  of	  patients.	  	  	  
Cell	  free	  nucleic	  acids	  Cell-­‐free	  nucleic	  acids	  (cfNAs)	  came	  to	  the	  forefront	  as	  a	  possible	  diagnostic	  tool	  in	  1994	   when	   two	   independent	   studies	   published	   the	   detection	   of	   mutated	   RAS	  fragments	   in	   the	   blood	   of	   cancer	   patients57,58.	   cfNAs	   is	   a	   broad	   category	  encompassing	  cell	  free	  DNA	  as	  well	  as	  cell	  free	  RNA.	  Particularly	  cfDNA	  is	  thought	  to	  arise	   in	   the	   blood	   stream	   of	   patients	   via	   a	   variety	   of	   processes.	   It	   is	   primarily	  thought	  to	  be	  a	  result	  of	  apoptotic	  or	  necrotic	  cell	  death	  of	  cancer	  cells	  in	  the	  tumor	  microenvironment,	  while	  other	  studies	  show	  the	  active	  secretion	  of	  mitochondria,	  containing	  cfDNA59.	  Lastly	  cfDNA	  is	  thought	  to	  be	  released	  in	  the	  bloodstream	  upon	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the	  death	  of	  circulating	  tumor	  cells	  (CTCs)60,61.	  In	  terms	  of	  stability,	  cfDNA	  is	  cleared	  from	   the	   blood	   by	   the	   liver	   and	   kidney	   and	   has	   an	   approximate	   half-­‐life	   in	  circulation	   ranging	   from	   15	   minutes	   to	   several	   hours62.	   Cell	   free	   RNA	   (cfRNA)	  appears	  to	  be	  highly	  stable	   in	  the	  bloodstream,	  although	  its	  clearance	  rate	  has	  not	  been	   explicitly	   quantified	   yet.	   This	   implies	   that	   cfRNA	   may	   be	   protected	   from	  degradation	  by	  being	  packaged	  into	  exosomes,	  microparticles	  or	  microvesicles	  that	  are	  either	  actively	  secreted	  or	  shed	  from	  cellular	  surfaces	  into	  the	  bloodstream63,64.	  	  The	  hope	   regarding	   cfDNA	   is	   that	   it	  will	   carry	   specific	   gene	  mutations	   relevant	   in	  cancer	  therapy,	  such	  as	  KRAS,	  BRAF	  and	  EGFR.	  However,	  as	  this	  technology	  is	  still	  in	  a	   nascent	   stage	   issues	   of	   assay	   specificity	   and	   sensitivity	   need	   to	   be	   addressed.	  Assays	   targeting	   DNA	   mutations	   require	   that	   the	   mutation	   in	   the	   tumor	   occur	  frequently	  and	  at	  a	  specific	  genomic	  site.	  However,	  that	  is	  generally	  not	  the	  case	  for	  clinically	   relevant	   mutations.	   An	   illustrative	   example	   is	   the	   detection	   of	   KRAS	  mutation	   in	   tumor	   tissue	  derived	   from	  pancreas,	   colon	  and	   lung	  but	   the	   failure	  of	  detecting	   the	   mutation	   in	   cfDNA	   derived	   from	   the	   respective	   patient’s	   blood	  samples65–67.	   Beyond	   cfDNA,	   circulating	   nucleosomes	   -­‐which	   are	   histone	   octamer	  structures	  wrapped	  by	  a	  200	  base	  pair-­‐long	  DNA	  strand-­‐	  are	  also	   found	  in	  patient	  circulation.	  The	  presence	  of	  circulating	  nucleosomes	   in	   itself	   is	  not	  an	   indicator	  of	  malignant	   disease68.	   However,	   due	   to	   the	   fact	   that	   nucleosomes	   are	   typically	  products	   of	   cancer	   cell	   death,	   they	   have	   been	   used	   for	  monitoring	   the	   efficacy	   of	  cytotoxic	   cancer	   therapies.	   For	   example,	   platinum-­‐based	   chemotherapy	   induced	  caspase-­‐dependent	   apoptosis	   of	   tumor	   cells	   and	   an	   increase	   in	   circulating	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nucleosomes	   in	   the	   blood	   of	   patients	   with	   ovarian	   cancer69.	   Overall	   the	   cfNA	  technologies	   are	   facing	   practical	   difficulties	   of	   standardizing	   procedures	   across	  clinical	  centers.	  Below	  we	  will	  specifically	  discuss	  alternate	  technologies	  that	  have	  gained	  FDA-­‐approval	  and	  have	  translated	  in	  clinical	  practice.	  	  	  
Circulating	  tumor	  cells	  (CTCs)	  Tumor-­‐derived	   epithelial	   cells	   have	   been	   identified	   in	   peripheral	   blood	   of	   cancer	  patients	  and	  are	  thought	  to	  be	  the	  origin	  of	  intractable	  metastatic	  disease70–72.	  The	  advantage	  of	  CTCs	  as	  a	  diagnostic	  technology	  is	  that	  they	  are	  rarely	  found	  in	  healthy	  subjects,	   while	   they	   are	   prevalent	   and	   detectable	   in	   patients	   with	   solid	   tumors.	  Particularly	   studies	  performed	   in	  breast70,	   colorectal73	   and	  prostate74	   cancer	  have	  established	   the	   number	   of	   CTCs	   before	   treatment	   as	   an	   independent	   predictor	   of	  progression-­‐free	  survival.	  CellSearch,	  was	  the	  first	  diagnostic	  technology	  to	  receive	  FDA-­‐approval	  for	  the	  isolation	  of	  CTCs	  from	  peripheral	  blood.	  The	  technology	  relies	  on	  immuno-­‐magnetic	  separation	  of	  epithelial	  cells	  using	  anti-­‐epithelial	  cell	  adhesion	  molecule	  (EpCAM)	  antibodies	  and	  subsequent	  staining	  for	  visualization75.	  There	  are	  a	  number	  of	  caveats	  associated	  with	  this	  approach.	  EpCAM-­‐based	  detection	  has	  low	  sensitivity	   in	   EpCAM-­‐negative	   cancers.	   Agressive	   tumor	   cells	   often	   downregulate	  EpCAM	   as	   a	   result	   of	   the	   epithelial-­‐mesenchymal	   transition	   process	   during	  metastasis	   and	   can	   pass	   undetected	   through	   the	   CellSearch	   system76.	   In	   addition,	  the	   lengthy	   isolation	   and	   staining	   steps	   are	   accompanied	   by	   considerable	   cell	  loss77,78.	   Taking	   into	   consideration	   that	   CTCs	   are	   already	   extremely	   rare	   in	   the	  bloodstream,	   comprising	   as	   few	   as	   one	   cell	   for	   every	   109	   blood	   cells	   in	   the	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circulation	   of	   patients	   with	   metastatic	   cancer79,80,	   cell	   losses	   during	   the	   isolation	  process	   hold	   the	   potential	   of	   a	   false-­‐negative	   diagnosis.	   To	   remedy	   these	   issues,	  novel	  technologies	  are	  under	  investigation	  that	  would	  improve	  the	  capturing	  rate	  of	  CTCs.	  These	   include	  but	   are	  not	   limited	   to	  nuclear	  magnetic	   resonance	  profiling81	  	  and	  microfluidic	  approaches82.	  	  
Cancer	  exosomes	  and	  microvesicles	  Exosomes	   are	   nanovesicles	   of	   30	   to	   100nm	  diameter	   that	   form	   in	   the	   endosomal	  cytoplasmic	  compartment	  and	  are	  subsequently	  released	  in	  the	  extracellular	  space.	  Exosome	  production	  is	  not	  unique	  to	  epithelial	  cancer	  cells.	  On	  the	  contrary,	  a	  wide	  variety	  of	   cell	   types	  have	  demonstrated	   the	  capability	  of	  producing	   these	  vesicles,	  including	   reticulocytes,	   dendritic	   cells,	   B	   cells,	   T	   cells,	   mast	   cells	   and	   embryonic	  cells83,84.	   However,	   their	   accumulation	   in	   the	   peripheral	   circulation	   appears	   to	   be	  unique	  to	  cancer	  and	  pregnancy85,86.	  	  Clinical	   studies	   performed	   in	   melanoma	   and	   glioblastoma	   have	   shown	   that	  exosomes	   carry	   cancer-­‐specific	   protein	   signatures	   characteristic	   of	   the	   primary	  tumor	  mass87,88.	  In	  vitro	  proteomic	  studies	  of	  the	  colon	  tumor	  cell	  line	  LIM1215	  and	  the	  breast	  cancer	  cell	  line	  MDAMB231	  reinforce	  these	  clinical	  findings	  and	  confirm	  the	   presence	   of	   multiple	   host	   cell-­‐specific	   proteins	   in	   the	   corresponding	  exosomes89,90.	   In	   addition	   to	   the	   specificity	   of	   the	   exosome	   protein	   content,	   the	  exosomal	  protein	  concentration	  in	  itself	  has	  been	  recognized	  as	  a	  clinical	  marker	  of	  disease	   progression.	   Peinado	   et	   al.	   showed	   that	   in	   melanoma-­‐derived	   exosomes,	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protein	  concentration	  in	  patients	  with	  stage	  4	  disease	  was	  the	  highest	  compared	  to	  all	   other	   stages	   and	   normal	   controls87.	   Taylor	   et	   al.	   recorded	   an	   equivalent	  observation	   in	   exosomes	   derived	   from	   patients	   with	   varying	   stages	   of	   ovarian	  cancer91.	  Beyond	  their	  protein	  composition,	  exosomes	  carry	  yet	  another	  payload	  of	  diagnostic	   value:	  microRNAs.	   Studies	   in	   glioblastoma92	   and	   ovarian	   cancer91	   have	  identified	   miRNA	   signatures	   indicative	   of	   the	   specific	   malignancy	   in	   circulating	  exosomes.	   Nilsson	   et	   al.93	   reached	   a	   similar	   conclusion	   in	   a	   study	   that	   examined	  urine-­‐derived	  exosomes	  from	  patients	  with	  prostate	  cancer	  for	  mRNA	  biomarkers.	  	  In	  terms	  of	  their	  physiological	  role	  during	  disease	  progression,	  cancer	  exosomes	  are	  thought	  to	  be	  modulators	  of	  the	  tumor	  microenvironment	  and	  once	  in	  circulation,	  to	  participate	  in	  the	  priming	  of	  the	  metastatic	  niche.	  Exosomes	  are	  known	  to	  promote	  the	  horizontal	   transfer	  of	  molecules	   to	  recipient	  cells94–96.	   In	  particular,	  Skog	  et	  al.	  showed	   that	   glioblastoma	   exosomes	   carry	   angiogenic	   proteins	   that	   stimulate	  endothelial	   cells	   and	   furthermore	   promote	   the	   proliferation	   of	   glioma	   cells92.	  Peinado	   et	   al.	   published	   another	   illustrative	   example	   of	   exosome	   activity.	   The	  authors	   incubated	  bone	  marrow-­‐derived	  cells	  with	  purified	  exosomes	   from	  highly	  metastatic	  melanoma	  carrying	  the	  tyrosine	  kinase	  MET	  receptor.	  They	  showed	  that	  a	   functional	  MET	  was	   successfully	   transferred	  on	   the	   surface	  of	   the	  bone	  marrow	  cells	   and	   were	   subsequently	   able	   to	   detect	   the	   phosphorylation	   of	   downstream	  mediators	  of	  MET	  upon	  treatment	  of	  the	  cells	  with	  hepatocyte	  growth	  factor87.	  Yet	  another	   study	   in	  breast	   cancer,	   linked	  HER2-­‐overexpressing	  breast	   tumor	  derived	  exosomes	  with	  chemoresistance	  to	   targeted	  Trastuzumab	  and	  Lapatinib	   therapies.	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The	   authors	   showed	   that	   exosomes	   carry	   a	   functional	  HER2	   on	   their	   surface	   that	  successfully	   binds	   the	   targeted	   therapies.	   Their	   findings	   suggest	   that	   cancer	  exosomes	   can	   act	   as	   a	   drug	   sink	   in	   the	   patients’	   circulation,	  modulating	   targeted	  therapy	  sensitivity97.	  	  In	   contrast	   to	   the	   rareness	   of	   circulating	   tumor	   cells	   (CTCs),	   tumor	   exosomes	   are	  advantageous	   for	   diagnostic	   purposes	   due	   to	   their	   ubiquity	   in	   the	   circulation	   of	  patients	   with	   malignant	   and	   advanced	   disease.	   However,	   diagnostic	   technologies	  geared	  towards	  exosome	  isolation	  from	  plasma	  face	  some	  common	  challenges	  with	  the	   technologies	   developed	   for	   CTC	   detection.	   Protocols	   for	   exosome	   purification	  usually	   entail	   multiple	   rounds	   of	   ultracentrifugation	   in	   order	   to	   pellet	   the	   small	  vesicles.	   In	   addition	   to	   tumor	   exosomes,	   ultracentrifugation	   co-­‐precipitates	  exosomes	   of	   blood	   and	   immune	   cell	   origin.	   These	   contaminating	   vesicles	   carry	  miRNAs,	  which	   can	   confound	  miRNA	   cancer	   specific	   signatures	   leading	   to	   clinical	  diagnoses98.	   In	   order	   to	   separate	   specifically	   the	   tumor-­‐derived	   vesicles,	  immunoprecipitation	  with	  EpCAM	  antibodies	  is	  frequently	  employed89,91.	  Much	  like	  in	  CTC	   isolation,	   exosomes	   from	  aggressive	   tumor	  cells	   that	  downregulate	  EpCAM	  will	   remain	  undetected	  by	   this	  method.	   It	   is	   therefore	  not	   surprising	   that	   the	   first	  exosome	  diagnostic	  technology	  to	  make	  it	  to	  the	  clinic	  is	  a	  kit	  commercializing	  the	  purification	   of	   exosomes	   from	   urine	   samples	   –a	   significantly	   simpler	   biological	  fluid-­‐	   for	   the	   detection	   of	   kidney	   and	   prostate	   cancer99.	   The	   absence	   of	  contaminating	  vesicles	   from	  non-­‐tumor	  cell	  sources	   in	  urine	  obviates	   the	  need	   for	  an	  immunoprecipitation	  step.	  In	  addition	  to	  this	  approach,	  alternative	  technologies	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for	   exosome	   capture	   –such	   as	   nuclear	   magnetic	   resonance	   profiling88	   and	  microfluidic	   approaches100-­‐	   have	   been	   scaled	   to	   the	   exosome	   nanometer	   length-­‐scale	  and	  are	  being	  tested	  for	  exosome	  capture	  efficacy.	  	  	  	  
1.4	  Specific	  aims	  of	  the	  present	  study	  
Specific	   aim	  #1:	   This	   research	   aims	   to	   identify	   chemical	   cues	   secreted	   by	   breast	  cancer	  cells,	  and	  more	  specifically	  focuses	  on	  the	  unveiling	  of	  anti-­‐proliferative	  and	  pro-­‐apoptotic	  signals	  among	  the	  prolific	  secretions	  of	  breast	  cancer	  cell	  lines.	  	  	  The	   epigenetic	   plasticity	   of	   cancer	   cells	   along	   with	   the	   heterogeneity	   and	   clonal	  evolution	   observed	   within	   solid	   tumors	   were	   the	   spring	   board	   for	   this	   research	  project.	   While	   heterogeneity	   in	   tumors	   has	   been	   well	   documented,	   the	  consequences	   of	   this	   heterogeneity	   on	   the	   growth	   of	   different	   cell	   clones	   has	   not	  been	  systematically	  investigated	  until	  now.	  Seeing	  that	  tumor	  clones	  physiologically	  compete	   for	   dominance	   given	   a	   re	   stricted	   nutrient	   environment,	   we	   anchor	   our	  research	   in	   the	   hypothesis	   that	   cancer	   cells	   are	   in	   competition	   to	   either	   halt	   the	  growth	  or	  downright	  initiate	  an	  apoptotic	  cascade	  on	  neighboring	  clones.	  We	  reason	  that	   cancer	   cell	   secreted	   factors	   that	   hamper	   the	   growth	   of	   neighboring	   cell	   lines	  make	   attractive	   low-­‐toxicity	   drug	   candidates,	   since	   such	   molecules	   might	  specifically	  target	  malignancy	  while	  leaving	  healthy	  tissue	  intact.	  	  In	   chapter	   2,	   we	   launch	   this	   investigation	   by	   presenting	   a	   20x20	   conditioned	  medium	  (CM)	  breast	  cancer	  cell	  culture	  screen.	  This	  screen	  reveals	  two	  conditioned	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media	  that	  have	  strong	  pro-­‐apoptotic	  activity	  on	  the	  majority	  of	  cell	  lines	  tested.	  	  We	  embark	  in	  further	  biochemical	  characterization	  of	  the	  strongest	  apoptosis-­‐inducing	  conditioned	  media.	   Next,	   we	   fractionate	   the	   CMs	   into	   a	   particulate	   and	   a	   soluble	  fraction	   by	   ultracentrifugation	   and	   test	   both	   fractions	   for	   apoptotic	   activity.	   In	  chapter	  3	  transcriptomic	  and	  proteomic	  approaches	  are	  employed	  to	  identify	  gene	  and	  protein	  candidates	  in	  the	  cancer	  cell	  secretions	  that	  have	  pro-­‐apototic	  activity.	  We	   conclude	   the	   chapter	   with	   a	   comparison	   of	   the	   proteomic	   content	   of	   the	  particulate	   fractions	   to	   the	   full	   conditioned	  media.	  We	   identify	   a	   small	   number	   of	  proteins	  unique	   to	   the	  CMs	  and	  absent	   from	  the	  activity-­‐free	  particulate	   fractions,	  which	  are	  mechanistic	  candidates	  for	  the	  apoptotic	  activity.	  	  
Specific	  aim	  #2:	  This	  research	  aims	  to	  evaluate	  the	  effectiveness	  and	  functionality	  of	  breast	  cancer	  exosomes	  as	  diagnostic	  material.	  	  	  	  In	   addition	   to	   soluble	   extracellular	   signals,	   the	   literature	   indicates	   and	   our	  experiments	  confirm	  that	  cancer	  cell	  lines	  also	  secrete	  a	  particulate	  fraction:	  cancer	  exosomes.	   Several	   studies	   have	   highlighted	   the	   diagnostic	   potential	   of	   cancer	  exosomes.	   However	   no	   study	   has	   specifically	   and	   systematically	   addressed	   the	  protein	  composition	  of	  breast	  cancer	  exosomes.	  We	  hypothesize	  that	  breast	  cancer	  exosomes	   carry	   cell	   line	   receptors,	   and	   possibly	   also	   downstream	   cytoplasmic	  kinases,	  matching	   their	   cell	   lines	   of	   origin.	   The	   implications	   of	   this	   finding	  would	  carry	   diagnostic	   significance,	   seeing	   that	   the	   protein	   profiling	   of	   tumor	   exosomes	  could	  guide	  the	  choice	  of	  specific	  inhibitor	  treatment	  in	  a	  clinical	  setting.	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  In	  chapter	  4	  we	  therefore	  explore	  the	  diagnostic	  potential	  of	  exosomes,	  by	  screening	  six	   breast	   cancer	   cell	   lines	   and	   their	   corresponding	   exosomes	   for	   common	  diagnostic	  markers	  as	  well	  as	  downstream	  protein	  kinases.	  	  We	  follow	  this	  up	  by	  a	  proteomic	  analysis	  of	  two	  types	  of	  breast	  cancer	  exosomes,	  in	  order	  to	  formulate	  a	  broader	  understanding	  of	  overall	  content	  of	  these	  vesicles	  and	  the	  possible	  cellular	  functions	  conserved	  within	  these	  anuclear	  units.	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Chapter	  2	  
	  
Pro-­apoptotic	  Activity	  in	  Conditioned	  Medium	  Culture	  
	  
Abstract	  In	  this	  chapter	  we	  describe	  an	  approach	  that	  simultaneously	  interrogates	  the	  factors	  secreted	  by	  diverse	  breast	   cancer	   cells,	   and	   the	   response	  of	  diverse	  breast	   cancer	  cells	  to	  secreted	  factors.	  We	  develop	  a	  conditioned	  medium	  exchange	  protocol	  that	  measures	  the	  effect	  of	  factors	  generated	  by	  20	  breast	  cancer	  cell	  lines	  on	  the	  same	  20	   cell	   lines,	   in	   all	   possible	   permutations.	   We	   measure	   two	   responses	   with	  important	  roles	  in	  cancer	  biology,	  proliferation	  and	  apoptosis,	  as	  outputs	  from	  this	  conditioned	  medium	  culture	  assay.	  We	  define	  producers	  as	  the	  cells	  that	  make	  the	  conditioned	  medium,	  and	  responders	  as	  the	  cells	  that	  respond	  to	  each	  medium	  with	  changes	  in	  proliferation	  or	  apoptosis.	  We	  generate	  20x20	  matrices	  for	  the	  effects	  of	  conditioned	  medium	  and	  analyze	  them	  to	  uncover	  trends	  in	  both	  secretion	  of	  active	  factors	  and	  cell	  line	  responses.	  We	  are	  able	  to	  separate	  conditioned	  media	  in	  groups,	  depending	   on	   the	   dominant	   phenotype	   they	   induce	   on	   multiple	   responder	   lines.	  These	  include	  groups	  that	  tend	  to	  promote	  growth	  in	  responders,	  as	  well	  as	  groups	  that	   tend	   to	   promote	   apoptosis.	   Additionally,	   we	   observe	   patterns	   in	   responder	  behavior.	   Two	   conditioned	   media	   emerge	   as	   strong	   apoptotic	   inducers.	   We	  undertake	  some	  basic	  biochemical	  characterization	  of	  the	  apoptotic	  activity,	   in	  the	  form	   of	   heat-­‐shock,	   freeze/thaw,	   concentration	   and	   dilution	   series	   of	   the	  conditioned	  media.	  We	  develop	  the	  hypothesis	  that	  in	  addition	  to	  soluble	  proteins,	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these	   cancer	   cells	   also	   secrete	   a	  membranous	   particulate	   fraction	   and	   proceed	   to	  isolate	   this	   fraction	   from	  both	  conditioned	  media	  and	   test	   it	   for	  apoptotic	  activity.	  The	  activity	  assay	   is	  performed	  both	  as	  an	  apoptotic	   luminescence-­‐based	  assay	  as	  well	  as	  a	  live-­‐cell	  timelapse	  microscope	  series,	  that	  allows	  for	  closer	  observation	  of	  conditioned	  media	  responder	  cells	  and	  phenotypic	  characterization	  of	  the	  apoptotic	  phenomenon.	  
	  
2.1	   Conditioned	   Medium	   Exchange:	   a	   Platform	   for	   Unveiling	   Paracrine	  
Interactions	  in	  Breast	  Cancer.	  
	  This	   study	   is	   focused	   on	   the	   chemical	   cues	   secreted	   by	   breast	   cancer	   cells.	   More	  specifically,	   the	   aim	   of	   this	   study	   was	   to	   swap	   secreted	   protein	   cues	   between	  different	  cancer	  cells	  and	  observe	  how	  these	  impact	  cell	   fate	  decisions.	  In	  order	  to	  de-­‐couple	   the	   chemical	   from	   the	   mechanical	   interactions	   between	   distinct	   breast	  cancer	  cells,	  we	  designed	  a	  conditioned	  medium	  (CM)	  cell	  culture	  assay.	  In	  this	  first	  large	  scale	  screen	  we	  sought	  to	  answer	  the	  following	  questions:	  	  
◊ Does	  culture	  in	  pre-­‐conditioned	  medium	  affect	  the	  cell	  line	  that	  made	  it?	  
◊ How	   often	   do	   conditioned	   media	   cause	   an	   inhibitor	   or	   toxic	   effect	   on	  responder	  lines?	  How	  strong	  is	  this	  effect?	  
◊ Are	   there	   specific	   outlier	   cell	   lines	   that	   emerge	   from	   this	   screen,	   either	   as	  producers	  or	  responders?	  Do	  the	  culture	  media	  from	  some	  cell	  lines	  induce	  a	  strong	  effect	  on	  the	  majority	  of	  cancer	  cells	  tested?	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Methods	  The	   protocol	   for	   conditioned	   medium	   production	   required	   seeding	   the	   cells	   at	   a	  density	  of	  106	  cells/ml	  in	  T-­‐150	  culture	  flasks.	  Cells	  were	  allowed	  to	  adhere	  to	  flask	  surface,	  after	  which	  monolayers	  were	  washed	  twice	  with	  PBS	  and	  growth	  medium	  was	  replaced	  with	  serum-­‐free	  RPMI,	  supplemented	  with	  1%	  Penicillin-­‐Streptomycin	  and	   buffered	   with	   10mM	   Hepes.	   Conditioned	  medium	  was	   harvested	   24hrs	   later	  and	   centrifuged	   3min	   at	   1,000g	   to	   exclude	   cell	   debris.	   It	   was	   subsequently	  immediately	  transferred	  on	  the	  receiver	  cell	  lines.	  	  The	  receiver	  cell	  lines	  were	  seeded	  at	  a	  density	  of	  104	  cells/well	  in	  96-­‐well	  plates	  in	  triplicate	   wells.	   Seeding	   took	   place	   in	   regular	   growth	   medium.	   After	   24hrs,	   cell	  monolayers	   were	   washed	   twice	   with	   PBS	   and	   switched	   to	   100µl	   of	   conditioned	  medium.	  The	  chosen	  outputs	  for	  this	  assay	  were	  proliferation	  and	  apoptosis.	  EdU	  incorporation	  was	  employed	  as	  an	   indicator	  of	   cell	  proliferation.	  Therefore,	  48hrs	  after	   switching	   the	   cells	   to	   CM	   culture,	   EdU	   was	   added	   in	   the	   wells	   at	   a	   final	  concentration	  of	  10µM.	  After	  an	  additional	  24hrs	  of	  EdU	  incubation,	  cells	  were	  fixed	  and	  permeabilized	  with	  a	  solution	  of	  3.7%	  formaldehyde	  and	  0.5%	  Triton-­‐X.	  In	  total,	  the	  duration	  of	  live	  cell	  culture	  was	  5	  days.	  	  For	  proliferative	  staining,	  EdU	  was	  coupled	   to	   fluorescent	  Alexa488	  Azide	  by	  click	  chemistry.	  For	  apoptotic	  staining,	  plates	  were	  blocked	  in	  buffer	  containing	  2%	  BSA	  and	  0.3%	  TritonX,	  then	  incubated	  with	  cPARP	  mAb	  at	  1:1000	  ratio	  overnight	  at	  4C.	  Primary	   antibody	   was	   washed	   out	   and	   cells	   were	   incubated	   for	   2hrs	   at	   room	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temperature	   with	   a	   solution	   of	   1:5000	   secondary	   488	   anti-­‐mouse	   mAb	   as	   well	  1ug/ml	  Hoescht,	   in	  order	   to	  obtain	   a	   total	  nuclear	   count.	  The	  plates	  were	   imaged	  and	  scored	  on	  an	  automated	  microscope	  at	  the	  ICCB	  screening	  facility	  at	  HMS.	  	  The	   two	   outputs	   of	   the	   screen	   were:	   1)	   proliferation,	   documented	   by	   using	   the	  synthetic	  thymidine	  analogue	  EdU	  in	  the	  last	  24hrs	  of	  conditioned	  medium	  culture.	  This	  provided	  us	  with	  a	  measure	  of	   the	   fraction	  of	   the	  cell	  population	   that	  passed	  through	  S-­‐phase	  of	   the	  cell	   cycle,	   and	  constitutes	   the	  Proliferative	   Index	  (PI)	   for	  that	   cell	   line	   in	   that	   particular	   culture	   condition.	   	   2)	   Apoptosis,	   documented	   by	  cleaved-­‐PARP	  monoclonal	   antibody	   staining	   of	   the	   fixed	   cultures.	   This	   constitutes	  the	   Apoptotic	   Index	   (AI)	   of	   the	   cell	   line	   in	   a	   particular	   culture	   condition.	   In	  addition	   to	   conditioned	   medium	   (CM)	   culture,	   each	   cell	   line	   is	   also	   cultured	   in	  serum-­‐free	  (SF)	  medium	  and	  regular,	  FBS-­‐supplemented	  growth	  medium	  (Serum),	  both	   conditions	   serving	   as	   comparative	   controls.	   Another	   endogenous	   control	  condition	   in	   this	   screen	   is	   the	   cell	   line’s	   response	   to	   its	   own	   pre-­‐conditioned	  medium	  (self-­‐CM).	  Below	  we	  normalize	  and	  plot	   the	  data	   from	  this	   screen	  by	   this	  self-­‐CM	  condition.	  	  	  
20x20	  Conditioned	  Medium	  Matrices	  The	  outcome	  of	  this	  double	  apoptotic	  and	  proliferative	  conditioned	  medium	  screen	  clearly	   demonstrates	   that	   the	   swapping	   of	   extracellular	   secretions	   is	   a	   potent	  regulator	  of	  cell	   fate.	  Some	  cell	   lines	  were	  as	  high	  as	  27x	  more	  proliferative	  when	  grown	   is	  heterologous	  CM	  as	  opposed	   to	   growth	   in	   their	   own	  CM.	   Similarly	   some	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CMs	   were	   able	   to	   induce	   10-­‐fold	   more	   apoptosis	   when	   compared	   to	   the	   control	  condition.	  One	  caveat	  of	  this	  screen	  was	  that	  cells	  were	  grown	  in	  100%	  CM,	  with	  no	  addition	  of	  fresh	  medium.	  Also,	  in	  order	  to	  eradicate	  the	  strong	  proliferative	  signal	  supplied	  by	  fetal	  bovine	  serum	  in	  regular	  growth	  medium,	  the	  CMs	  were	  produced	  under	   serum-­‐free	   culture	   conditions.	   Therefore,	   at	   the	   time	   of	   the	   screen	   the	  responder	  cell	  lines	  were	  grown	  in	  serum-­‐free	  and	  nutrient-­‐depleted	  media,	  which	  possibly	   sensitized	   them	   to	   the	   secreted	   factors	   in	   the	   CMs	   and	   amplified	   their	  responses.	   One	   concern	   regarding	   some	   of	   the	   high	   apoptotic	   counts	   recorded,	   is	  that	   the	   measured	   responses	   are	   a	   result	   of	   nutrient	   depletion	   rather	   than	   toxic	  factor	  addition	  in	  the	  CMs.	  This	  concern	  is	  addressed	  in	  the	  following	  section,	  where	  the	  pro-­‐apoptotic	  nature	  of	  the	  CMs	  is	  confirmed	  by	  repeating	  some	  of	  the	  apoptotic	  assays	  in	  50%	  CM	  /	  50%	  SF	  culture	  conditions.	  	  	  Furthermore,	   in	   accordance	   to	   our	   original	   expectation,	   the	   screen	   points	   to	   two	  outlier	   CMs	   that	   demonstrate	   strong	   pro-­‐apoptotic	   effect	   in	   the	   majority	   of	  responder	  cell	  lines.	  CM	  HCC38	  and	  CM	  BT20	  were	  singled	  out	  since	  they	  were	  able	  to	   induce	   significant	   apoptosis	   in	   15	   and	   16	   out	   of	   the	   19	   cell	   lines	   respectively	  (fig2.1).	  Interestingly	  enough,	  CM	  HCC38	  is	  not	  pro-­‐apoptotic	  to	  BT20	  cells	  and	  the	  opposite	   is	   also	   true:	   CM	   BT20	   is	   not	   pro-­‐apoptotic	   to	   HCC38	   cells.	   A	   possible	  interpretation	  of	  this	  phenomenon	  is	  that	  the	  pro-­‐apoptotic	  effect	  of	  both	  media	  is	  due	  to	  a	  common	  apoptosis-­‐inducing	  secreted	  factor.	  Most	  cell	  lines	  are	  sensitive	  to	  the	  factor,	  yet	  the	  producer	  cell	  lines	  are	  resistant	  to	  autocrine	  stimulation	  in	  order	  to	  be	  able	  to	  grow	  and	  thrive	  in	  its	  presence.	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19),	   including	   BT20	   cells.	   While	   in	   the	   apoptotic	   dataset	   the	   two	   CMs	   behave	  similarly,	   the	   proliferative	   dataset	   implies	   that	   there	   are	   also	   differences	   in	   the	  mechanism	  of	  action	  of	  the	  two	  CMs.	  	  
CM	  Typing	  According	  to	  Dominant	  Phenotype	  Induction	  When	   comparing	   the	   two	   data	   matrices,	   one	   surprising	   finding	   was	   that	   pro-­‐apoptotic	  CMs	  are	  not	  necessarily	  endowed	  with	  anti-­‐proliferative	  activity.	  Instead	  distinct	  CM-­‐responder	  pairs	  scored	  all	  over	  the	  quadrants	  of	  low-­‐proliferation/high	  apoptosis,	   low-­‐proliferation/low-­‐apoptosis,	   high-­‐proliferation/low-­‐apoptosis	   and	  high	  proliferation/high	  apoptosis,	  as	  demonstrated	  in	  figure	  2.3.	  This	  is	  perhaps	  not	  as	   surprising	   when	   considering	   that	   in	   cancer	   cells	   the	   apoptosis	   and	   survival	  pathways	  are	  cross-­‐wired.	  Figure	  2.3	  is	  a	  closer	  look	  at	  this	  phenomenon.	  Here	  the	  CMs	  are	  classified	  in	  different	  program	  categories	  depending	  on	  their	  apoptotic	  and	  proliferative	  readouts:	  	  	  
◊ The	  growth	  program	  is	  defined	  as	  a	  high	  proliferative	  index	  combined	  with	  a	  low	  apoptotic	  index,	  corresponding	  to	  32%	  of	  responders.	  
◊ The	   opposite	   of	   this	   is	   the	  death	   program,	   defined	   by	   a	   low	   proliferative	  index	   matched	   by	   a	   high	   apoptotic	   index,	   corresponding	   to	   34%	   of	  responders.	   In	   addition	   to	   these	   two	   programs	   of	   approximately	   equal	  prevalence	  in	  the	  20x20	  dataset,	  we	  also	  observe	  two	  hybrid	  states.	  
◊ The	   acceleration	   program,	   where	   both	   the	   proliferative	   and	   apoptotic	  indices	  are	  high,	  which	  amounted	  to	  29%	  of	  responders.	  These	  are	  CMs	  that	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stimulate	   a	   higher	   proliferation	   but	   also	   cause	   higher	   apoptosis	   in	   the	  responder	  cells.	  	  Interestingly	  enough	  this	  state	  is	  almost	  as	  prevalent	  as	  the	  more	  clear-­‐cut	  growth	  and	  death	  programs	  in	  the	  dataset.	  
◊ Finally	   the	   deceleration	   program,	   defined	   as	   low	   proliferative	   and	  apoptotic	  indices.	  This	  program,	  at	  5%	  occurrence,	  is	  the	  least	  frequent	  in	  the	  data.	   The	   biological	   significance	   of	   this	   program	   is	   potentially	   cell	  senescence.	  	  	  In	   figures	   2.3b	   to	   2.3e	   CMs	   are	   grouped	   together	   according	   to	   their	   dominant	  phenotype	  induction	  based	  on	  the	  above	  model.	  It	  is	  noteworthy	  that	  no	  one	  CM	  is	  consistently	   able	   to	   induce	   the	   deceleration	   program.	   Instead,	   about	   half	   the	   CMs	  trigger	  the	  deceleration	  program	  is	  one	  or	  two	  cell	  lines	  at	  a	  time.	  	  Also	  of	  interest,	  the	   CMs	   that	   demonstrate	   high	   acceleration	   program	   counts	   (panel	   2.3d),	   no	  deceleration	   activity	   was	   observed,	   which	   implies	   that	   in	   these	   CMs	   the	   two	  programs	  are	  mutually	  exclusive.	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apoptotic	  and	  proliferative	  readouts,	  the	  growth,	  acceleration	  and	  death	  programs	  were	  almost	  equal	  in	  their	  prevalence	  whereas	  the	  deceleration	  program	  occurred	  rarely	  in	  our	  dataset.	  	  b)	  This	  group	  of	  CMs	  demonstrates	  death-­‐promoting	  activity	  in	  the	  majority	  of	  responder	  cell	  lines.	  c)	  In	  contrast,	  this	  group	  of	  CMs	  promoted	  growth	  in	  the	  majority	  of	  responders.	  d)	  This	  group	  of	  CMs	  induced	  an	  acceleration-­‐promoting	   program	   in	   most	   responders	   tested.	   e)	   The	   remaining	   CMs	   are	   plotted	  together	  in	  this	  chart.	  There	  was	  no	  majoritary	  program	  induced	  in	  these	  cases,	  but	  instead	  the	  CMs	  had	  varied	  effects	  dependent	  on	  the	  responder	  cells.	  	  The	  difference	  between	  the	  two	  most	  pro-­‐apoptotic	  CM	  hits	  is	  salient	  in	  figure	  2.3.	  CM	  BT20	  induces	  a	  strong	  death	  phenotype	   in	  the	  majority	  of	  responder	  cell	   lines	  while	  a	  couple	  of	  cell	  lines	  score	  in	  the	  acceleration	  category	  under	  its	  influence.	  On	  the	  other	  hand,	  CM	  HCC38	  is	  a	  mild	  player	  in	  the	  acceleration	  category,	  counting	  9	  accelerating	   responders.	   However,	   seven	   more	   responders	   commit	   to	   a	   death	  phenotype	   upon	   CM	   HCC38	   stimulation.	   	   Both	   CMs	   induce	   growth	   in	   a	   small	  minority	  of	  responders.	  Based	  on	  this	  we	  expect	  the	  two	  strong	  pro-­‐apoptotic	  CMs	  to	  share	  some	  similarities	  in	  content.	  Possibly	  a	  common	  set	  of	  toxic	  factors,	  yet	  at	  different	   concentrations,	   or	   a	   common	   strong	   toxic	   factor	   in	   combination	   with	   a	  diverse	  and	  different	  set	  of	  growth	  factors.	  	  	  
	  
2.2	  Correlation	  of	  Phenotypic	  Matrices	  to	  Cell	  Line	  Molecular	  Subtype	  	  Breast	  cancer	  is	  classified	  into	  three	  categories,	  depending	  on	  expression	  of	  surface	  markers.	   Breast	   cancers	   which	   express	   the	   estrogen	   (ER)	   and	   progesterone	   (PR)	  receptors	   are	   known	   as	   luminal	   and	   are	   targeted	   by	   hormonal	   therapies.	   Cancers	  which	   show	   human-­‐epidermal-­‐growth-­‐factor-­‐receptor-­‐2	   amplification	   (HER2)	   are	  labeled	   as	   HER2+	   and	   are	   clinically	   targeted	   by	   the	   monoclonal	   antibody	  Trastuzumab.	  Those	  which	  are	  negative	   for	  ER,	  PR	  and	  HER2	  are	  known	  as	   triple	  negative	  breast	  cancers,	  and	  constitute	  a	  clinical	  challenge	  since	  there	  exists	  yet	  no	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targeted	  molecular	   therapy	   for	   them.	   In	   table	   1,	   the	   cell	   lines	   used	   in	   the	   20x20	  conditioned	   medium	   are	   classified	   according	   to	   the	   presence	   of	   these	   critical	  receptors1,2.	   The	   table	   and	   subsequent	   data	   analysis	   in	   this	   section	   excludes	   cell	  lines	  HCC1395	  and	  HCC1419,	  since	  we	  were	  unable	  to	   identify	  the	  receptor	  status	  information	  of	  these	  cells	  in	  the	  literature.	  	  
	  Table	  2.1:	  Breast	  cancer	  cell	  line	  classification	  according	  to	  receptor	  status1,2.	  	  The	  analysis	  presented	  in	  this	  section	  aims	  to	  answer	  the	  following	  questions:	  	  
◊ On	  average,	  are	  there	  trends	   in	  how	  each	  cell	   line	  category	  responds	  to	  CM	  stimulation?	  	  
◊ Which	   CMs	   have	   the	   strongest	   effect	   in	   each	   category	   of	   responders?	   And	  inversely,	  how	  does	  each	  CM	  category	  affect	  each	  cell	  line?	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Methods	  To	  address	  each	  question	  we	  use	  slightly	  different	  strategies.	  We	  average	  over	  the	  proliferative/apoptotic	  indices	  for	  each	  cell	  line	  in	  each	  CM	  category.	  By	  plotting	  the	  bar	  chart	  of,	  for	  example,	  MCF7	  response	  to	  CMs	  derived	  from	  luminal,	  HER2+	  and	  triple	   negative	   cell	   lines	   we	   are	   able	   to	   distinguish	   which	   CM	   ensemble	   was	   on	  average	  more	  toxic	  to	  these	  cells	  and	  by	  how	  much.	  We	  omit	  the	  control	  condition	  of	  cell	   line	  response	   to	   its	  own	  CM,	  as	   the	  dataset	  has	  been	  normalized	   to	   that	  value	  and	   including	   it	   in	   the	   CM-­‐ensemble	  would	   bias	   that	   ensemble’s	   average	   towards	  the	  value	  of	  1.	  	  	  Next	   we	   want	   to	   investigate	   whether	   several	   cell	   lines	   within	   a	   receptor	   status	  group	  respond	  similarly	  to	  luminal/HER2+/triple	  negative	  CM	  stimulation.	  For	  this	  purpose	  we	  construct	  the	  correlation	  matrix	  that	  compares	  apoptotic/proliferative	  indices	  between	   two	  cell	   line	   responders	   for	  all	   cell	   line	  pair	  permutations	  within	  that	  group.	  The	  correlation	  function	  employed	  for	  these	  charts	  is:	  
	  
	  Where	   	  and	   	  are	  the	  average	  apoptotic/proliferative	   indices	  for	  cell	   line	  x	  and	  cell	  line	  y	  respectively.	  	  	  
! 
Correlation(x,y) = (x " x )(y " y )#
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Finally,	  after	  inspecting	  all	  correlation	  matrices	  we	  single	  out	  the	  datasets	  exhibiting	  highest	  correlation	  and	  plot	  the	  corresponding	  line	  charts	  of	  cell	  line	  response	  to	  CM	  stimulation.	  These	  line	  charts	  allow	  for	  a	  closer	  inspection	  of	  which	  CMs	  within	  the	  ensemble	   drive	   the	   response	   curves,	   as	  well	   as	  which	   cell	   lines	   in	   the	   set	   are	   the	  strongest	  responders.	  	  
Luminal	  Responders	  Upon	  observation	  of	  the	  luminal	  responder	  panel	  (figure	  2.4),	  we	  note	  that	  luminal	  cell	   lines	   are	   the	   most	   adversely	   affected	   by	   conditioned	   medium	   culture.	   When	  comparing	   figure	   2.4a,	   to	   figures	   2.5a	   and	   2.6a	   it	   was	   observed	   that	   the	   average	  proliferative	   indices	   in	   luminal	   cell	   lines	   are	   lower	   that	   in	   HER2+	   and	   in	   triple	  negative	  cells.	  We	  conclude	  that	  luminal	  cells	  are	  significantly	  dependent	  upon	  fetal	  bovine	   serum	   growth	   factors	   to	   proliferate	   in	   culture	   and	   are	   therefore	   more	  impacted	  by	  conditioned	  medium	  serum-­‐free	  culture.	  Figure	  2.4b	  indicates	  that	  for	  most	   luminal	   cells	   (with	   the	   exception	   of	   CAMA1	   and	   LY2),	   luminal	   CMs	  were	   on	  average	   less	   apoptosis-­‐inducing	   than	   HER2+	   CMs	   and	   that	  moreover	   HER2+	   CMs	  were	   less	   apoptosis-­‐inducing	   than	   triple	   negative	   CMs.	   The	   pattern	   is	   completely	  reversed	  for	  CAMA1	  cells.	  	  The	  correlation	  matrices	  2.4c	  and	  2.4d	  do	  not	   indicate	  any	  coherence	  between	  the	  luminal	  cell	  responses	  to	  HER2+	  CMs.	  However,	  we	  do	  observe	  a	  higher	  correlation	  of	   responses	   to	   triple	   negative	   CMs.	   The	   correlation	   is	   strongest	   in	   the	   apoptotic	  index	  matrix	  (figure	  2.4f),	  but	  also	  present	  for	  the	  some	  of	  the	  same	  cell	  line	  pairs	  in	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the	  proliferative	  matrix	  (figure	  2.4e).	  The	  corresponding	  line	  charts	  (figure	  2.4g	  and	  2.4h)	   show	   that	   all	   luminal	   cell	   line	   responses	   converge	   to	   roughly	   the	   same	  proliferative	  and	  apoptotic	  index	  for	  CM	  HS578T.	  Proliferative	  indices	  also	  converge	  for	   in	   CM	   BT20	   culture.	   In	   addition,	   CM	   BT20	   and	   CM	   HCC38	   are	   the	   top	   pro-­‐apoptotic	  media	  for	  luminal	  cells,	  eliciting	  the	  highest	  apoptotic	  indices.	  MCF7,	  T47D	  and	  600MPE	  are	  the	  most	  sensitive	  cell	  lines	  to	  these	  CMs,	  whereas	  LY2,	  ZR751	  and	  CAMA1	  also	  respond	  with	  heightened	  apoptosis	  but	  to	  a	  lesser	  extent.	  	  	  
HER2+	  Responders	  In	  the	  HER2+	  panel,	  cell	  lines	  BT474	  and	  ZR7530	  are	  the	  strongest	  responders	  both	  in	  the	  apoptotic	  as	  well	  as	  the	  proliferative	  dataset	  (figure	  2.5a	  and	  2.5b).	  Luminal	  CMs	   are	   on	   average	  more	   proliferative	   and	   less	   apoptotic	   than	   HER2+	   and	   triple	  negative	   CMs.	   This	   observation	   is	   somewhat	   surprising	   since	   it	   implies	   that	  permuting	   CMs	   within	   the	   group	   of	   HER2+	   cells	   yields	   pro-­‐apoptotic	   and	   anti-­‐proliferative	   reactions.	   There	   appears	   to	   be	   a	   competitive	   mechanism	   in	   place	  between	  HER2+	  cell	  lines.	  Particularly	  for	  BT474	  and	  ZR7530,	  the	  HER2+CMs	  yield	  the	   highest	   apoptotic	   indices,	   whereas	   for	   the	   remainder	   of	   the	   HER2+	   cell	   lines	  triple	  negative	  CMs	  take	  the	  apoptotic	  lead.	  	  	  In	   inspecting	   the	   correlation	  matrices	  we	  note	   once	   again	   that	   the	   triple	   negative	  apoptotic	  matrix	  (figure	  2.5f)	  is	  the	  one	  of	  highest	  correlation.	  We	  subsequently	  plot	  the	  CM-­‐response	  line	  charts	  (figure	  2.5g)	  and	  see	  that	  once	  again	  CM	  BT20	  and	  CM	  HCC38	  yield	  the	  highest	  apoptotic	  counts,	  with	  BT474,	  ZR7530	  and	  SKBR3	  being	  the	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highest	   responders.	   In	   comparison	   to	   the	   luminal	   responders	  however,	  where	   the	  apoptotic	   indices	   were	   10-­‐fold	   higher	   than	   control,	   the	   HER2+	   responders	   only	  climb	  up	  to	  4-­‐fold.	  There	  is	  one	  more	  similarity	  between	  figures	  2.4h	  and	  2.5g	  and	  that	  is	  the	  response	  to	  CM	  MDA435s:	  apoptotic	  indices	  converge	  for	  this	  CM	  on	  both	  luminal	  and	  HER2+	  responder	  charts.	  	  
Triple	  Negative	  Responders	  On	   this	   responder	   panel,	   HCC1143	   is	   a	   clear	   outlier	   in	   the	   proliferation	  measurement	   (figure	   2.6a).	   This	   cell	   line	   becomes	   14-­‐fold	   more	   proliferative	   in	  conditioned	  medium	   from	  any	   category	  of	   cells!	   It	   is	   unlikely	   that	   this	   indicates	   a	  high	   proliferative	   activity	   of	   every	   CM	   when	   used	   on	   HCC1143	   cells.	   Rather	   we	  interpret	   this	   as	   a	   rare	   occasion	  when	   the	   normalizing	   condition	   of	   culturing	   the	  cells	  in	  their	  own	  pre-­‐conditioned	  CM	  resulted	  in	  a	  very	  low	  proliferative	  count.	  All	  other	   triple	   negative	   cells	   exhibit	   very	   mild	   proliferative	   activity	   that	   is	   slightly	  higher	  when	  they	  are	  culture	  in	  luminal	  CMs.	  	  The	  apoptotic	  bar	  chart	  (figure	  2.6b)	  indicates	  that	  most	  triple	  negative	  cells	  remain	  unaffected	  by	  CM	  culture.	  Combined	  with	  the	  proliferative	  results	  this	   implies	  that	  triple	   negative	   cells	   are	   the	   least	   dependent	   on	   soluble	   environmental	   cues	   for	  proliferation	   and	   survival.	   	   They	   are	   located	   therefore	  on	   the	  opposite	   side	  of	   the	  spectrum	   from	   luminal	   cells,	   which	   as	   previously	   discussed	   were	   the	   most	  sensitized	   to	   environmental	   cues.	   Within	   the	   triple	   negative	   group,	   HCC38	   and	  MDA435s	  cells	  exhibit	  the	  highest	  apoptotic	  counts.	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  The	   correlation	  heatmaps	   that	   follow	   indicate	  high	   correlation	   in	   the	  proliferative	  response	  of	  triple	  negative	  cells	  to	  HER2+	  CMs	  (figures	  2.6c	  and	  2.6e).	  We	  plot	  the	  corresponding	  line	  chart,	  excluding	  the	  HCC1143	  outlier,	  on	  figure	  2.6f.	  All	  cell	  lines	  in	   the	   chart	   follow	   the	   same	   response	   pattern,	   with	   HS578T	   and	   BT20	   being	   the	  strongest	  responders	  of	  the	  group,	  while	  CM	  ZR7530	  and	  CM	  HCC1569	  are	  the	  most	  proliferative	  stimulants.	  	  	  As	  a	  final	  reflection	  on	  the	  20x20	  dataset,	  we	  asked	  the	  question	  of	  how	  did	  triple	  negative	   CMs	   affect	   triple	   negative	   cells.	   Particularly	   since	   it	   was	   previously	  observed	   that	   two	   triple	   negative	   CMs	   -­‐CM	   BT20	   and	   CM	   HCC38-­‐	   yielded	   high	  apoptotic	  counts	  in	  HER2+	  and	  luminal	  cells,	  we	  wanted	  to	  see	  how	  these	  fare	  when	  used	   to	   induce	  apoptosis	   in	   the	  more	  aggressive	   triple	  negative	  cell	   lines.	  For	   this	  purpose	   we	   construct	   figure	   2.7,	   where	   the	   triple	   negative	   proliferative	   and	  apoptotic	  responses	  are	  charted	  on	  two	  different	  axes	  for	  four	  triple	  negative	  CMs.	  We	  observe	  that	  the	  pro-­‐apoptotic	  CMs	  BT20	  and	  HCC38	  induce	  a	  similar	  response	  pattern	   on	   triple	   negative	   cells.	   Both	   CMs	   stimulate	   the	   proliferation	   of	   HCC1143	  cells	   but	   beyond	   that	   did	   not	   exhibit	   any	   significant	   proliferative	   effect	   on	   the	  remaining	  charted	  cells.	  Interestingly,	  the	  apoptosis	  curves	  demonstrated	  that	  both	  CMs	   are	   mildly	   pro-­‐apoptotic	   to	   HCC1937	   cells	   and	   more	   strongly	   apoptotic	   to	  MDA435s	   cells.	   In	   the	   remaining	   triple	  negative	   cell	   lines,	   they	  do	  not	   induce	   and	  apoptotic	  effect	  and	  that	  includes	  a	  mutual	  apoptosis-­‐proof	  relationship.	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For	  comparative	  purposes	  we	  included	  the	  CM	  HS578T	  and	  CM	  HCC1143	  responses	  on	   figure	  2.7c	   and	  2.7d	   respectively.	  Here	  we	   see	   a	  different	   trend.	   In	   addition	   to	  HCC1937	   and	   MDA435s,	   HCC38	   cells	   responded	   to	   both	   these	   CMs	   with	   high	  apoptotic	   indices,	   while	   BT20	   are	   still	   at	   neutral	   apoptotic	   level.	   The	   trend	   is	  conserved	  in	  the	  proliferative	  curves,	  which	  to	  a	  great	  extent	  mirror	  the	  apoptosis	  curves.	   The	   lower	   the	   apoptotic	   count	   the	   higher	   the	   proliferative	   count	   and	   vice	  versa	   for	   these	   two	  CMs.	  More	   specifically,	   the	  BT20	  proliferative	   response	   to	  CM	  HS578T	   is	   once	   again	   neutral,	   while	   the	   remainder	   of	   the	   cell	   lines	   are	  proliferatively	   suppressed	   by	   this	   CM.	   CM	  HCC1143	   gives	   a	   proliferative	   boost	   to	  HS578T	  and	  BT20	  cells,	  while	  it	  proliferatively	  suppresses	  HCC1937	  and	  HCC38.	  	  	  In	  conclusion,	  there	  is	  no	  single	  CM	  that	  successfully	  inhibits	  all	  triple	  negative	  cell	  lines.	  MDA435s	  cells	  were	  the	  most	  successfully	   inhibited	  triple	  negative	  cells	  and	  CM	  HCC38/	  CM	  BT20	  inhibited	  these	  more	  strongly	  than	  other	  triple	  negative	  CMs.	  In	  addition	  CM	  HCC38	  and	  CM	  BT20	  elicited	  a	  similar	  response	  pattern	  from	  triple	  negative	  cells,	   that	  was	  distinct	   from	  other	  triple	  negative	  CM	  patterns.	  This	   is	  yet	  another	  similarity	  that	  points	  to	  the	  possibility	  of	  common	  secreted	  factors	  in	  these	  two	  cell	  lines.	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triple	  negative	  	  CM	  stimulation.	  g)	  Line	  chart	  of	  apoptotic	  indices	  illustrating	  HER2+	  response	  to	  triple	  negative	  CMs.	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and	  apoptotic	  indices	  respectively	  derived	  from	  triple	  negative	  responders	  to	  luminal	  CM	  stimulation.	  e)	  and	  f)	  Correlation	  matrices	  of	  	  proliferative	  and	  apoptotic	  indices	  respectively	  derived	  from	  triple	  negative	  responders	  	  to	  triple	  negative	  	  CM	  stimulation.	  g)	  Line	  chart	  of	  proliferative	  indices	  illustrating	  triple	  negative	  response	  to	  luminal	  CMs.	  HCC1143	  response	  is	  excluded	  from	  the	  chart	  due	  to	  being	  a	  strong	  outlier	  in	  the	  group.	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2.3	  Biochemical	  Characterization	  of	  Apoptosis-­Inducing	  Conditioned	  Medium	  This	  section	  examines	  the	  apoptotic	  effect	  induced	  by	  CM	  HCC38	  more	  closely	  and	  seeks	  to	  identify	  the	  extent	  to	  which	  this	  effect	  can	  be	  concentrated	  and	  diluted.	  In	  addition	  we	   test	  whether	   the	   apoptotic	   effect	   is	   heat	   labile	   and	  whether	   it	   can	  be	  cryo-­‐preserved.	   Finally,	   we	   fractionate	   CM	   HCC38	   into	   large	   and	   small	   vesicular	  fractions	  then	  test	  all	  fractions	  for	  apoptotic	  activity.	  	  	  
Methods	  
M30	  CytoDeath	  ELISA	  The	   assay	   employed	   for	   apoptosis	   quantification	   in	   this	   section	   is	   the	   M30	  CytoDeath	  ELISA	  (Peviva).	  This	  assay	  is	  founded	  upon	  the	  biological	  knowledge	  that	  caspases	  cleave	  various	  cellular	  proteins	  during	  apoptosis.	  In	  epithelial	  cells,	  one	  of	  those	   substrates	   is	   the	   intermediate	   filament	   protein	   keratin	   18	   (K18).	   The	   M30	  antibody	  recognizes	  a	  neo-­‐epitope	  exposed	  after	  caspase	  cleavage	  of	  K18	  after	  the	  aspartic	  acid	  residue	  396	  3.	  Cleavage	  at	  this	  position	  occurs	  early	  during	  apoptosis	  by	  caspase-­‐9	  and	  during	  the	  execution	  phase	  by	  caspase-­‐3	  and	  caspase-­‐7	  4.	  The	  M30	  CytoDeath	   ELISA	   measures	   the	   levels	   of	   soluble	   caspase-­‐cleaved	   K18	   (ccK18)	  fragments	   containing	   the	   K18Asp396	   neo-­‐epitope.	   After	   induction	   of	   apoptosis	   of	  epithelial	  cells,	  ccK18	  increases	  are	  first	  observed	  in	  cell	  extracts.	  Release	  of	  antigen	  into	  the	  extracellular	  compartment	  occurs	  later	  and	  is	  due	  to	  secondary	  necrosis	  of	  apoptotic	  bodies.	  The	  ccK18	  increase	  during	  apoptosis	   is	   inhibited	  by	  the	  caspase-­‐inhibitor	   zVAD-­‐fmk.	   The	   M30	   capture	   antibody	   is	   a	   mouse	   monoclonal	   IgG2b	  antibody	  suitable	  for	  human,	  monkey	  and	  bovine	  cells.	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Assay	  Procedure	  For	  the	  purpose	  of	  this	  assay	  receiver	  cell	  lines	  MDAMB231	  and	  MCF7	  were	  seeded	  at	  a	  density	  of	  10,000	  cells/well	  in	  96	  well	  plates	  in	  duplicate.	  Cells	  were	  allowed	  to	  sediment	  and	  adhere	  to	  the	  plate	  bottom	  overnight,	  after	  which	  the	  culture	  medium	  was	   replaced	   with	   serum	   free	   RPMI	   and	   serum	   supplemented	   RPMI:	   the	   two	  negative	   controls	   in	   this	   assay.	   We	   employed	   a	   known	   apoptotic	   agent,	  staurosporine,	  as	  a	  positive	  control	  at	  a	  2	  µM	  final	  well	  concentration.	  We	  incubated	  cells	  with	  controls	  and	  experimental	  conditions	  for	  48hrs.	  Cells	  were	  then	  lysed	  by	  the	   addition	   of	   10	   µL	   10%	  NP-­‐40	   and	   shaking	   the	   plate	   at	   room	   temperature	   for	  5min	  	  before	  proceeding	  with	  cell	  lysis	  and	  quantification	  of	  the	  CK18	  substrate.	  	  25	  µL	   from	   each	   well	   were	   transferred	   on	   M30	   mAb-­‐coated	   ELISA	   plate	   and	   the	  incubations	   and	   washes	   were	   performed	   according	   to	   the	   assay	   manufacturer’s	  instructions5.	   The	   absorbance	   at	   450nm	   was	   measured	   on	   a	   Perkin	   Elmer	  microplate	  reader	  and	  converted	  to	  units/L	  of	  CK18	  based	  on	  a	  recombinant	  CK18	  calibration	  control	  curve.	  	  
Conditioned	  Medium	  Production	  The	  conditioned	  medium	  for	  this	  assay	  was	  produced	  much	  like	  in	  chapter	  1.	  HCC38	  cells	   were	   seeded	   at	   a	   density	   of	   106	   cells/ml	   in	   T-­‐150	   culture	   flasks.	   Cells	   were	  allowed	  to	  adhere	  to	  flask	  surface,	  after	  which	  monolayers	  were	  washed	  twice	  with	  PBS	  and	  growth	  medium	  was	   replaced	  with	   serum-­‐free	  RPMI,	   supplemented	  with	  1%	  Penicillin-­‐Streptomycin	   and	   buffered	  with	   10mM	  Hepes.	   Conditioned	  medium	  was	  harvested	  48hrs	  later	  and	  centrifuged	  3min	  at	  1,000g	  to	  exclude	  cell	  debris.	  For	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the	  1x	  CM	  HCC38	  experimental	  condition,	  100µL	  of	  CM	  were	  directly	  transferred	  on	  the	  receiver	  cell	  well.	  	  	  
Concentration	  and	  Dilution	  Series	  For	   the	   CM	   concentration	   series,	   100ml	   of	   CM	  HCC38	  were	   passed	   through	   a	   3K	  centrifugal	   filtration	  device,	  decanting	  and	   filtrate	  and	  conserving	   the	  concentrate,	  until	   the	   original	   CM	   volume	   was	   reduced	   down	   to	   8ml.	   This	   constituted	   a	   12x	  concentrated	   CM	   solution,	   100	   µL	   of	   which	  were	   transferred	   on	   the	   receiver	   cell	  wells.	  For	  the	  lower	  concentrations	  of	  6x,	  3x	  and	  2x,	  we	  diluted	  the	  12x	  concentrate	  with	  the	  appropriate	  amount	  of	  serum	  free	  RPMI.	  For	  the	  CM	  dilution	  series	  newly	  harvested	   CM	   HCC38	   was	   diluted	   down	   3x,	   10x,	   30x	   and	   100x	   with	   serum	   free	  RPMI.	  	  	  
Freeze/Thaw	  and	  Heat	  Shock	  For	   the	   freeze/thaw	  portion	  of	   the	  experiment,	  120µL	  aliquots	  of	  6x	  concentrated	  CM	   HCC38	   were	   snap-­‐frozen	   in	   liquid	   nitrogen	   and	   subsequently	   thawed	   and	  immediately	   transferred	   on	   receiver	   cell	   wells.	   For	   the	   heat	   shock	   portion	   of	   the	  experiment,	  120µL	  aliquots	  of	  6x	   concentrated	  CM	  HCC38	  were	  heated	  at	  95C	   for	  10min	   then	   briefly	   centrifuged	   to	   bring	   condensation	   back	   in	   solution.	   The	   CMs	  were	  subsequently	  transferred	  on	  receiver	  cell	  wells.	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Particulate	  Fractionation	  For	   the	   fractionation	   portion	   of	   the	   experiment,	   a	   series	   of	   centrifugations	   was	  employed	   to	  differentially	  precipitate	  membranous	  particles	  of	   varied	   sizes	  out	  of	  the	   CM.	   The	   centrifugation	   method	   is	   extensively	   discussed	   in	   chapter	   3.	   Briefly,	  100ml	  of	   conditioned	  medium	  were	  harvested	   from	   cells	   and	   centrifuged	   at	   300g	  for	   10	  min	   to	   remove	   cells,	   then	   at	   2000g	   for	   10min	   to	   remove	   apoptotic	   bodies.	  Conditioned	   medium	   was	   subsequently	   passed	   through	   a	   3k	   centrifugal	   filtering	  device	  at	  4000g	  for	  30min	  in	  order	  to	  concentrate	  the	  large	  CM	  volume	  down	  to	  a	  few	  milliliters.	  	  The	  concentrated	  CM	  was	  ultra-­‐centrifuged	  at	  10,000g	  for	  30min	  to	  pellet	  cell	  debris	  and	  large	  vesicles.	  The	  pellet	  from	  this	  step	  was	  conserved	  and	  re-­‐suspended	   in	   300µL	   of	   PBS.	   Each	   receiver	   cell	   well	   received	   60	   µL	   of	   this	   giant	  vesicle	  fraction	  (guv)	  in	  addition	  to	  100	  µL	  of	  serum	  free	  RPMI.	  	  	  The	   supernatant	   from	   this	   centrifugation	   step	   was	   further	   ultra-­‐centrifuged	   at	  100,000g	  for	  70min	  to	  pellet	  the	  exosomes.	  The	  exosomal	  pellet	  underwent	  a	  final	  wash	  step	  and,	  was	   re-­‐suspended	   in	  300	  µL	  PBS.	  Similarly,	   each	  receiver	  cell	  well	  received	  60	  µL	  of	   this	  exosome	   fraction	   (exo)	   in	  addition	   to	  100	  µL	  of	   serum	   free	  RPMI.	   Finally,	   the	   supernatant	   (exosup)	   from	   the	   ultracentrifugation	   spin,	   which	  amounts	  to	  approximately	  a	  12x	  concentrated	  CM,	  was	  conserved	  and	  100	  µL	  of	  it	  were	  transferred	  onto	  the	  receiver	  cell	  wells.	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Statistical	  Analysis	  For	  statistical	  analysis	  of	  MDAMB231	  apoptotic	  results,	  all	  experimental	  conditions	  were	   compared	   to	   serum	   supplemented	   culture	   and	   statistical	   significance	   was	  determined	   by	   performing	   unpaired,	   two–tailed,	   homoscedastic	   t-­‐tests.	   For	   the	  statistical	   analysis	   of	   MCF7	   apoptotic	   results,	   all	   experimental	   conditions	   were	  compared	  to	  serum	  free	  culture	  since	  it	  was	  found	  to	  be	  significantly	  more	  apoptotic	  than	  the	  serum	  supplemented	  condition.	  Statistical	  significance	  was	  determined	  by	  performing	  unpaired,	  two–tailed,	  homoscedastic	  t-­‐tests.	  In	  both	  cases	  P-­‐values	  were	  computed.	   Results	   are	   graphically	   represented	   as	   average	   values	   over	   duplicate	  experimental	  conditions	  with	  error	  bars	  denoting	   the	  standard	  deviation	   from	  the	  mean.	  	  
Concentration	  and	  Dilution	  Series	  of	  CM	  HCC38	  For	   both	   receiver	   cell	   lines,	   MDAMB231	   and	   MCF7,	   the	   concentration	   series	  indicates	   that	   the	   apoptotic	   effect	   can	   indeed	   be	   concentrated	   in	   the	   conditioned	  medium	  (figures	  2.8a	  and	  2.8c).	  As	  mentioned	  in	  the	  methods	  section,	  concentration	  was	   achieved	   by	   centrifugal	   filtration	   through	   a	   3,000kDa	   membrane.	   When	  comparing	  3x	  and	  2x	  concentrated	  CM	  HCC38	  to	  1x	  non-­‐concentrated	  CM	  HCC38	  we	  see	  that	   in	  both	  cases	  the	  concentration	  results	   in	  some	  loss	  of	  potency	  of	  the	  CM.	  	  We	  hypothesize	  that	  this	  is	  due	  to	  retention	  of	  small	  quantities	  of	  the	  active	  factor	  in	  the	  centrifugal	  device.	  By	  consequence,	  the	  3x	  concentrated	  CM	  HCC38	  is	  equivalent	  in	  apoptotic	  potency	  to	  the	  1x	  unperturbed	  CM	  HCC38.	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A	   closer	   look	   to	   MDAMB231	   apoptotic	   response	   (figure	   2.8a)	   reveals	   that	  staurosporine-­‐induced	  apoptosis	  produces	  a	   lower	  concentration	  of	   cytokeratin18	  fragments	  when	   compared	   to	   CM-­‐induced	   apoptosis.	   This	  was	   a	   puzzling	   finding,	  particularly	   because	   after	   visual	   inspection	   of	   the	   staurosporine-­‐treated	  wells	  we	  see	  that	  2µM	  of	  staurosporine	  are	  quite	  effective	  at	  killing	  the	  entire	  cell	  content	  of	  the	  well	  within	  a	   few	  hours.	  One	  possible	  explanation	  of	   this	  phenomenon	   is	   that,	  particularly	   in	   MDAMB231	   cells,	   staurosporine-­‐induced	   cell	   death	   follows	   a	  different	  apoptotic	  pathway	  that	  is	  not	  as	  reliant	  in	  caspase	  3,	  caspase	  9	  and	  caspase	  7	  –the	  three	  caspases	  that	  cleave	  cytokeratin18.	  In	  contrast,	  the	  data	  indicates	  that	  CM	   HCC38-­‐induced	   apoptosis	   relies	   on	   this	   caspase-­‐dependent,	   cytokeratin18-­‐cleaving	  pathway.	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Figure	  2.7:	  Concentration	  and	  dilution	  series	  of	  CM	  HCC38	  using	  the	  M30	  ELISA	  apoptotic	  readout	  assay.	  Bars	  denote	  average	  values	  over	  duplicate	  wells	  and	  error	  bars	  denote	  standard	  deviation	  from	  the	  mean.	  Statistical	  significant	  is	  determined	  by	  un-­‐paired,	  two-­‐tailed,	  homoscedastic	  T-­‐tests.	  	  A	  single	  *	  denotes	  P	  ≤	  0.05,	  a	  double	  **	  denotes	  P	  ≤	  0.01	  a	  triple	  ***	  denotes	  P	  ≤	  0.001	  while	  ns	  stands	  for	  P	  >	  0.05.	  	  Upon	  inspection	  of	  MCF7	  apoptotic	  response	  (figure	  2.8c)	  we	  see	  that	  this	  cell	  type	  is	  apoptotically	  impacted	  simply	  by	  the	  absence	  of	  serum	  supplementation	  from	  the	  culture	  medium.	   Staurosporine	   has	   a	   strong	   apoptotic	   effect	   on	  MCF7	   cells,	  while	  CM	  HCC38	  has	  a	  moderate	  apoptotic	  effect	  that	  is	  lost	  at	  the	  3x	  to	  6x	  concentration	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Finally	  on	  figures	  2.8b	  and	  2.8d	  we	  see	  that	  the	  CM	  HCC38-­‐induced	  apoptotic	  effect	  cannot	   be	   diluted.	   Any	   attempt	   at	   diluting	   the	   newly-­‐harvested	   CM	   HCC38	  eliminates	  the	  apoptotic	  activity.	  	  	  
Freezing,	  heating	  and	  fractionation	  of	  CM	  HCC38	  For	   both	   receiver	   cell	   lines,	   MDAMB231	   and	  MCF7,	   the	   apoptotic	   assay	   indicates	  that	  snap-­‐freezing	  in	  liquid	  nitrogen	  and	  subsequent	  thawing	  of	  CM	  HCC38	  does	  not	  significantly	   affect	   its	   apoptotic	   potency	   (figures	   2.9a	   and	   2.9b).	   This	   finding	  suggests	  that	  the	  active	  factor	  in	  the	  CM	  can	  survive	  freezing	  –at	  least	  for	  short	  time	  periods.	  Denaturing	  the	  protein	  content	  of	  the	  CM	  by	  heating	  it	  at	  95°C	  in	  both	  cases	  results	   in	   a	   slight	   boost	   of	   apoptotic	   activity.	   This	   result	  was	   puzzling	   to	   us.	   	   One	  possible	   interpretation	   is	   that	   heat	   shock	   denatures	   protective	   growth	   factors	  present	   in	   the	   CM,	   thus	   increasing	   its	   toxicity	   to	   receiver	   cells.	   The	   underlying	  implication	  is	  that	  heat	  shock	  does	  not	  irreversibly	  denature	  the	  toxic	  factor	  present	  in	  the	  CM,	  a	  viable	  possibility	  if	  the	  active	  factor	  is	  either	  a	  small	  molecule	  or	  a	  small	  peptide	   with	   heat	   labile	   tertiary	   structure.	   However	   we	   have	   already	   established	  that	   the	   active	   factor	   is	   retained	   by	   centrifugation	   of	   the	   CM	   through	   a	   3,000kDa	  cutoff	  membrane.	  We	  can	  think	  of	  two	  scenarios	  that	  can	  reconcile	  these	  seemingly	  contradictory	   findings.	  The	   first	   scenario	   is	   that	   the	  active	   toxic	   factor	   is	   indeed	  a	  small	  heat	  labile	  peptide	  that	  is	  retained	  during	  filtration	  as	  part	  of	  a	  larger	  complex.	  The	  second	  scenario	  is	  that	  the	  active	  factor	  is	  in	  fact	  larger	  than	  3000kDa,	  yet	  able	  to	  renature	   itself	  after	  boiling	  with	  the	  aid	  of	  molecular	  chaperones	  present	   in	  the	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CM.	  Mass	  spectrometry	  analysis	  presented	  in	  the	  following	  chapter	  showed	  that	  CM	  HCC38	  is	  rich	  in	  heat	  shock	  proteins	  and	  other	  molecular	  chaperones.	  	  	  	  The	  final	  question	  we	  seek	  to	  answer	  in	  this	  series	  of	  quantitative	  apoptotic	  assays	  is	  whether	  the	  apoptotic	  factor	  is	  part	  of	  a	  particulate	  fraction	  in	  the	  CM	  HCC38.	  For	  this	  purpose	  we	  differentially	  centrifuge	   large	  membranous	  particles	  (guv)	  as	  well	  as	  small	  exosomes	  (exo)	  from	  the	  CM,	  as	  described	  in	  the	  methods	  section.	  We	  test	  these	   fractions	   for	   activity	   in	   addition	   to	   the	   supernatant	   from	   the	   final	   exosomal	  spin	  and	  the	  original	  non-­‐fragmented	  12x	  concentrated	  CM.	  As	  figures	  2.9c	  and	  2.9d	  show,	   the	   supernatant	   clearly	   retains	   the	   apoptotic	   potency	   for	   both	   receiver	   cell	  lines.	  In	  addition	  to	  that	  however,	  in	  MDAMB231	  receiver	  cells	  the	  exosomes	  show	  a	  mild	  (P	  ≤0.05)	  apoptotic	  activity	  whereas	  the	  guvs	  show	  no	  apoptotic	  activity.	  In	  the	  case	   of	   MCF7	   receiver	   cells	   neither	   the	   exosomes	   nor	   the	   guvs	   show	   statistically	  significant	  apoptotic	  activity.	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Figure	  2.9:	  Freezing/Thawing,	  Heat	  Shock	  and	  Fractionation	  of	  CM	  HCC38	  using	  the	  M30	  ELISA	  apoptotic	  readout	  assay.	  Bars	  denote	  average	  values	  over	  duplicate	  wells	  and	  error	  bars	  denote	  standard	  deviation	  from	  the	  mean.	  Statistical	  significant	  is	  determined	  by	  un-­‐paired,	  two-­‐tailed,	  homoscedastic	  T-­‐tests.	  	  A	  single	  *	  denotes	  P	  ≤	  0.05,	  a	  double	  **	  denotes	  P	  ≤	  0.01	  a	  triple	  ***	  denotes	  P	  ≤	  0.001	  while	  ns	  stands	  for	  P	  >	  0.05	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2.4	   Live	   Cell	   Imaging	   of	   Apoptosis-­Inducing	   Conditioned	   Media	   and	  
Corresponding	  Exosomes	  This	  section	  examines	  the	  apoptotic	  effect	  induced	  by	  both	  CM	  HCC38	  and	  CM	  BT20	  employing	  a	  direct	  live	  cell	  imaging	  approach	  over	  a	  period	  of	  48	  hours.	  	  We	  seek	  to	  elucidate	   the	   specific	   phenotype	   of	   the	   apoptotic	   effect	   and	   compare	   it	   to	   that	   of	  staurosporine	   treatment,	   a	   standard	   apoptotic	   agent.	   In	   addition,	   we	   are	   able	   to	  purify	  and	  fluorescently	  label	  CM-­‐derived	  cancer	  exosomes	  and	  incubate	  them	  with	  receiver	  cell	  lines	  to	  visualize	  their	  uptake	  and	  potential	  apoptotic	  activity.	  	  	  
Methods	  
Assay	  Procedure	  Cells	   were	   seeded	   in	   12-­‐well	   glass	   bottom	  Matek	   dishes	   at	   a	   density	   of	   100,000	  cells/well.	  Cells	  were	  allowed	  to	  sediment	  and	  adhere	  to	  the	  plate	  bottom	  overnight,	  after	  which	  monolayers	  were	  washed	  twice	  with	  PBS	  and	  the	  culture	  medium	  was	  replaced.	   	   Negative	   control	  wells	   received	   1ml	   of	   serum	   free	  RPMI	  while	   positive	  apoptosis	   controls	   received	   1ml	   of	   serum	   free	   RPMI	   supplemented	   with	   2	   µM	  staurosporine.	  For	  CM-­‐cultured	  wells,	  culture	  medium	  was	  replaced	  with	  1ml	  of	  CM.	  For	  exosome-­‐cultured	  conditions,	  20µl	  of	  concentrated	  exosome	  stock	  (comprising	  approximately	   15%	   of	   a	   single	   exosome	   prep)	  was	   resuspended	   in	   1ml	   of	   serum	  free	   RPMI.	   All	   wells	   also	   received	   2.5	   µM	   NucView488,	   a	   caspase-­‐3	   substrate	  routinely	  used	  for	  real	  time	  detection	  of	  apoptotic	  activity	   in	   live	  cells6.	  Cells	  were	  incubated	  and	  imaged	  for	  a	  total	  duration	  of	  48hrs.	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Conditioned	  Medium	  Production	  HCC38	   and	   BT20	   cells	   were	   seeded	   at	   a	   density	   of	   106	   cells/ml	   in	   T-­‐150	   culture	  flasks.	  Cells	  were	  allowed	  to	  adhere	   to	   flask	  surface,	  after	  which	  monolayers	  were	  washed	   twice	  with	   PBS	   and	   growth	  medium	  was	   replaced	  with	   serum-­‐free	  RPMI,	  supplemented	   with	   1%	   Penicillin-­‐Streptomycin	   and	   buffered	   with	   10mM	   Hepes.	  Conditioned	  medium	  was	  harvested	  after	  24hrs	  and	  centrifuged	  3min	  at	  1,000g	  to	  exclude	  cell	  debris.	  The	  CM	  was	  then	  passed	  through	  a	  0.22	  µm	  cutoff	  filter	  to	  rule	  out	  the	  presence	  of	  bacterial	  impurities.	  	  
	  
Exosome	  Purification	  and	  Fluorescent	  Labeling	  We	  purified	  exosomes	  out	  of	  tissue	  culture	  supernatant	  as	  described	  previously	   in	  section	   I	   of	   this	   chapter	   (Particulate	   Fractionation).	   For	   live	   cell	   imaging	   studies	  exosomes	  recovered	  by	  differential	  centrifugation	  were	  fluorescently	  labeled	  using	  the	   lipophilic	  dye	  PKH26.	  PKH-­‐26	  was	  designed	  as	  a	   live	   fluorescent	  probe	  of	   cell	  membrane,	   therefore	   the	   manufacturer’s	   protocol	   had	   to	   be	   adapted	   for	   this	  application.	  Briefly,	  exosomes	  were	  resuspended	  in	  a	  solution	  of	  Diluent	  C	  (500µl)	  and	  PKH-­‐26	  dye	  (2µl).	  The	  exosomal/dye	  mixture	  was	   left	   to	   incubate	   for	  5min	  at	  room	  temperature.	  Next	  the	  staining	  was	  halted	  by	  introducing	  1ml	  of	  an	  aqueous	  solution	   of	   1%	   BSA.	   Exosomes	   were	   recovered	   by	   ultracentrifugation	   and	  resuspended	  in	  200ul	  serum-­‐free	  medium,	  supplemented	  by	  1%	  BSA.	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Live	  Cell	  Imaging	  studies	  of	  Breast	  Cancer	  Cell	  Treatment	  with	  HCC38	  and	  
BT20-­Derived	  Conditioned	  Media	  	  To	   further	   elucidate	   the	   specific	   phenotype	   of	   conditioned	   medium-­‐induced	  apoptosis	  in	  this	  section	  we	  present	  live	  cell	  timelapse	  microscopy	  images	  of	  three	  breast	  cancer	  cell	  lines	  treated	  with	  HCC38	  and	  BT20-­‐derived	  CMs.	  We	  observe	  that	  the	  degree	  of	  apoptosis	  as	  well	  as	  the	  time	  to	  apoptotic	  onset	  varies	  depending	  on	  the	  recipient	  cell	  line.	  	  At	  the	  same	  time,	  we	  are	  also	  able	  to	  discern	  some	  common	  apoptotic	  phenotypic	  traits	  between	  the	  three	  recipient	  cell	  lines.	  	  
	  Figure	  2.10	  monitors	  the	  activity	  of	  CM	  HCC38,	  CM	  BT20,	  staurosporine	  and	  serum	  free	  culture	  on	  HCC1937	  cells.	  Both	  CMs	  are	  the	  cause	  of	  total	  cell	  death	  in	  this	  cell	  line	   by	   48hrs.	   However,	   in	   contrast	   to	   staurosporine-­‐induced	   cell	   death	   that	   is	  immediate	   and	   unfolds	   in	   a	   period	   of	   approximately	   three	   hours	   after	   treatment,	  CM-­‐induced	   apoptosis	   is	   incremental	   and	   slower	   to	   take	   place.	   In	   addition,	   we	  observe	   slight	   differences	   in	   the	   apoptotic	   phenotypes	   between	   the	   two	   CMs.	   By	  14hrs	  several	  of	  the	  cells	  in	  both	  CM-­‐treated	  wells	  are	  caspase-­‐3	  positive.	  However,	  in	   the	  CM	  BT20-­‐treated	  well	   the	  majority	  of	   the	  culture	  has	  assumed	  a	  contracted	  rounded	   form,	   whereas	   in	   the	   CM	   HCC38-­‐treated	   well	   apoptotic	   cells	   are	  interspersed	  between	  normal	  and	  elongated	   in	  appearance	  cells.	  By	  24hrs	   in	  both	  wells	  the	  majority	  of	  cells	  are	  rounded,	  yet	  not	  all	  appear	  caspase-­‐3	  positive.	  Instead	  cells	  linger	  in	  this	  rounded	  pre-­‐apoptotic	  stage,	  a	  phenotype	  that	  we	  recognize	  as	  a	  CM-­‐induced	  response	  in	  other	  recipient	  cells	  as	  well.	  By	  48hrs	  the	  NucView	  reporter	  is	  activated	  in	  all	  cells.	  The	  culture	  is	  now	  visibly	  apoptotic	  and	  accompanied	  by	  the	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characteristic	  cell	  blebbing,	  an	  unequivocal	  sign	  of	  cell	  death.	  	  CM-­‐treated	  wells	  look	  markedly	  different	   from	   the	   serum	   free-­‐treated	  negative	   control	  where	   cells	   keep	  dividing	  and	  the	  monolayer	  keeps	  growing	  over	  the	  48hr	  period.	  	  	  Figure	   2.11	   presents	   the	   response	   of	   HS578T	   cells	   to	   the	   same	   set	   of	   culture	  conditions.	   This	   cell	   line	   appears	   significantly	   more	   resistant	   to	   CM-­‐induced	  apoptosis	  than	  HCC1937	  cells.	  In	  both	  CM-­‐treated	  wells,	  cells	  keep	  dividing	  and	  the	  monolayer	   keeps	   growing	   albeit	   at	   a	   slower	   rate	   than	   the	   SF-­‐treated	   negative	  control.	  We	  observe	   in	   this	  cell	   type	  as	  well	   the	  characteristic	  cell	  contraction	  and	  rounding	   that	   we	   saw	   in	   HCC1937	   cells	   in	   response	   to	   CM	   treatment.	   SF-­‐treated	  cells	  also	   round	  up	  by	  48	  hrs,	  however	   the	  essential	  difference	  between	   the	   three	  conditions	   is	   that	   CM-­‐treated	   cells	   activate	   caspase-­‐3	   whereas	   SF-­‐treated	   cells	  remain	  dark	  -­‐an	  indicator	  of	  imminent	  mitosis	  rather	  than	  apoptosis.	  	  	  Finally	  figure	  2.12	  presents	  the	  response	  of	  MCF7	  cells	  to	  CM	  HCC38	  comparatively	  to	  controls.	  In	  this	  case	  again,	  CM	  treatment	  prolongs	  cell	  doubling	  time	  yet	  does	  not	  completely	  block	  cell	  division.	  Caspase-­‐3	  positive,	  apoptotic	  cells	  first	  appear	  in	  the	  interior	   of	   the	   cell	   island	   and	   by	   48hrs	   the	   apoptotic	   effect	   spreads	   outward.	  However	  at	  the	  end	  of	  the	  experiment	  a	  significant	  fraction	  of	  the	  culture	  is	  still	  live.	  In	  contrast	  the	  entirety	  of	  the	  staurosporine	  treated	  cell	  island	  dies,	  with	  no	  events	  of	   cell	   division,	   extremely	   early	   in	   the	   culture.	   The	   SF	   control	   also	   presents	   a	  somewhat	   lower	   amount	   of	   apoptosis	   by	   48hrs.	   This	   result	   agrees	   with	   ELISA	  findings	  presented	  in	  the	  previous	  section	  and	  complements	  that	  assay	  with	  a	  visual	  
	   70	  
image	   of	   the	   susceptibility	   of	   this	   cell	   type	   to	   cell	   death	   in	   serum	   free	   culture	  conditions.	  
	  
Live	   Cell	   Imaging	   studies	   of	   Breast	   Cancer	   Cell	   Treatment	   with	   HCC38	   and	  
BT20-­Derived	  Exosomes	  Next	   we	   incubate	   receiver	   cell	   lines	   with	   exosomes	   isolated	   from	   the	   same	   CM-­‐producing	   cell	   lines.	   The	   primary	   purpose	   of	   this	   experiment	   was	   to	   try	   and	  recapitulate	  some	  of	  the	  apoptotic	  activity	  by	  using	  solely	  the	  exosome	  fraction	  from	  the	   original	   conditioned	   media.	   A	   secondary	   end	   point	   was	   to	   examine	   exosome	  uptake	  by	  different	  breast	  cancer	  cell	  lines.	  	  Figure	   2.13	   captures	   MDAMB231	   cells	   incubated	   with	   BT20-­‐derived	   exosomes	  using	  a	  10x	  magnification	  objective,	  while	  figure	  2.14	  represents	  the	  same	  cells	  this	  time	  incubated	  with	  HCC38-­‐derived	  exosomes	  and	  imaged	  with	  a	  20x	  magnification	  objective.	   Regarding	   exosome-­‐induced	   cell	   death,	   neither	   HCC38	   nor	   BT20	  exosomes	  not	  appear	   to	  elicit	   significant	  cell	  death	   in	   the	  MDAMB231	  cell	   culture.	  On	   figure	   2.15	   we	   present	  MCF7	   cells	   incubated	   with	   BT20	   exosomes.	  Here	   too	  apoptosis	  incidence	  is	  identical	  in	  the	  control	  and	  exosome-­‐treated	  wells.	  	  
	  One	  striking	  finding	  in	  this	  imaging	  dataset	  is	  the	  actual	  uptake	  of	  the	  exosomes	  by	  recipient	  cell	  lines.	  MDAMB231	  cells	  appear	  to	  endocytose	  the	  exosome,	  which	  once	  internalized	  aggregate	  in	  the	  perinuclear	  region.	  The	  internalization	  of	  exosomes	  in	  this	  cell	  type	  appears	  to	  happen	  irrespectively	  of	  the	  cellular	  origin	  of	  the	  vesicles,	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although	  more	   rigorous	  and	  quantitative	   study	   -­‐which	   is	  beyond	   the	   scope	  of	   this	  project-­‐	  would	  need	  to	  be	  undertaken	  to	  further	  qualify	  this	  statement.	  In	  contrast,	  exosome	  uptake	  is	  less	  efficient	  in	  MCF7	  cells.	  Here	  exosomes	  seem	  to	  remain	  in	  the	  exterior	  of	  the	  cell	  membrane	  and	  drift	  in	  the	  extracellular	  space	  during	  the	  48-­‐hour	  imaging	  period.	  	  A	  question	  open	   for	   investigation	   is	  whether	  exosome	  uptake	   is	  a	  prerequisite	   for	  any	  exosome	  activity	  on	  recipient	  cells.	  The	  precise	  mechanism	  of	  exosome	  uptake	  is	   unknown	   at	   this	   point.	   Moreover,	   it	   is	   unclear	   whether	   the	   uptake	   reflects	   a	  mechanistic	   matching	   between	   exosome	   ligand	   and	   recipient	   cell	   receptor	   or	   is	  instead	  solely	  due	  to	  the	  phagocytic	  aptitude	  of	  the	  recipient	  cell	  line.	  	  	  A	   way	   of	   testing	   and	   differentiating	   between	   the	   two	   hypotheses	   would	   be	   to	  extrude	  biologically	   inert	   liposomes,	  matching	   the	  size	  of	  breast	   cancer	  exosomes,	  and	  monitor	  their	  uptake	  from	  recipient	  cell	  lines.	  A	  step	  further	  would	  be	  to	  embed	  ligands	  of	  known	  cell	   surface	   receptors	  on	   the	   liposomes	  and	  again	  quantify	   their	  uptake	   comparatively	   to	   the	   uptake	   of	   inert	   liposomes	   and	   exosomes	   in	   turn.	  However	   this	   type	   of	   investigation	   was	   not	   conducted	   since	   it	   strays	   from	   our	  primary	  area	  of	  research	  interest:	  the	  apoptotic	  factors	  present	  in	  the	  tissue	  culture	  supernatants	  of	  triple	  negative	  breast	  cancer	  cell	  lines.	  	  	  Feng	   et	   al.	   have	   conducted	   interesting	   research	   pertinent	   to	   this	   question7.	   Their	  findings	  confirm	  that	  exosome	  internalization	  occurs	  primarily	  through	  a	  phagocytic	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Chapter	  3	  
	  
Transcriptomic	  and	  Proteomic	  Analysis	  of	  Conditioned	  Media	  
	  
Abstract	  We	   previously	   screened	   twenty	   breast	   cancer	   cell	   lines	   for	   apoptotic	   and	  proliferative	  response	  to	  twenty	  conditioned	  media	  (CM).	  This	  screen	  revealed	  that	  CM	  BT20	  and	  CM	  HCC38	  have	  strong	  pro-­‐apoptotic	  activity	  on	  the	  majority	  of	  cell	  lines	  tested.	  As	  a	  systematic	  approach	  to	  uncovering	  molecular	  pathways	  underlying	  response	   to	   conditioned	   media,	   we	   proceed	   to	   correlate	   the	   phenotypic	   data	  matrices	   to	   transcriptomic	   data.	   This	   analysis	   identifies	   genes	   whose	   expression	  correlates	   strongly	  with	   the	   conditioned	  media	  matrices.	  Moreover	  we	   undertake	  mass	  spectrometry	  analysis	  of	  the	  two	  most	  apoptosis-­‐inducing	  conditioned	  media,	  which	  reveals	  a	  list	  of	  common	  pro-­‐apoptotic	  proteins	  in	  the	  two	  media.	  In	  addition	  to	   pro-­‐apoptotic	   hits,	   the	   CM	   mass	   spectrometry	   dataset	   reveals	   a	   significant	  amount	  of	  cytoplasmic	  proteins	  as	  well	  as	  cell	  membrane	  receptors	  present	   in	  the	  extracellular	   space.	   We	   hypothesize	   that	   these	   molecules	   are	   expelled	   in	   the	  extracellular	  space	  as	  a	  result	  of	  a	  particulate	  secretory	  mechanism,	  and	  we	  proceed	  to	  purify	   this	  particulate	   fraction.	  The	   last	   section	  of	   this	   chapter	   covers	   the	  mass	  spectrometry	  analysis	  of	  the	  particulate	  fraction	  and	  compares	  it	  to	  the	  full	  CM	  in	  an	  attempt	  to	  shorten	  the	  list	  of	  candidate	  apoptotic	  molecules	  present	  in	  the	  CMs.	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3.1	  Correlation	  of	  Phenotypic	  Datasets	  to	  Transcriptional	  Gene	  Sets	  In	  this	  part,	  we	  attempted	  to	  make	  a	  prediction	  as	  to	  the	  molecular	  nature	  of	  select	  conditioned	   media	   interactions,	   by	   correlating	   the	   phenotypic	   proliferative	   and	  apoptotic	  matrices	  to	  the	  transcriptional	  profiles	  of	  the	  cell	  lines.	  	  	  
Methods	  Microarray	   gene	   expression	   data	   were	   obtained	   from	   a	   public	   database	  (http://cancer.lbl.gov/breastcancer/data),	   which	   contains	   the	   transcriptional	  characterization	   of	   51	   breast	   cancer	   cell	   lines.	   The	   authors	   of	   that	   work	   used	   an	  Affymetrix	   high-­‐density	   oligonucleotide	   array	   human	   HG-­‐U133A	   chip1,	   and	  generated	   probe	   set	   based	   gene	   expression	   measurements	   from	   quantified	  Affymetrix	  image	  files	  (‘’.CEL’’	  files)	  using	  the	  BioConductor	  tool	  suite.	  All	  CEL	  files	  were	  analyzed	  simultaneously,	  creating	  a	  data	  matrix	  of	  probe	  sets	  by	  cell	   lines	   in	  which	  each	  value	  is	  the	  calculated	  log	  abundance	  of	  each	  probe	  set	  gene	  for	  each	  cell	  line.	  	  From	   this	   file,	   containing	   information	   for	   51	   cell	   lines,	   we	   obtained	   the	   log	  transcriptional	   profiles	   of	   18	   cell	   lines	   involved	   in	   the	   conditioned	   medium	  experimental	  matrix.	  The	  file	  was	  annotated	  using	  IPA	  Ingenuity	  software.	  Gene	  set	  enrichment	  was	  also	  performed	  with	   IPA	   Ingenuity,	   to	  obtain	   two	  gene	   sets	   to	  be	  used	   in	   this	   correlative	   analysis:	   ‘Proliferation	   of	   Breast	   Cancer	   Cell	   Lines’	   and	  ‘Apoptosis	  of	  Breast	  Cancer	  Cell	  Lines’.	  These	  gene	  sets	  were	   further	  annotated	  so	  that	   the	   genes	   were	   separated	   into	   four	   localization	   categories:	   secreted,	   plasma	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membrane,	   cytoplasmic,	   nuclear.	   Only	   the	   secreted	   and	   plasma	   membrane	  molecules	  were	  retained	  for	  this	  analysis.	  	  For	   the	  purpose	  of	   correlation	   the	   two	  data	   sets,	   both	   the	   gene	   set	   as	  well	   as	   the	  phenotypic	  data	  set	  were	  normalized	  to	  a	  value	  between	  0	  and	  1.	  This	  was	  achieved	  in	   the	   transcriptional	   data	   set	   by	   dividing	   each	   gene	   with	   by	   the	   maximum	  expression	  value	  that	  gene	  attains	  across	  all	  18	  cell	   lines.	   In	   turn,	  phenotypic	  data	  sets	  were	  normalized	  to	  the	  highest	  apoptosis/proliferative	  response	  of	  one	  cell	  line	  across	  all	  CM	  stimuli.	  	  	   Next,	   the	   absolute	  distances	  between	  the	  CM	  response	   and	   the	   gene	  expression	   value	   for	   a	  particular	   gene	   are	  calculated	   across	   all	   cell	  lines	  (figure	  3.1).	  These	  distances	  are	  added	  up	  and	  constitute	   the	   ‘Gene	  Score’,	  of	  how	   well	   that	   particular	   gene	   correlates	   with	   the	   phenotypic	   profile	   that	   a	   CM	  causes	  across	  all	  cell	  lines:	  
€ 
GeneScore = x − y∑ 	  The	   lowest	   the	   score,	   the	   stronger	   the	   correlation.	   Seeing	   that	   several	   genes	   are	  represented	   by	  multiple	   gene	   probes	   in	   the	   data	   set,	   the	   correlation	   algorithm	   is	  repeated	   separately	   for	   each	   probe.	   	   Then,	   the	   probe	   displaying	   the	   closest	  
Figure	  3.8:	  Correlation	  of	  phenotypic	  data	  set	  to	  transcription	  data	  set.	  Adding	  absolute	  distances	  over	  all	  cell	  lines.	  	  
	   83	  
correlation	   is	   inserted	   into	   the	   final	   data	   matrix,	   while	   remaining	   probes	   are	  discarded.	  	  
Results	  of	  correlation	  to	  transcriptional	  gene	  sets	  Repeating	   this	   for	   both	   gene	   sets	   gives	   rise	   to	   two	   correlation	   matrices.	   On	   the	  apoptosis	  correlative	  matrix	  (fig	  3.2),	  we	  observe	  CM	  HCC38	  and	  CM	  BT20	  to	  cluster	  together	  and	  display	  a	  high	  correlation	  to	  most	  apoptotic	  genes.	  They	  are	  followed	  by	  CM	  HCC1954	  and	  CM	  HS578T,	  which	  were	  also	  identified	  as	  pro-­‐apoptotic	  CMs	  in	  the	  previous	  section.	  On	  the	  proliferation	  correlative	  matrix	  (fig	  3.3),	  we	  observe	  CM	  BT20,	  which	  also	  has	  a	  strong	  anti-­‐proliferative	  activity	  	  -­‐as	  discussed	  previously-­‐	  to	  correlate	   the	   least	  of	  all	  CMs	  to	   the	  proliferative	  gene	  set.	  Genes	   that	  had	  a	  strong	  correlation	   with	   the	   majority	   of	   conditioned	   media	   were	   singled	   out	   as	   hits,	  meriting	   further	   investigation.	  These	  are	  denoted	  with	  red	  boxes	  on	   the	  apoptotic	  and	  proliferative	  clusters.	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  Next,	  the	  expression	  levels	  of	  hit	  genes	  is	  examined	  across	  all	  cell	  lines	  (fig	  3.4	  &	  fig	  3.5).	  We	  make	  the	  simplifying	  assumption	   that	  genes	  whose	  expression	   level	  does	  not	  considerably	   fluctuate	  across	  cell	   lines,	  are	  most	   likely	  not	   responsible	   for	   the	  CM	   interactions,	   since	   their	   levels	  are	   the	  same	   in	  all	  CMs	  and	  subsequently	  cross	  them	   out	   on	   figure	   3.4.	   In	   order	   to	   compare	   expression	   levels,	   we	   center	   the	   log	  values	  in	  the	  original	  transcriptional	  data	  set,	  by	  subtracting	  the	  median	  of	  a	  cell	  line	  across	  all	  genes	   from	  each	  gene’s	  expression	  value.	  We	  compare	  expression	   levels	  for	  a	  particular	  hit	  gene	  by	  averaging	  over	  the	  multiple	  gene	  probes	  on	  figure	  3.4.	  On	  
Figure	  3.9:	  Correlation	  of	  apoptosis	  phenotypic	  dataset	  to	  apoptotic	  transcriptional	  gene	  set.	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figure	  3.5	  we	  go	  even	  further	  in	  depth	  by	  comparing	  each	  gene	  probe	  separately	  in	  those	  hit	  genes	  that	  display	  great	  probe-­‐to-­‐probe	  variability.	  	  
	  	  
One	   application	   of	   this	   analysis	   is	   identifying	   overexpression	   of	   specific	   gene	  products	  in	  our	  pro-­‐apoptotic	  CMs	  of	   interest:	  CM	  BT20	  and	  CM	  HCC38.	  These	  are	  denoted	  on	  figure	  3.4	  &	  3.5	  by	  red	  arrows.	  The	  findings	  are	  summarized	  in	  table	  3.2.	  Starting	   with	   HCC38	   cells	   we	   observe	   that	   according	   to	   this	   correlative	   analysis,	  insulin	   growth	   factor	   binding	   protein	   3	   (IGFBP3)	   and	   fibronectin	   1	   (FN1)	   are	  over-­‐secreted	  and	  set	  this	  CM	  apart	  from	  the	  majority	  of	  breast	  cancer	  cell	  lines.	  The	  
Figure	  3.10:	  Correlation	  of	  proliferation	  phenotypic	  dataset	  to	  proliferative	  transcriptional	  gene	  set.	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overexpression	  of	  IGFBP3	  is	  a	  common	  trait	  in	  triple	  negative	  cells,	  since	  HCC1937,	  HCC1143	  and	  HS578T	  also	  share	  it	  in	  varying	  amounts.	  The	  overexpression	  of	  FN1	  is	  a	  rarer	  occurrence,	  also	  present	  in	  a	  single	  other	  cell	  line:	  HS578T	  cells.	  IGFBP3	  is	  a	  documented	  antagonist	  of	   the	  IGF	  receptor	  and	  therefore	  a	  recognized	  apoptotic	  molecule.	   Exogenous	   IGFBP3	   has	   been	   shown	   to	   inhibit	   proliferation	   of	   HS578T	  cells2,	  as	  well	  as	  induce	  apoptosis	  in	  MCF7	  cells3.	  However	  since	  other	  cell	  lines,	  that	  are	  producers	  of	  less	  toxic	  CMs,	  also	  feature	  an	  increased	  transcript	  of	  IGFBP3,	  this	  alone	   cannot	   explain	   the	   strong	   apoptotic	   activity	   of	   HCC38	   CM.	   In	   addition	   to	  regulating	  IGF-­‐ligand	  bioavailability,	  IGFBPs	  can	  also	  influence	  cell	  fate	  through	  IGF-­‐independent	  mechanisms.	  	  	  
Fibronectin	   1	   on	   the	   other	   hand	   is	   only	   overexpressed	   in	   two	   considerably	   pro-­‐apoptotic	   CM	   producers	   (HCC38	   and	   HS578T).	   It	   is	   perhaps	   not	   surprising	   that	  these	   two	   triple	   negative	   breast	   cancer	   cell	   lines	   produce	   higher	   amounts	   of	  extracellular	  matrix,	  as	  that	  would	  improve	  their	  survival	  and	  migratory	  phenotypes	  as	  compared	  to	  less	  aggressive	  luminal	  cells.	  But	  how	  do	  cell	  lines	  of	  more	  epithelial	  phenotype	   react	   to	   culture	   in	   fibronectin-­‐rich	   conditioned	   media?	   Soluble	  fibronectin	  can	  actually	  promote	  cell	  detachment	  and	  rounding	   in	  epithelial	   tissue	  culture	   monolayers4.	   Most	   importantly,	   in	   a	   study	   performed	   with	   HS578T	   cells,	  McCaig	   et	   al.5	   showed	   that	   soluble	   fibronectin	   interacts	   directly	  with	   IGFBP3	   and	  IGFBP5	   to	   modulate	   cell	   attachment.	   According	   to	   the	   transcriptional	   profiles,	  neither	  IGFBP3	  of	  FN1	  alone	  is	  sufficient	  to	  induce	  apoptosis.	  However	  the	  cocktail	  of	  the	  two	  combined	  can	  promote	  an	  anoikis	  phenotype	  in	  breast	  cancer	  cells.	  	  
	   87	  
	  
	  
Figure	  3.11:	  Heat	  map	  of	  expression	  levels	  of	  hit	  genes,	  averaged	  against	  all	  gene	  probes.	  Red	  boxes	  enclose	  the	  two	  cell	   lines	  producing	  the	  strongest	  apoptotic	  media.	  Red	  arrows	   indicate	  genes	  that	  are	   significantly	   overexpressed	   in	   these	   cell	   lines,	   in	   comparison	   to	   the	   rest.	   Crossed	   out	   genes	   in	  blue	  have	   relatively	   stable	  expression	  value	  across	  all	   cell	   lines	  and	  are	   therefore	   considered	  non-­‐critical	  for	  the	  CM-­‐interaction	  experiments.	  	  Surprisingly	   there	   are	   no	   common	   secreted	   protein	   hits	   between	   our	   two	   pro-­‐apoptotic	  media	   producing	   cell	   lines:	   BT20	   and	   HCC38.	   The	   only	   secreted	   hit	   for	  BT20	  cells	  is	  cystatin	  M	  (CST6),	  a	  secreted	  cysteine	  protease	  inhibitor	  that	  has	  been	  identified	   as	   a	   tumor	   suppressor	   gene	   that	   is	   epigenetically	   silenced	   during	  mammary	  tumorigenesis6.	  Cystatin	  M	  is	  a	  cathepsin	  inhibitor7	  –a	  protein	  class	  that	  we	   will	   touch	   upon	   in	   the	   following	   section	   of	   this	   chapter.	   According	   to	   the	  transcriptional	  dataset,	  BT20	  cells	  are	  the	  only	  ones	  over-­‐expressing	  this	  particular	  molecule.	  	  	  
!"#$#%&$#''()*+
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Figure	  3.12:	  Heat	  map	  of	  expression	  levels	  of	  hit	  genes,	  showing	  individual	  gene	  probes.	  Vertical	  red	  arrows	  delineate	  the	  two	  cell	   lines	  producing	  the	  strongest	  apoptotic	  media.	  Horizontal	  red	  arrows	  indicate	  genes	  that	  are	  significantly	  overexpressed	  in	  these	  cell	  lines,	  in	  comparison	  to	  the	  rest.	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protein	   that	   couples	   integrins	   to	   various	   upstream	   tyrosine	   kinases.	   This	   gene	   is	  considered	  a	   tumor	  suppressor8,	   and	   therefore	   is	  also	  unlikely	   to	  be	   involved	   in	  a	  pro-­‐apoptotic	  activity.	  The	  remaining	  plasma	  membrane	  hits	  fro	  BT20	  cells	  are	  the	  
epidermal	   growth	   factor	   receptor	   (EGFR)	   and	   hepatocyte	   growth	   factor	  
receptor	  (MET).	  Both	  of	  these	  are	  receptors	  of	  ubiquitous	  and	  multiple	  ligands	  and	  could	  very	  well	  be	  depleting	  the	  media	  from	  proliferative	  signals.	  	  
	  
Table	  3.1:	  Hit	  gene	  candidates	  for	  HCC38	  and	  BT20	  cell	  lines.	  One	  caveat	  of	  this	  analysis	  is	  that	  the	  gene	  set	  information	  for	  the	  breast	  cancer	  cell	  lines	   was	   acquired	   on	   the	   transcriptional	   level.	   However	   there	   are	   numerous	  biological	   events	   that	   can	   alter	   the	   expression	   of	   a	   final	   protein	   product	   after	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transcription.	   To	   name	   a	   few:	   post-­‐transcriptional	   regulation,	   alternative	   splicing,	  RNA	  degradation,	  translational	  inefficiency,	  protein	  modification	  and	  varied	  protein	  half-­‐lives.	   Even	   though	   comparing	   the	   cell	   lines	   on	   the	  mRNA	   level	   is	   a	   good	   first	  step	   in	   visualizing	   their	   diverse	   genetic	   identities	   and	   yields	   some	   tentative	  predictions	   on	   the	   secreted	   content	   of	   the	   corresponding	   CMs,	   only	   proteomic	  analysis	   can	   irrefutably	   prove	   the	   presence	   of	   secreted	  proteins	   in	   the	  CM.	   In	   the	  following	   section	  we	  will	   do	   just	   that	   and	   examine	  how	   the	  proteomic	  makeup	  of	  select	  CMs	  compares	  to	  the	  transcriptional	  predictions.	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3.2	  Proteomic	  Analysis	  of	  HCC38	  and	  BT20	  Derived	  Conditioned	  Media	  
	  In	   this	   section	  we	   performed	   proteomic	   analysis	   of	   the	  HCC38	   and	   BT20	   derived	  conditioned	   media.	   We	   subsequently	   compare	   the	   resulting	   protein	   lists	   against	  each	  other	  and	  identified	  common	  pro-­‐apoptotic	  hits	  present	  in	  both	  CMs	  as	  well	  as	  pro-­‐apoptotic	   proteins	   unique	   to	   each	   CM.	   Finally	   we	   scanned	   both	   lists	   for	   the	  presence	   of	   the	   protein	   products	   predicted	   in	   the	   previously	   reported	  transcriptional	  analysis.	  For	  brevity	  and	  clarity	  we	  did	  not	  feature	  the	  complete	  list	  of	  mass	   spectrometry	   results	   in	   this	   section,	   but	   rather	   an	   abridged	   comparative	  version	  of	  it,	  focused	  on	  apoptosis	  associated	  molecules.	  	  	  
Methods	  Cells	  were	  seeded	  at	  a	  density	  of	  106	  cells/ml	  in	  T-­‐150	  culture	  flasks	  and	  allowed	  to	  adhere	  to	  flask	  surface	  overnight.	  The	  monolayers	  were	  then	  washed	  twice	  with	  PBS	  and	   growth	  medium	  was	   replaced	  with	   serum-­‐free	   RPMI,	   supplemented	  with	   1%	  Penicillin-­‐Streptomycin	   and	   buffered	   with	   10mM	   Hepes.	   12	   ml	   of	   conditioned	  medium	  were	  harvested	  24hrs	  later	  and	  centrifuged	  3min	  at	  1,000g	  to	  exclude	  cell	  debris.	   The	   CMs	   were	   then	   concentrated	   by	   centrifugation	   at	   4,000g	   through	   a	  3,000kDa	  membrane.	  25ul	  of	  concentrate	  from	  the	  centrifugation	  were	  loaded	  and	  run	   halfway	   on	   an	   SDS-­‐PAGE	   gel,	   using	  MOPS	   buffer.	   	   	   The	   gel	   was	   stained	  with	  Coomassie	   Blue	   and	   each	   gel	   lane	   was	   cut,	   under	   sterile	   conditions,	   into	   two	  sections.	  All	  sections	  were	  submitted	  for	  micro-­‐capillary	  LC/MS/MS	  analysis	  at	  the	  Taplin	  Mass	  Spectrometry	  Facility	  of	  Harvard	  Medical	  School.	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  Excised	  gel	  bands	  were	  cut	  into	  approximately	  1mm3	  pieces.	   	  Gel	  pieces	  were	  then	  subjected	  to	  a	  modified	  in-­‐gel	  trypsin	  digestion	  procedure.	  	  Gel	  pieces	  were	  washed	  and	   dehydrated	  with	   acetonitrile	   for	   10	  min.	   followed	   by	   removal	   of	   acetonitrile.	  	  Pieces	  were	  then	  completely	  dried	  in	  a	  speed-­‐vac.	  	  Rehydration	  of	  the	  gel	  pieces	  was	  with	   50	   mM	   ammonium	   bicarbonate	   solution	   containing	   12.5	   ng/µl	   modified	  sequencing-­‐grade	  trypsin	  (Promega,	  Madison,	  WI)	  at	  4ºC.	  	  After	  45	  min.,	  the	  excess	  trypsin	   solution	   was	   removed	   and	   replaced	   with	   50	  mM	   ammonium	   bicarbonate	  solution	   to	   just	   cover	   the	   gel	   pieces.	   	   Samples	   were	   then	   placed	   in	   a	   37ºC	   room	  overnight.	   	  Peptides	  were	   later	  extracted	  by	  removing	  the	  ammonium	  bicarbonate	  solution,	  followed	  by	  one	  wash	  with	  a	  solution	  containing	  50%	  acetonitrile	  and	  1%	  formic	  acid.	  	  The	  extracts	  were	  then	  dried	  in	  a	  speed-­‐vac	  (~1	  hr).	  	  The	  samples	  were	  then	  stored	  at	  4ºC	  until	  analysis.	  	  	  	  On	  the	  day	  of	  analysis	  the	  samples	  were	  reconstituted	  in	  5	  -­‐	  10	  µl	  of	  HPLC	  solvent	  A	  (2.5%	   acetonitrile,	   0.1%	   formic	   acid).	   	   A	   nano-­‐scale	   reverse-­‐phase	  HPLC	   capillary	  column	  was	  created	  by	  packing	  5	  µm	  C18	  spherical	   silica	  beads	   into	  a	   fused	  silica	  capillary	  (125	  µm	  inner	  diameter	  x	  ~20	  cm	   length)	  with	  a	   flame-­‐drawn	  tip.	   	  After	  equilibrating	   the	   column	   each	   sample	   was	   loaded	   via	   a	   Famos	   auto	   sampler	   (LC	  Packings,	  San	  Francisco	  CA)	  onto	  the	  column.	  	  	  	  A	  gradient	  was	  formed	  and	  peptides	  were	  eluted	  with	   increasing	  concentrations	  of	   solvent	  B	   (97.5%	  acetonitrile,	  0.1%	  formic	  acid).	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As	  peptides	  eluted	  they	  were	  subjected	  to	  electrospray	  ionization	  and	  then	  entered	  into	   an	   LTQ	   Velos	   ion-­‐trap	   mass	   spectrometer	   (ThermoFisher,	   San	   Jose,	   CA).	  	  Peptides	   were	   detected,	   isolated,	   and	   fragmented	   to	   produce	   a	   tandem	   mass	  spectrum	  of	  specific	  fragment	  ions	  for	  each	  peptide.	  	  Peptide	  sequences	  (and	  hence	  protein	  identity)	  were	  determined	  by	  matching	  protein	  databases	  with	  the	  acquired	  fragmentation	  pattern	  by	   the	   software	  program,	  Sequest	   (ThermoFisher,	   San	   Jose,	  CA).	   	   Spectral	  matches	   were	  manually	   examined	   and	  multiple	   identified	   peptides	  per	  protein	  were	  required.	  	  	  	  
Results	  Figure	   3.6	   summarizes	   the	   results	   from	   the	  mass	   spectrometry	   analysis.	   The	   two	  conditioned	  media	  had	  155	  proteins	  in	  common,	  which	  in	  both	  cases	  corresponded	  to	   more	   than	   half	   of	   the	   total	   protein	   count.	   The	   list	   of	   common	   proteins	   was	  annotated	  for	   localization	  and	  function	  using	  IPA	  Ingenuity.	  This	  allowed	  us	  to	  bin	  the	  proteins	   in	   functional	   categories	   (figure	  3.6b).	  The	  most	   salient	   feature	  of	   this	  analysis	   is	   that	   the	   majority	   of	   proteins	   in	   both	   conditioned	   media	   are	   of	  cytoplasmic	   origin.	   Next	   in	   abundance	   are	   extracellular	   proteins,	   followed	   by	  plasma	   membrane	   proteins.	   Finally,	   we	   observe	   a	   small	   percentage	   of	   nuclear	  proteins	  present	  in	  the	  CMs.	  	  	  In	  terms	  of	  functional	  annotation,	  the	  largest	  functional	  group	  of	  proteins	  comprise	  -­‐or	   associate	   with-­‐	   the	   cell’s	   cytoskeleton.	   That	   is	   not	   surprising,	   considering	   that	  these	   are	  high	   abundance	  proteins	   is	   cells.	   The	  next	   largest	   functional	   category	   is	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glycolysis-­‐associated	  proteins,	  followed	  by	  heat	  shock	  proteins.	  After	  that	  follows	  a	  large	   group	   of	   proteases/peptidases,	   extracellular	  matrix	   proteins,	   transcriptional	  and	   translational	   regulators	   and	   molecular	   chaperones.	   Most	   of	   these	   abundant	  protein	   categories,	   perhaps	   with	   the	   exception	   of	   proteases,	   are	   housekeeping	   in	  origin	   and	   cannot	   be	   readily	   associated	   with	   pro-­‐apoptotic	   or	   anti-­‐proliferative	  phenotypes.	   However,	   some	   of	   the	   less	   abundant	   proteins	   groups	   have	   more	  interesting	   functional	   characterization	  attached	   to	   them.	  Namely,	  we	   found	  kinase	  inhibitors,	   tumor	   suppressors,	   cytokines	   and	   inflammatory	   molecules	   within	   the	  common	  protein	  list.	  	  	  In	  table	  (a)	  of	  figure	  3.6,	  we	  list	  the	  common	  apoptosis-­‐related	  molecules	  between	  CMs	   HCC38	   and	   BT20.	   Among	   those	   we	   note	   a	   family	   of	   kallikrein-­related	  
peptidases	   characteristic	   of	   steroid-­‐regulated	   cancers.	   Perhaps	   the	   most	   famous	  member	   of	   the	   kallikrein	   family	   is	   kallikrein	   3,	   also	   known	   as	   prostate-­‐specific	  antigen	  (PSA),	  a	  key	  diagnostic	  molecule	  in	  prostate	  cancer.	  While	  kallikrein	  3	  and	  4	  are	   androgen-­‐regulated	   genes	   expressed	   almost	   exclusively	   in	   the	   prostate,	  kallikrein	  5	  (KLK5)	  and	  kallikrein	  6	  (KLK6)	  are	  estrogen-­‐regulated	  and	  expressed	  in	  the	   breast	   and	  ovaries.	   In	   a	   study	  using	  human	   tissue	   samples,	   kallikrein	   genes	   5	  and	   6	   were	   found	   to	   be	   down-­‐regulated	   in	   breast	   cancer	   relative	   to	   healthy	  mammary	   tissue9.	   It	   is	   presently	  unclear	  whether	   these	  proteases	  promote	   tumor	  progression	  or	  amount	  to	  a	  pro-­‐apoptotic	  signal	   for	  the	  cancerous	  mass.	  However,	  what	   is	   known	   is	   that	   serpins	   are	   active	   inhibitors	   of	   kallikreins10.	   These	   two	  secreted	   protein	   groups	   can	   therefore	   interact	   in	   the	   extracellular	   space	   and	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modulate	  the	  tumor	  environment.	  When	  considered	  within	  the	  scope	  of	  this	  study,	  different	   cancer	   cell	   lines	  express	  different	   amounts	  of	   serpins	  as	   shown	   in	   figure	  2.4	   for	   SERPINA1	   and	   SERPINB5.	   In	   addition	   to	   that,	   our	   two	   pro-­‐apoptotic	   CMs	  secrete	  varying	  amounts	  of	  KLK5	  and	  KLK6.	  The	  interaction	  between	  the	  kallikreins	  of	   the	  donor	   cell	   line	  and	   the	   serpins	   secreted	  by	   the	   receiver	   cell	   line	   could	  very	  well	  contribute	  to	  the	  regulation	  of	  the	  receiver	  cell	  fate.	  	  	  Among	  the	  proteases,	  cathepsin	  D	  (CTSD)	  is	  another	  common	  hit	  between	  the	  two	  CMs	  worth	  mentioning.	  This	  aspartic	  protease	  has	  been	  long	  identified	  as	  a	  clinical	  marker	   for	  poor	  prognosis	   in	  breast	  cancer	  patients11.	  Similarly	  to	  kallikreins,	   it	   is	  estrogen-­‐regulated.	   However,	   in	   contrast	   to	   other	   proteases	   it	   only	   becomes	  activated	  under	  acidic	  pH	  conditions.	   	   Its	  potential	  role	   in	  apoptosis	   is	  ambiguous.	  When	   secreted,	   cathepsin	   D	   acts	   as	   a	   mitogen	   for	   cancer	   cells,	   either	   by	   directly	  binding	   unknown	   growth	   receptors	   on	   the	   cells	   or	   by	   proteolytic	   degradation	   of	  growth	   factor	   inhibitors	   or	   by	   proteolytic	   activation	   of	   growth	   factor	   receptors.	  However	   it	  has	  also	  been	  shown	  to	  enhance	  apoptotic	  cascades	  that	  were	   induced	  by	  apoptotic	  agents,	  including	  serum	  starvation	  or	  oxidative	  stress12.	  	  
Quiescin	   (QSOX)	   is	   another	   common	  protein	  present	   in	  both	  CMs.	  Pernodet	  et	   al.	  have	  quantified	  expression	  levels	  of	  QSOX	  in	  different	  breast	  cancer	  cells	  and	  found	  MCF7	  to	  express	  it	  more	  than	  MDA-­‐MB-­‐231	  cells.	  Quiescin	  is	  therefore	  differentially	  expressed	   in	   different	   breast	   cancer	   cells.	   In	   the	   same	   study,	   the	   authors	  investigated	   the	   effect	   of	   exogenous	   quiescin	   over-­‐expression	   in	   these	   cell	   lines.	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They	   found	   that	   the	  QSOX-­‐overexpressing	   clones	  proliferated	   less	   and	  were	  more	  dependent	  on	  extracellular	  matrix	  adhesion	  for	  survival13.	  	  	  In	   tables	   (c)	   and	   (d)	   of	   figure	   3.6	  we	   display	   the	   apoptosis-­‐related	   hits	   that	  were	  unique	   to	   CM	   BT20	   and	   CM	   HCC38	   respectively.	  We	   note	   that	   both	   CMs	   contain	  additional	   yet	   different	   members	   of	   the	   cathepsin	   family.	   The	   same	   is	   true	   for	  proteasome	   subunits.	   In	   addition,	   CM	   BT20	   contains	   insulin-­growth-­factor-­
binding-­protein	   5	   (IGFBP5),	   a	   secreted	   antagonist	   of	   the	   IGF	   receptor	   that	  captures	   and	   arrests	   IGF	   ligands.	   IGFBPs	   are	   well	   documented	   pro-­‐apoptotic	  molecules	  shown	  to	  induce	  apoptosis	  of	  MCF7	  cells	  in	  culture3.	  However	  their	  pro-­‐apoptotic	  activity	  in	  the	  extracellular	  space	  can	  be	  curtailed	  by	  secreted	  kallikreins	  and	   cathepsins14.	   Once	   again	   the	   breast	   cancer	   conditioned	   media	   emerge	   as	  complex	  solutions	  of	  pro-­‐apoptotic	  and	  pro-­‐proliferative	  molecules	  that	  in	  addition	  to	  stimulating	  the	  receiver	  cells,	  are	  also	  actively	  interacting	  with	  each	  other.	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CPA4 carboxypeptidase A4 11.000 Extracellular Space 
APEH 
N-acylaminoacyl-peptide 
hydrolase 3.000 Cytoplasm 
CTSH cathepsin H 3.000 Cytoplasm 
LGMN legumain 3.000 Cytoplasm 
PSMD5 
proteasome (prosome, 
macropain) 26S subunit, non-
ATPase, 5 3.000 Cytoplasm 
CAPN1 calpain 1, (mu/I) large subunit 4.000 Cytoplasm 
CTSA cathepsin A 4.000 Cytoplasm 
CTSL2 cathepsin L2 4.000 Cytoplasm 
PSMA7 
proteasome (prosome, 
macropain) subunit, alpha 
type, 7 4.000 Cytoplasm 
PSME2 
proteasome (prosome, 
macropain) activator subunit 
2 (PA28 beta) 4.000 Cytoplasm 
Growth Factor Binding 
IGFBP5 
insulin-like growth factor 
binding protein 5 5.000 Extracellular Space 







aminopeptidase 9.000 Plasma Membrane 
C1S 
complement component 1, s 
subcomponent 6.000 Extracellular Space 
UCHL1 
ubiquitin carboxyl-terminal 
esterase L1 (ubiquitin 
thiolesterase) 5.000 Cytoplasm 
MMP7 
matrix metallopeptidase 7 
(matrilysin, uterine) 5.000 Extracellular Space 
ACE 
angiotensin I converting enzyme 
(peptidyl-dipeptidase A) 1 5.000 Plasma Membrane 
PSMA3 
proteasome (prosome, macropain) 
subunit, alpha type, 3 4.000 Cytoplasm 
USP15 ubiquitin specific peptidase 15 4.000 Cytoplasm 
C1R 
complement component 1, r 
subcomponent 4.000 Extracellular Space 
CTSB cathepsin B 3.000 Cytoplasm 
PSMD2 
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 2 3.000 Cytoplasm 
PSME1 
proteasome (prosome, macropain) 
activator subunit 1 (PA28 alpha) 3.000 Cytoplasm 
PSMB1 
proteasome (prosome, macropain) 
subunit, beta type, 1 3.000 Cytoplasm 
PSMB3 
proteasome (prosome, macropain) 
subunit, beta type, 3 3.000 Cytoplasm 
MMP2 
matrix metallopeptidase 2 
(gelatinase A, 72kDa gelatinase, 
72kDa type IV collagenase) 3.000 Extracellular Space 
Calcium Binding 
S100A11 
S100 calcium binding 
protein A11 5.000 Cytoplasm 
S100A6 
S100 calcium binding 
protein A6 3.000 Cytoplasm 
SRI sorcin 3.000 Cytoplasm 








QSOX1 quiescin Q6 sulfhydryl oxidase 1 14.000 11.000 Cytoplasm 
PDCD6IP 
programmed cell death 6 interacting 
protein 3.000 3.000 Cytoplasm 
Peptidases 
PDIA3 
protein disulfide isomerase family A, 
member 3 10.000 6.000 Cytoplasm 
CTSD cathepsin D 14.000 4.000 Cytoplasm 
PSMA4 
proteasome (prosome, macropain) subunit, 
alpha type, 4 3.000 3.000 Cytoplasm 
PSMA5 
proteasome (prosome, macropain) subunit, 
alpha type, 5 3.000 3.000 Cytoplasm 
CNDP2 
CNDP dipeptidase 2 (metallopeptidase 
M20 family) 3.000 4.000 Cytoplasm 
PSMA6 
proteasome (prosome, macropain) subunit, 
alpha type, 6 3.000 4.000 Cytoplasm 
GGH 
gamma-glutamyl hydrolase (conjugase, 
folylpolygammaglutamyl hydrolase) 3.000 5.000 Cytoplasm 
CFI complement factor I 4.000 3.000 Extracellular Space 
KLK5 kallikrein-related peptidase 5 4.000 3.000 Extracellular Space 
KLK6 kallikrein-related peptidase 6 5.000 3.000 Extracellular Space 




monooxygenase activation protein, epsilon 
polypeptide 11.000 5.000 Cytoplasm 
PEBP1 
phosphatidylethanolamine binding protein 
1 3.000 4.000 Cytoplasm 
PPP2R1A 
protein phosphatase 2, regulatory subunit 
A, alpha 3.000 5.000 Cytoplasm 
SFN stratifin 5.000 6.000 Cytoplasm 
YWHAZ 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta 
polypeptide 6.000 5.000 Cytoplasm 
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  Within	   CM	   HCC38	   we	   identify	   two	   members	   of	   the	   S100A	   family:	   S100A11	   and	  S100A6.	  These	  are	  intracellular	  calcium-­‐binding	  proteins	  that	  regulate	  a	  wide	  range	  of	   cell	   functions,	   namely	   cytoskeletal	   dynamics,	   immune	   response	   and	  differentiation.	   A	   microarray	   study	   of	   pancreatic	   cancer	   identified	   S100A11	   as	   a	  tumor	   suppressor	   that	   is	   upregulated	   in	   healthy	   tissue	   and	   the	   early	   stages	   of	  pancreatic	  carcinogenesis	  and	  decrease	  in	  expression	  during	  progression	  to	  cancer.	  Another	   study	   showed	   that	   intracellular	   S100A6	   enhanced	   the	   sensitivity	   to	  apoptosis	   in	  hepatocellular	   carcinoma	  cells,	   via	  upregulation	  of	   caspase-­‐315.	  While	  there	   has	   been	   significant	   research	   elucidating	   intracellular	   functions	   of	   S100A	  proteins	  in	  cancer,	  it	  remains	  unclear	  whether	  these	  proteins	  have	  a	  functional	  role	  when	  found	  in	  the	  extracellular	  environment.	  	  	  One	  additional	  advantage	  of	  this	  analysis	  is	  that	  it	  allows	  us	  to	  test	  the	  validity	  of	  the	  transcriptional	   dataset	   in	   terms	   of	   predicting	   the	   protein	   products	   in	   the	  extracellular	  and	  membranous	  fraction	  of	  the	  two	  cell	  lines.	  We	  construct	  table	  3.2	  for	   this	   purpose.	   	   Fibronectin	   (FN1)	   which	   was	   identified	   as	   a	   hit	   in	   the	  transcriptional	  analysis	  is	  actually	  present	  in	  both	  CMs,	  yet	  at	  larger	  quantity	  in	  CM	  HCC38.	   The	   remaining	   transcriptional	   hits	   for	   HCC38	   cells	   (CAV1,	   CD44	   and	  IGFBP3)	  were	  not	  actually	  present	  in	  the	  corresponding	  proteomic	  dataset.	  Instead	  we	  found	  IGFBP5,	  which	  was	  not	  transcriptionally	  predicted,	  present	  in	  CM	  BT20.	  In	  addition	  we	   see	   the	   growth	   factor	   receptors	   EGFR	   and	  MET	   to	   be	   present	   in	   the	  proteomic	  analysis	  of	  CM	  BT20,	  which	  again	  took	  us	  by	  surprise.	  Seeing	  that	  these	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are	  receptors	  embedded	  in	  the	  plasma	  membrane	  we	  did	  not	  expect	  to	  find	  them	  in	  the	  secreted	  fraction	  of	  the	  CM,	  and	  yet	  they	  were	  present.	  	  
	  
Table	  3.2:	  Hit	  overlap	  between	  transcriptional	  data	  set	  results	  (as	  summarized	  in	  table	  2)	  and	  mass	  spectrometry	  analysis	  of	  conditioned	  media	  HCC38	  and	  BT20.	  Overall	   the	   proteomic	   analysis	   of	   the	   two	   CMs	   indicated	   that	   contrary	   to	  expectation,	   the	   extracellular	   medium	   of	   cultured	   breast	   cancer	   cells	   is	   not	  dominated	   by	   secreted	   protein	   products,	   but	   is	   instead	   rich	   in	   cytoplasmic	   and	  membrane	  proteins,	  including	  growth	  factor	  receptors	  and	  cell	  adhesion	  molecules.	  One	  possible	   interpretation	  of	   this	   finding	   is	   that	  during	  CM	  production	  apoptotic	  cells	  release	  their	  contents	  in	  the	  media	  or	  that	  during	  CM	  harvesting	  whole	  cells	  are	  lysed	  and	  cytosplasmic	  contaminants	  enter	  the	  CM.	  	  Another	  possibility	  is	  that	  cells	  actively	   shed	   or	   export	   part	   of	   their	   cytoplasm	   and	   plasma	   membrane	   in	   the	  extracellular	  space.	  The	  following	  chapter	  will	  further	  explore	  this	  possibility.	  
	  	  	  
Symbol Entrez Gene Name 
CM BT20  
Peptide Count 
CM HCC38  
Peptide Count Location  
FN1 fibronectin 1 7 46 Extracellular Space 
IGFBP5 
insulin-like growth factor 
binding protein 5 5 - Extracellular Space 
EGFR 
epidermal growth factor 
receptor 7 - Plasma Membrane 
MET 
met proto-oncogene 
(hepatocyte growth factor 
receptor) 5 - Plasma Membrane 
CD44 
CD44 molecule  
(Indian blood group) 3 - Plasma Membrane 
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3.3	  Proteomic	  Analysis	  of	  HCC38	  and	  BT20	  Exosome	  Fractions	  In	   previous	   sections	   we	   established	   that	   breast	   cancer	   cells	   secrete	   exosome	  particles	  that	  we	  were	  able	  to	  successfully	  isolate	  from	  tissue	  culture	  supernatants.	  However,	  multiple	  apoptosis	  assays	  –both	  live	  cell	  imaging	  and	  M30	  ELISA-­‐	  showed	  that	  these	  microvesicles	  do	  not	  have	  significant	  apoptotic	  effect	  on	  recipient	  cells.	  In	  contrast	   our	   experiments	   indicate	   that	   the	   apoptotic	   activity	   is	   preserved	   in	   the	  supernatant	   of	   the	   exosome	   ultracentrifugation	   spin.	   In	   this	   section	   we	   perform	  mass	  spectrometry	  analysis	  of	  the	  HCC38	  and	  BT20	  exosome	  fractions.	  The	  purpose	  of	   this	   analysis	   is	   twofold.	   First,	   it	   is	   informative	   on	   the	   protein	   composition	   of	  exosomes.	  We	  will	   elaborate	   further	   on	   this	   point	   in	   the	   following	   chapter	   that	   is	  entirely	   dedicated	   to	   the	   characterization	   of	   exosome	   particles.	   Second,	   by	  comparing	  the	  mass	  spectrometry	  datasets	  of	  the	  exosome	  fraction	  to	  that	  of	  the	  full	  CM	   we	   are	   able	   to	   identify	   specific	   proteins	   unique	   to	   the	   CM	   fraction	   and	   by	  consequence	  narrow	  down	  the	  apoptotic	  candidate	  protein	  list.	  	  
Methods	  
LC/MS/MS	  Analysis	  	  We	  purified	  exosomes	  out	  of	  tissue	  culture	  supernatant	  as	  described	  in	  the	  previous	  chapter.	   During	   the	   final	   ultracentrifugation	   step	   in	   the	   exosome	   purification	  process,	  the	  exosome	  pellet	  was	  resuspended	  in	  25µl	  Laemmli	  buffer.	  The	  samples	  were	  heated	  at	  95°C	   for	  10min,	   then	   loaded	  and	  run	  halfway	  on	  an	  SDS-­‐PAGE	  gel,	  using	  MOPS	  buffer.	  	  	  The	  gel	  was	  stained	  with	  Coomassie	  Blue	  and	  each	  gel	  lane	  was	  cut,	   under	   sterile	   conditions,	   into	   two	   sections.	   All	   sections	   were	   submitted	   for	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micro-­‐capillary	   LC/MS/MS	   analysis	   at	   the	   Taplin	   Mass	   Spectrometry	   Facility	   of	  Harvard	  Medical	  School	  and	  processed	  as	  described	  in	  the	  previous	  section.	  	  
Comparison	  of	  CM	  HCC38	  and	  CM	  BT20	  to	  corresponding	  exosomes	  One	  overarching	  question	  we	  had	  when	  launching	  into	  this	  analysis	  was	  the	  size	  of	  the	  exosome	  protein	  content	  as	  compared	  to	  that	  of	  the	  full	  CM.	  In	  other	  words,	  are	  most	  proteins	  in	  the	  CM	  free-­‐floating	  or	  are	  they	  organized	  in	  membrane-­‐packaged	  exosomes?	   Figure	   3.7a	   reveals	   that	   the	   majority	   of	   proteins	   from	   the	   mass	  spectrometry	   analysis	   are	   common	  between	   the	   exosome	  and	   full	   CM	   samples.	   In	  fact	  only	  64	  unique	  proteins	  in	  CM	  HCC38	  were	  not	  identified	  in	  the	  corresponding	  exosomes.	   Of	   these,	   the	   majority	   were	   either	   of	   cytoplasmic	   or	   extracellular	  provenance,	   while	   there	   was	   also	   a	   smaller	   fraction	   of	   nuclear	   and	   plasma	  membrane	  proteins	  present	  (figure	  3.7d).	  	  	  Another	   relevant	   observation	   is	   that	   among	   these	   64	   unique	   protein	   hits,	   we	  identify	  both	  pro-­‐apoptotic	  proteins	   (figure	  3.7b)	   as	  well	   as	  pro-­‐growth	   cytokines	  (figure	   3.7c).	   	   The	   pro-­‐apoptotic	   table	   contains	   a	   short	   list	   of	   proteases,	  many	   of	  which	  were	   already	   discussed	   in	   the	   proteomic	   analysis	   of	   the	   preceding	   section	  (figure	  3.6).	  Specifically,	  the	  aspartic	  proteases,	  cathepsin	  D	  (CTSD)	  and	  cathepsin	  
B	  (CTSB)	  that	  activate	  under	  acidic	  pH	  conditions,	  as	  well	  as	  the	  estrogen-­‐regulated	  protease	  kallikrein	  6	  (KLK6)	  were	  all	  discussed	  in	  the	  previous	  chapter.	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In	   addition	   to	   the	   proteases	   we	   also	   identify	   a	   list	   of	   proteins	   related	   to	  inflammatory	   processes	   in	   cancer.	   Vasorin	   (VASN)	   is	   a	   transmembrane	   protein	  whose	  extracellular	  domain	  is	  cleaved	  and	  released	  in	  the	  extracellular	  environment	  in	  soluble	  form	  by	  the	  metalloprotease	  ADAM17.	  Malapeira	  et	  al.16	  recently	  showed	  that	   the	   soluble	   form	   of	   vasorin	   is	   capable	   of	   sequestering	   transforming	   growth	  factor	  beta	  (TGFβ)	  and	  in	  this	  way	  regulate	  epithelial-­‐to-­‐mesenchymal	  transitions	  in	  breast	   cancer.	   Their	   immuno-­‐blots	   confirm	   the	   presence	   of	   the	   soluble	   form	   of	  vasorin	   is	   the	   condition	   media	   of	   multiple	   breast	   cancer	   cell	   lines	   (SKBR3,	  MDAMB416	   and	   MDAMB631),	   while	   show	   that	   the	   protein	   is	   absent	   from	  MCF7	  conditioned	  media.	  	  Another	   pro-­‐inflammatory	   hit	   is	   pentraxin	   3	   (PTX3),	   a	   protein	   most	   commonly	  secreted	   by	   macrophages	   and	   dendritic	   cells	   in	   response	   to	   pro-­‐inflammatory	  cytokines	   LPS,	   IL-­‐1	   and	   TNFα17.	   In	   a	   murine	   melanoma	   model,	   Leali	   et	   al.18,19	  showed	   that	   PTX3	   is	   able	   to	   sequester	   fibroblast	   growth	   factor-­‐2	   (FGF2)	   and	  therefore	   suppress	   tumor	   growth	   and	   vascularization.	   Margheri	   et	   al.	   stably	  transfected	  breast	  cancer	  cell	  lines	  MCF7	  and	  MDAMB231	  with	  PTX3	  and	  found	  that	  the	  PTX3-­‐overexpressing	  clones	  showed	  powerful	  anti-­‐FGF2	  activity,	  particularly	  in	  an	  FGF2-­‐dependent	  capillary	  morphogenesis	  assay20.	  The	  anti-­‐angiogenic	  activity	  of	  PTX3	  is	  well-­‐documented	  in	  the	  literature,	  however	  no	  research	  has	  been	  conducted	  regarding	  pentraxin’s	  3	  pro-­‐apoptotic	  effect	  in	  cancer.	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Among	  the	  cytokines	  that	  were	  uniquely	  identified	  in	  CM	  HCC38,	  attractin	  (ATRN)	  is	  a	   secreted	  cytokine	  associated	  with	  an	   invasive	  diagnostic	   signature	   in	  prostate	  cancer21.	  Particularly	  in	  glioma	  and	  malignant	  astrocytoma,	  Kwaja	  et	  al.	   found	  that	  attractin	  has	  promigratory	  activity	  on	  tumor	  cells22.	  	  	  
	  







GGH gamma-glutamyl hydrolase  5 Cytoplasm 
CNDP2 
CNDP dipeptidase 2 
(metallopeptidase M20 family) 4 Cytoplasm 
CTSD cathepsin D 4 Cytoplasm 
USP15 ubiquitin specific peptidase 15 4 Cytoplasm 
CTSB cathepsin B 3 Cytoplasm 
CFI complement factor I 3 Extracellular Space 
KLK6 kallikrein-related peptidase 6 3 Extracellular Space 
Inflammation 
CHI3L1 
chitinase 3-like 1 (cartilage 
glycoprotein-39) 4 Extracellular Space 
VASN vasorin 4 Plasma Membrane 







SCG2 secretogranin II 8 Extracellular Space 
ATRN attractin 7 Extracellular Space 
FAM3C 
family with sequence similarity 3, 
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When	  comparing	  CM	  BT20	  to	  its	  corresponding	  exosomes	  we	  see	  that	  the	  exosome	  proteomic	   dataset	   is	   larger	   than	   that	   of	   the	   CM’s,	   possibly	   a	   consequence	   of	   the	  exosome	  fraction	  being	  more	  concentrated	  than	  the	  CM.	  Next,	  we	  observe	  a	  similar	  pattern	  as	   in	   the	  CM	  HCC38	  comparison,	   that	   is	   the	  majority	  of	  CM	  BT20	  proteins	  are	  alos	  identified	  in	  the	  exosomes	  and	  only	  a	  minority	  of	  50	  protein	  hits	  are	  unique	  to	  the	  CM.	  Annotation	  reveals	  that	  most	  of	  these	  proteins	  are	  of	  cytoplasmic	  cellular	  origin.	   There	   are	   approximately	   equal	   amounts	   of	   extracellular	   and	   plasma	  membrane	  proteins	  in	  the	  set	  and	  a	  small	  minority	  of	  nuclear	  proteins	  (figure	  3.8d).	  Among	  these	  proteins	  we	  list	  a	  set	  possibly	  related	  to	  apoptosis	  (figure	  3.8b)	  as	  well	  as	  a	  set	  of	  pro-­‐proliferative	  hits	  (figure	  3.8c).	  	  	  In	   the	   apoptosis	   related	  hits,	   legumain	   (LGMN)	   	   stands	  out	   among	   the	  proteases.	  Legumain	  is	  an	  asparaginyl	  endopeptidase	  that	  was	  first	  identified	  in	  plant	  cells	  and	  later	  shown	  to	  be	  conserved	  among	  many	  mammalian	  cells.	  It	  has	  been	  recognized	  as	  a	  prognostic	  marker	  in	  breast	  cancer	  tumors	  by	  immunohistochemistry	  of	  patient	  neoplastic	   tissue	   sections23.	   In	   addition,	   it	   was	   shown	   that	   cancer	   cells	  overexpressing	   cytoplasmic	   legumain	   adopt	   an	   invasive	   and	   metastatic	  phenotype24.	  Another	  study	  has	  shown	  that	   legumain	  expression	  occurs	   in	  murine	  breast-­‐tumor	   associated	   macrophages,	   while	   classical	   macrophages	   of	   the	   M1	  phenotype,	   which	   perform	   key	   immune	   surveillance	   and	   antigen-­‐presentation	  functions,	  do	  not	  express	  legumain25.	  No	  study	  has	  yet	  been	  conducted	  on	  secreted	  legumain	  and	  its	  potential	  functions.	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In	  addition	  to	  proteases,	  we	  note	  the	  presence	  of	  kinase	  inhibitors	  in	  the	  unique	  CM	  BT20	   protein	   hits.	   Particularly	   the	   serine	   peptidase	   inhibitor	   Kunitz	   type	   1	  (SPINT1)	   is	   of	   interest	   to	   us,	   since	   the	   literature	   indicates	   it	   interacts	   with	  
hepatocyte	  growth	  factor	  (HDGF),	  a	  growth-­‐promoting	  factor	  also	  identified	  in	  the	  unique	  soluble	  protein	  hits	  of	  this	  analysis	  (figure	  3.8c).	  In	  fact,	  the	  alternate	  name	  for	   SPINT1	   is	   hepatocyte	   growth	   factor	   activator	   inhibitor	   1	   (HAI-­‐1)	   since	   it	  sequesters	   HDGF	   and	   curtails	   its	   activity26.	   Cheng	   et	   al	   showed	   that	   SPINT1-­‐knockout	   clones	   of	   pancreatic	   cancer	   cells	   assumed	   an	   invasive	   and	   metastatic	  phenotype	  comparative	   to	   the	  wild-­‐type	  control	  cells26.	  More	  specifically	   in	  breast	  cancer,	   Parr	   et	   al.	   showed	   that	   elimination	   of	   SPINT1	   and	   SPINT2	   expression	   in	  MDAMB231	  breast	  cancer	  cells	  enhances	  the	  migratory	  and	  proliferative	  nature	  of	  these	  cells.	  They	  concluded	  that	  SPINT1	  and	  SPINT2	  serine	  protease	  inhibitors	  have	  strong	  therapeutic	  potential	  in	  the	  anti-­‐HDGF	  cancer	  therapy	  arena27.	  	  Upon	  closer	   inspection	  we	  see	   that	  a	   third	  player	   in	   the	  hepatocyte	  growth	   factor	  signaling	   pathway	   is	   also	   present	   in	   the	   protein	   hit	   list.	   Indeed,	   the	   hepatocyte	  
growth	   factor	   receptor	   (MET)	   itself	   is	   found	   in	   soluble	   form	   in	   the	   CM	   BT20	  secretions	  (figure	  3.8c).	  This	  was	  an	  unexpected	  finding,	  particularly	  because	  as	  we	  will	   be	   discussing	   in	   the	   following	   chapter,	   when	   tyrosine	   kinase	   receptors	   are	  found	   in	   the	   extracellular	   space,	   it	   is	   usually	   as	   part	   of	   the	   secreted	   exosome’s	  membranes.	  However,	  there	  is	  precedence	  for	  this	  finding	  as	  Athauda	  et	  al.28	  using	  a	  sensitive	   electro-­‐chemiluminescence	   immunoassay,	   confirmed	   c-­‐MET	   ectodomain	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shedding	  from	  breast	  cancer	  cells	  in	  culture	  and	  furthermore	  demonstrated	  that	  the	  shedding	  rate	  correlates	  with	  malignant	  potential.	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bar	  color	  encoded	  for	  cellular	  localization:	  nucleus	  (purple),	  plasma	  membrane	  (green),	  extracellular	  (red)	  and	  cytoplasm	  (blue).	  	  	  Within	   the	   scope	   of	   our	   study,	   it	   is	   extremely	   intriguing	   that	   both	   the	   hepatocyte	  growth	  factor	  receptor,	  the	  receptor’s	  ligand	  as	  well	  as	  the	  ligand’s	  active	  inhibitor	  are	   all	   found	   in	   the	   extracellular	   secretions	   of	   CM	   BT20.	   One	   question	   arising	   is	  whether	  the	  soluble	  form	  of	  the	  MET	  receptor	  can	  bind	  the	  ligand	  and	  therefore	  also	  act	   as	   an	   antagonist	   to	   the	   HDGF	   mitogenic	   signal.	   Another	   question	   relates	   to	  quantity	  of	  all	   three	  proteins:	   is	  the	  pro-­‐growth	  signal	  of	  HDGF	  in	  abundance	  or	   is	  the	  SPINT1	   inhibitor	  presence	  high	  enough	   to	  completely	  quench	   it?	  Certainly	   the	  presence	  of	  SPINT1	  demonstrates	  a	  clear	  way	   that	  CM	  BT20	  could	  be	   toxic	   to	  any	  recipient	  cell	   line	  dependent	  on	  a	  HDGF	  autocrine	  loop	  for	   it’s	  proliferation.	  In	  the	  same	  vein,	  PTX3	  that	  was	  identified	  in	  CM	  HCC38	  is	  a	  clear	  mechanism	  of	  toxicity	  to	  any	  cell	  line	  dependent	  on	  FGF2	  autocrine	  signaling.	  In	  addition,	  the	  elimination	  or	  inactivation	   of	   HDGF	   from	   CM	   BT20	   will	   only	   increase	   this	   CM’s	   pro-­‐apoptotic	  activity	  on	  HDGF-­‐dependent	  CM-­‐recipient	  cells.	  	  Finally	  on	  figure	  3.9a	  we	  compare	  the	  unique	  proteins	  found	  in	  CM	  HCC38	  and	  CM	  BT20	  to	  each	  other	  and	  identify	  16	  common	  proteins	  between	  the	  two	  datasets.	  On	  figure	   3.9b	   we	   proceed	   to	   group	   the	   proteins	   into	   functional	   categories,	   while	  comparing	   the	  peptide	  count	  recorded	   in	  each	  CM.	  Among	  the	  common	  proteases,	  
cathepsin	  D	  (CTSD)	  stands	  out,	  while	  two	  other	  proteases	  are	  shared	  as	  well:	  CNDP	  
dipeptidase	  2	  and	  gamma	  glutamyl	  hydrolase	  (GGH).	   	  We	  also	  find	  the	  cytokine	  
attractin	   (ATRN)	   shared	   between	   the	   two	   CMs.	   The	   remainder	   of	   the	   common	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proteins	   are	   housekeeping	   in	   their	   function	   and	   unlikely	   to	   hold	   significant	   pro-­‐apoptotic	  or	  pro-­‐proliferative	  activity	  on	  CM-­‐recipient	  cells.	  	  
	  
Figure	  3.9:	  Comparative	  proteomic	  analysis	  of	  CM	  HCC38	  and	  CM	  BT20	  unique	  protein	  hits,	  excluding	  respective	  exosome	  protein	  content.	  	  a)	  The	  Venn	  diagram	  indicates	  the	  common	  proteins	  between	  the	  two	  conditioned	  media.	  b)	  Following	  ontology	  and	  localization	  analysis	  we	  group	  the	  common	  proteins	  by	  function	  and	  plot	  the	  detected	  peptide	  count	  in	  each	  CM	  respectively.	  The	  clue	  bars	  indicate	  the	  CM	  HCC38	  peptide	  count	  while	  red	  bars	  are	  for	  CM	  BT20.	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Chapter	  4	  
	  
Characterization	  and	  Functional	  Studies	  of	  Breast	  Cancer-­Derived	  Exosomes	  
	  
Abstract	  The	  present	   chapter	  discusses	   the	  biology	  of	   exosomes,	  nanometer-­‐sized	  particles	  secreted	  by	  most	  cell	   lines	  in	  culture.	  Exosomes	  form	  intracellularly	  by	  the	  inward	  budding	   of	   the	   limiting	  membrane	   of	   endocytic	   compartments,	   leading	   to	   vesicle-­‐containing	  endosomes	  called	  multivesicular	  bodies.	  Multivesicular	  bodies	  fuse	  with	  the	   plasma	   membrane,	   releasing	   the	   endosomes	   –now	   termed	   exosomes-­‐	   in	   the	  extracellular	   space.	  Although	  several	   studies	  address	   the	  composition	  and	  content	  of	   exosomes,	   their	   physiological	   roles	   both	   in	   healthy	   and	   diseased	   tissue	   remain	  vastly	   un-­‐explored.	   We	   begin	   this	   study	   with	   a	   description	   of	   methods	   of	  purification	   and	   characterization	   of	   the	   exosomal	   fraction	   from	   tissue	   culture	  supernatants.	  We	  then	  discuss	  methods	  of	  quantitation	  and	  fluorescent	   labeling	  of	  particles.	  We	  next	   turn	  our	  attention	   to	   the	  protein	  content	  of	  exosomes.	  First	  we	  employ	   a	   proteomic	   approach	   to	   qualify	   the	   overall	   protein	   content	   of	   breast	  cancer-­‐derived	   exosomes.	   	   Next	   we	   embark	   in	   a	   series	   of	   western	   blots	   which	  	  screen	   both	   cell	   lines	   and	   their	   corresponding	   exosomes	   for	   common	   diagnostic	  markers	   of	   breast	   cancer	   as	  well	   as	   drugable	   intracellular	   kinases.	   Following	   this	  screen	  we	  specifically	   focus	  on	  the	  EGFR	  tyrosine	  kinase	  and	  undertake	  functional	  studies	   of	   the	   receptor	   on	   the	   exosome	  membrane.	   Furthermore,	  we	   ask	  whether	  the	   phosphorylation	   status	   of	   EGFR	   reflects	   the	   phosphorylation	   status	   of	   the	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exosome-­‐producing	   cell	   line.	   Finally	   we	   attempt	   to	   uncover	   biological	   activity	   of	  exosomes,	   by	   incubating	   receptor-­‐positive	   exosomes	   with	   receptor-­‐negative	   cell	  types	  and	  observing	  whether	  receptor	  transfer	  takes	  place	  on	  the	  recipient	  cells.	  	  	  
4.1	  Methods	  in	  Exosome	  Biology	  
Exosome	  Purification	  There	   currently	   exist	   a	   variety	   of	   protocols	   for	   precipitating	   microvesicles	   from	  tissue	  culture	  supernatants	  and	  biological	  fluids.	  A	  size-­‐cutoff	  filter	  can	  be	  employed	  to	   isolate	   vesicles	   in	   the	   size	   range	   of	   exosomes1.	   Alternatively	   polymer	   co-­‐precipitation	  is	  a	  commercially	  proposed	  solution	  for	  speady	  recovery	  of	  exosomes2.	  However,	  the	  most	  popular	  and	  tested	  protocol	  for	  exosome	  recovery	  is	  differential	  ultracentrifugation	   proposed	   by	   Théry	   et	   al.3.	   The	   advantage	   of	   differential	  ultracentrifugation	   over	   other	   methods	   is	   the	   step-­‐wise	   elimination	   of	   larger	  vesicles	  and	  fragments	  of	  shed	  membrane	  from	  the	  conditioned	  medium,	  preceding	  the	  isolation	  of	  the	  exosomal	  fraction.	  	  In	  this	  way	  fraction	  purity	  is	  ensured.	  	  	  Differential	  ultracentrifugation,	  as	  described	  in	  figure	  1,	  is	  our	  method	  of	  choice	  for	  exosome	   purification	   throughout	   this	   study.	   The	   exosome	   production	   protocol	  begins	  with	  a	  48hr	  incubation	  of	  80%	  confluent	  cell	  monolayers	  in	  serum-­‐free	  RPMI	  medium.	   Serum-­‐free	   medium	   is	   essential	   if	   exosomes	   will	   be	   purified	   from	   the	  resulting	   conditioned	   medium	   (CM),	   because	   fetal	   calf	   serum	   contains	   bovine	  microvesicle	   that	   can	   contaminate	   the	   purity	   of	   the	   exosomal	   fraction.	   At	   48hrs	  conditioned	  medium	  is	  harvested	  from	  cells	  and	  centrifuged	  at	  300g	  for	  10	  min	  to	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remove	   cells,	   then	   at	   2000g	   for	   10min	   to	   remove	   apoptotic	   bodies.	   Conditioned	  medium	   is	   subsequently	  passed	   through	  a	  3k	   centrifugal	   filtering	  device	  at	  4000g	  for	   30min	   in	   order	   to	   concentrate	   the	   large	   CM	  volume	  down	   to	   a	   few	  milliliters.	  	  The	   concentrated	   CM	   is	   subsequently	   ultra-­‐centrifuged	   at	   10,000g	   for	   30min	   to	  pellet	   cell	   debris	   and	   large	   vesicles.	   The	   supernatant	   from	   this	   step	   is	   ultra-­‐centrifuged	   at	   100,000g	   for	   70min	   to	   pellet	   the	   exosomes.	   The	   exosomal	   pellet	  undergoes	  a	  final	  wash	  step,	  is	  re-­‐suspended	  in	  PBS	  and	  re-­‐pelleted	  at	  100,000g	  for	  60min.	  	  	  
	  
Figure	  3.13:	  Methods	  of	  exosome	  purification.	  Left	  panel:	  purification	  by	  differential	  centrifugation.	  Right	  panel:	  all	  proposed	  methods	  of	  purification	  ,	  with	  references.	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Exosome	  Characterization	  Following	  isolation,	  purity	  of	  the	  exosomal	  fraction	  can	  further	  be	  established	  by	  a)	  examining	   the	   protein	   composition	   of	   the	   exosomal	   membrane	   and	   b)	   sizing	   the	  purified	   particles.	   Due	   to	   the	   nanometer-­‐scale	   size	   of	   exosomes,	   imaging	   of	   this	  biological	   structure	   is	   mostly	   limited	   to	   electron	   microscopy	   techniques.	   We	  employed	  both	  negative	  stain	  labeling	  as	  well	  as	  negative	  stain	  immunogold	  labeling	  to	  visualize	  and	  characterize	  exosomes	  for	  the	  purpose	  of	  this	  study.	  	  	  The	  protocol	  followed	  for	  whole	  cell	  exosome	  mounting	  on	  Formvar-­‐carbon	  coated	  grids	   and	   subsequent	   negative	   stain	   labeling	  preparation	   of	   samples	   for	   elecrtron	  microscopy	   analysis	   is	   the	   one	   introduced	   by	   Théry	   et	   al.3.	   Briefly,	   following	  ultracentrifugation	   the	   exosome	   pellet	   is	   fixed	   by	   re-­‐suspension	   in	   2%	  paraformaldehyde	   (PFA).	   5ul	   of	   sample	   are	   adsorbed	   on	   Formvar-­‐carbon	   coated	  grids.	   The	   grids	   are	   washed	   in	   PBS	   drops	   and	   subsequently	   dropped	   on	   a	   1%	  glutaraldehyde	  solution.	  The	  grids	  are	  washed	  in	  distilled	  water	  and	  contrasted	  by	  incubation	   on	   a	   uranyl-­‐acetate	   drop,	   for	   a	   minimum	   of	   10min.	   Subsequently	   the	  grids	   are	   washed	   in	   distilled	   water	   and	   stored	   before	   imaging	   on	   electron	  microscope	  at	  80kV.	  	  For	   immunogold	   labeling	   exosomes	   were	   resuspended	   in	   PBS	   after	  ultracentrifugation.	   Fixation	   of	   exosomes	   was	   avoided	   here,	   since	   we	   found	   it	   to	  interfere	  with	  the	  structure	  and	  integrity	  of	  protein	  surface	  markers.	  	  Instead	  5ul	  of	  ‘live’	   exosomes	   were	   adsorbed	   on	   the	   Formvar-­‐carbon	   coated	   grids,	   Following	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adsorption,	   the	   grids	   were	   incubated	   with	   a	   succession	   of	   primary	   antibody	   –	  Protein	  A	   gold	  beads	   –	   bridging	   antibody	   –	   secondary	   antibody.	   Subsequently	   the	  grids	  were	  contrasted	  and	  embedded	  as	  described	  above.	  	  	  
	  
Figure	  3.14:	  Negative	  stain	  electron	  microscopy	  of	  HCC38-­‐derived	  exosomes.	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Figure	  3.15:	  Negative	  stain	  electron	  microscopy	  of	  BT20-­‐derived	  exosomes.	  
	  Proteins	   of	   the	   tetraspanin	   family	   are	   highly	   enriched	   in	   exosomes	   from	   virtually	  any	   cell	   type,	   as	   a	   result	   of	   the	   exosome	   biogenesis	   process4.	   Tetraspanins	   are	  membrane	  proteins	  with	  four	  transmembrane	  domains,	  involved	  in	  many	  different	  biological	   functions	   such	   as	   fusion,	   motility,	   immune	   stimulation,	   adhesion	   and	  protein	   sorting.	   In	   this	   study	   we	   blotted	   the	   exosomal	   fraction	   (exos),	   the	  supernatant	  from	  the	  exosomal	  ultracentrifugation	  (exosup)	  as	  well	  as	  the	  original	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non-­‐fractionated	   conditioned	  medium	   (CM)	   for	   tetraspanins	   CD63	   and	   CD81.	  We	  show	   that	   in	   both	   HCC38	   and	   BT20	   derived	   exosomes,	   CD63	   is	   present	   in	   the	  original	   CM	   and	   highly	   enriched	   in	   the	   exosomal	   fraction	   as	   compared	   to	  thsupernatant	  fraction	  (fig4&5).	  Additionally	  we	  observe	  a	  similar	  trend	  for	  CD81	  in	  the	  case	  of	  HCC38-­‐derived	  exosomes	  (fig4).	  Another	  marker	  of	  exosomal	  presence	  is	  Major	  Histocompatibility	  Complex	  I	  (MHC	  I).	  MHC	  I	  is	  found	  in	  the	  extracellular	  space	  at	  full	  length	  (50kDa)	  when	  attached	  on	  exosomal	  membrane	  as	  well	  as	  at	  a	  cleaved	  (40kDa)	  soluble	  version.	  We	  show	  that	  whereas	  the	  CM	  and	  exosomal	  supernatant	  feature	  both	  MW-­‐versions	  of	  MHC	  I,	  the	  exosome	  fractions	  contains	  solely	  the	  membrane	  bound	  full-­‐length	  version	  of	  MHCI	  (figures	  4&5).	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Figure	   16:	   Negative	   stain	   immunogold	   labeling	   and	   confirmation	   by	   western	   blot	   of	   exosomal	  markers	  CD63,	  CD81	  and	  MHC	  class	  I	  on	  the	  surface	  of	  HCC38-­‐derived	  exosomes	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Fluorescent	  Labeling	  of	  Exosomes	  In	   order	   to	   temporary	   follow	   the	   endocytosis	   of	   exosomes	   by	   target	   cell	   lines,	  fluorescent	  labeling	  of	  the	  vesicles	  is	  necessary.	  There	  currently	  exist	  two	  ways	  by	  which	   to	   fluorescently	   label	   exosomes.	   The	   first	   is	   by	   cloning	   a	  GFP-­‐CD63	  variant	  into	   the	   genome	   of	   the	   exosome-­‐producing	   cell	   line5.	   The	   alternative	   and	   more	  expedient	   way	   to	   fluorescent	   exosomes	   is	   direct	   labeling	   of	   the	   purified	   vesicles	  with	  the	  lipophilic	  dye	  PKH-­‐266–8.	  	  	  The	   PKH-­‐26	   dye	   was	   designed	   as	   a	   live	   fluorescent	   probe	   of	   cell	   membrane,	  therefore	  the	  manufacturer’s	  protocol	  has	  to	  be	  adapted	  for	  this	  application.	  Briefly,	  exosomes	   are	   recovered	   by	   ultracentrifugation	   as	   previously	   described	   and	  resuspended	   in	   a	   solution	   of	   Diluent	   C	   (500ul)	   and	   PKH-­‐26	   dye	   (2ul).	   The	  exosomal/dye	  mixture	   is	   left	   to	   incubate	   for	   5min	   at	   room	   temperature.	  Next	   the	  staining	  is	  halted	  by	  introducing	  1ml	  of	  an	  aqueous	  solution	  of	  1%	  BSA.	  Exosomes	  are	  recovered	  by	  ultracentrifugation	  and	  resuspended	  in	  100ul	  serum-­‐free	  medium,	  supplemented	  by	  1%	  BSA.	  	  
	  
Exosome	  Quantitation	  Again,	   there	   are	   a	   variety	   of	   methods	   for	   quantifying	   number	   of	   exosomes	   in	   a	  solution.	  The	  golden	  standard	  for	  exosome	  quantitation	  is	  NanoSight,	  a	  microscopy	  based	  method	  of	  laser-­‐assisted	  particle	  scattering	  that	  is	  able	  to	  determine	  not	  only	  concentration	  of	  particles,	  but	  also	  particle	  size,	  zeta	  potential	  and	  polydispersity	  of	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the	   particulate	   solution	   (http://www.nanosight.com/).	   However	   due	   to	   high	   cost	  and	  limited	  accessibility	  to	  this	  equipment,	  alternate	  ways	  of	  quantifying	  exosomes	  had	  to	  be	  explored	  for	  the	  purpose	  of	  this	  study.	  	  	  One	  alternative	  to	  particle	  number	  for	  sample	  quantitation	  was	  to	  measure	  instead	  the	   overall	  protein	   concentration	   of	   the	   exosome	   fraction.	   	   Exosome	   lysate	  was	  prepared	  by	  resuspension	  of	  the	  exosome	  ultracentrifugation	  pellet	  in	  100ul	  MPER	  supplemented	  with	  1x	  Roche	  protease	  inhibitor.	  The	  exosome	  lysate	  was	  incubated	  on	   ice	   for	  30min	  and	   then	  centrifuged	  15min	  at	  14,000g	   to	  pellet	  membrane.	  The	  supernatant	   from	   the	   spin	   was	   recovered	   and	   protein	   levels	   were	   quantified	  following	  the	  protocol	  for	  a	  microBCA	  assay9.	  	  Another	   alternative	   for	   quantitation	   of	   exosome	   yield	   is	   measuring	   the	   overall	  
phosphate	  content	  of	  the	  exosomal	  fraction,	  the	  phosphate	  serving	  as	  proxy	  for	  the	  amount	  of	  phospholipid	  present	  on	  the	  exosomal	  membrane.	  For	  the	  purpose	  of	  this	  assay	  the	  exosome	  pellet	  is	  re-­‐suspended	  in	  100ul	  of	  TBS	  buffer.	  A	  few	  microliters	  of	  sample	   are	   transferred	   in	  borosilicate	   test	   tubes	   and	   incubated	  with	  10%	  sulfuric	  acid	  (H2SO4)	  at	  200C	   for	  1hr.	  A	  solution	  of	  30%	  hydrogen	  peroxide	  (H2O2)	   is	   then	  added	   to	   the	   tubes	   and	   the	   samples	   are	   further	   heated	   for	   40min.	   The	   tubes	   are	  cooled	   to	   room	   temperature	   and	   water	   is	   added	   to	   each	   one.	   Colorimetry	   is	  performed	   by	   adding	   a	   solution	   of	   5%	   Ammonium	  Molybdate	   and	   10%	   Ascorbic	  Acid	  to	  the	  samples,	  then	  incubating	  in	  a	  45C	  water	  bath	  for	  20min	  to	  develop	  color.	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Absorbance	  is	  read	  at	  820nm.	  A	  standard	  curve	  for	  the	  assay	  is	  prepared	  by	  titrating	  0-­‐10ul	  DOPC	  lipids.	  	  This	   method	   is	   routinely	   used	   for	   phospholopid	   quantitation	   in	   liposome	  preparations,	  yet	   it	   is	   the	   first	   time	   it	   is	  used	   in	   the	  context	  of	  exosomes.	  Figure	  6	  demonstrates	   the	   efficiency	   of	   the	   assay	   in	   capturing	   the	   dose-­‐dependent	  augmentation	  of	  phosphate	  in	  MDAMB231-­‐derived	  exosomes.	  Also	  on	  figure	  6,	  the	  ratio	   of	   phosphate	   to	   protein	   is	   plotted	   for	   exosomes	   derived	   from	   five	   distinct	  breast	   cancer	   cell	   lines.	  We	  observe	   significant	  variability	  of	  protein	   to	  phosphate	  content	   in	   exosomes,	   dependent	   on	   the	   cell	   line	   of	   origin.	  HCC38-­‐derived	   vesicles	  feature	  100-­‐fold	  more	  phosphate	  than	  protein,	  BT20	  and	  T47D	  exosomes	  feature	  a	  1	   to	   1	   ratio,	   whereas	   SKBR3	   and	   MCF7	   exosomes	   feature	   more	   protein	   than	  phosphate.	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4.2	  Mass	  Spectrometry	  Analysis	  of	  BT20	  and	  HCC38-­derived	  exosomes.	  
	  The	  purpose	  of	   this	  analysis	   is	   to	  get	  an	   idea	  of	   the	  overall	  protein	  content	  within	  cancer-­‐derived	  exosomes.	  Immunoblots	  presented	  in	  the	  following	  section	  allowed	  us	   to	  probe	   specifically	   for	   therapeutically	   relevant	  molecules,	  whereas	  proteomic	  analysis	   supplies	   us	   with	   broader	   insights	   on	   breast	   cancer-­‐derived	   exosome	  composition.	  	  The	   purification	   of	   exosomes	   and	   micro-­‐capillary	   LC/MS/MS	   analysis	   protocols	  followed	  are	  described	  in	  chapter	  3,	  section	  3.	  The	  exosome	  dataset	  presented	  is	  the	  same	  as	   in	   chapter	  23	  however	  here	  we	  proceed	   to	   analyze	   the	  HCC83	  and	  BT20	  exosome	  proteomic	  contents	  alone.	  	  On	  figure	  3.7a	  we	  see	  that	  BT20	  and	  HCC38	  exosomes	  have	  in	  total	  572	  protein	  hits	  in	   common.	   For	   the	   purpose	   of	   this	   analysis	   we	   used	   the	   entire	   list	   of	   proteins	  including	  those	  of	  low	  peptide	  count	  as	  we	  found	  that	  exosome	  markers	  appeared	  in	  the	  dataset	  at	  very	   low	  peptide	  counts	  (1	  or	  2	  peptides	  detected).	   	   In	  terms	  of	   the	  cellular	   provenance	   of	   the	   exosome’s	   common	   572	   proteins,	   we	   find	   that	   the	  majority	  of	  proteins	  –about	  60%-­‐	  are	  of	  cytoplasmic	  origin.	  When	  compared	  to	  the	  mass	   spectrometry	   list	  of	   common	  proteins	  between	   the	   two	  CMs,	   that	  number	   is	  almost	   equal.	   The	   main	   difference	   between	   the	   two	   is	   that	   plasma	   membrane	  proteins	  appear	  enriched	  in	  the	  exosome	  fraction	  as	  compared	  to	  the	  full	  CM,	  while	  extracellular	   proteins	   are	   depleted	   (figure	   3.7c).	   Finally	   nuclear	   proteins	   are	   also	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more	   abundant	   in	   exosomes	   compared	   to	   the	   corresponding	   CMs.	   	   These	  observations	  are	   in	   line	  with	  expectations	  based	  on	  exosome	  biology.	  Cytoplasmic	  proteins	  are	  shuttled	  in	  the	  extracellular	  space	  by	  being	  packaged	  in	  microparticles.	  These	   microparticles	   conserve	   most	   membrane	   proteins	   present	   in	   the	   plasma	  membrane.	   They	   also	   encapsulate	   microRNAs,	   which	   explains	   the	   higher	  representation	  of	  nuclear	  proteins	  in	  the	  exosomes.	  	  	  In	  terms	  of	  functional	  characterization	  of	  the	  572	  common	  proteins	  we	  see,	  as	  in	  the	  corresponding	   CM	   analysis,	   an	   abundance	   of	   cytoskeletal	   proteins	   as	   well	   as	   a	  variety	  of	  other	  functional	  categories	  that	  are	  housekeeping	  in	  their	  nature	  such	  as	  transporters,	   translational	   regulators,	   calcium	   binding	   and	   heat	   shock	   proteins.	  Particularly	   the	   presence	   of	   a	   high	   number	   (approximately	   45)	   of	   glycolytic	  enzymes	   and	   regulators	   raises	   the	   question	   of	   whether	   exosomes	   have	   an	   intact	  glycolytic	   pathway	   and	   are	   able	   to	   convert	   extracellular	   glucose	   to	   ATP10.	  	  Accordingly,	  the	  fact	  that	  exosomes	  carry	  multiple	  cell	  adhesion	  molecules,	  the	  list	  ranging	  from	  a	  variety	  of	  integrins	  to	  epithelial-­‐specific	  CAMs,	  raises	  the	  question	  of	  whether	  these	  proteins	  are	  functional	  on	  the	  surface	  of	  exosomes	  and	  help	  anchor	  the	  vesicles	  to	  recipient	  cells.	  Moreover	  can	  these	  exosomal	  adhesion	  molecules	  be	  uptaken	   by	   recipient	   cells	   and	   alter	   their	   phenotype?	   These	   are	   fascinating	  questions	   about	   exosome	   function	   in	   the	   extracellular	   space	   that	   remain	   vastly	  unanswered	  in	  the	  literature	  at	  present.	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Beside	   the	   predictable	   housekeeping	   protein	   sets	   we	   also	   find	   some	   surprising	  protein	  categories	  on	  figure	  3.7c.	  The	  high	  abundance	  of	  ribosomal	  proteins	  is	  one	  such	  surprise.	  In	  fact,	  proteomic	  studies	  of	  exosomes	  derived	  from	  a	  variety	  of	  cell	  types	  and	  a	  range	  of	  biological	  fluids	  feature	  ribosomal	  proteins11.	  The	  presence	  of	  intact	   ribosomes	   encapsulated	   in	   exosomes	   is	   unlikely,	   since	   these	   cellular	  structures	  of	  20nm	  in	  size	  are	  marginally	  smaller	  than	  the	  100nm-­‐sized	  exosomes.	  One	   possibility	   is	   that	   ribosomes	   co-­‐precipitate	   with	   the	   exosomes	   during	   the	  purification	   process	   and	   are	   simply	   a	   contaminant.	   Another	   interpretation	   is	   that	  ribosomal	  proteins	  associate	  with	  RNA	  strands	  packaged	   in	   the	  exosomes	  and	  are	  therefore	  encapsulated	  in	  the	  vesicles.	  	  	  Another	   surprising	   finding	   is	   the	   presence	   of	   a	   variety	   of	   histones	   in	   the	  microvesicles.	  This	  finding	  is	  surprising	  yet	  not	  unprecedented.	  Peng	  et	  al.	  confirm	  the	  presence	  of	  histone	  H2A	  in	  exosomes	  isolated	  from	  the	  ascites	  of	  ovarian	  cancer	  patients,	  while	   they	  note	  that	   they	  do	  not	  know	  whether	  the	  histone	  can	  be	   found	  within	  the	  vesicle	  or	  rather	  teathered	  on	  the	  outside	  of	  the	  vesicle’s	  membrane	  as	  an	  extracellular	  contaminant12.	  The	  later	  is	  also	  the	  position	  of	  Mathivanan	  on	  the	  issue	  who	   notes	   that	   extracellular	   histones	   are	   a	   result	   of	   apoptotic	   blebs	   that	   co-­‐precipitate	  with	  exosomes	  during	  purification11.	  	  Another	  functional	  category	  of	  interest	  is	  the	  one	  labeled	  ‘oncogene’	  on	  figure	  3.7b.	  It	  consists	  mainly	  of	  RAB-­‐proteins,	  of	  the	  RAS	  oncogene	  family.	  These	  are	  GTPases	  involved	   in	   membrane	   trafficking,	   vesicle	   formation,	   vesicle	   movement	   and	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membrane	   fusion.	   Mathivanan	   et	   al.	   make	   a	   similar	   observation	   of	   RAS	   protein	  enrichment	   while	   conducting	   proteomic	   analysis	   of	   human	   colon	   tumor	   cell	   line	  LIM1215-­‐derived	   exosomes13.	   Thus,	   the	   presence	   of	   RAS	   onco-­‐proteins	   could	  potentially	  be	  a	  specific	  marker	  of	  tumor-­‐derived	  exosomes.	  Along	  with	  the	  category	  ‘G	  protein	  regulation’	  these	  proteins	  imply	  that	  there	  is	  some	  intact	  component	  of	  G	  protein	  signaling	  taking	  place	  within	  exosomes.	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the	  common	  proteins	  between	  the	  two	  types	  of	  exosomes,	  we	  plot	  the	  number	  of	  proteins	  found	  in	  each	  functional	  category.	  The	  bar	  color	  encodes	  for	  cellular	  localization.	  	  	  On	   table	   3.1a	   we	   list	   exosome	  markers	   that	   we	   identified	   by	   mass	   spectrometry	  analysis	  of	  HCC38	  and	  BT20-­‐derived	  exosomes,	  along	  with	  their	  respective	  peptide	  count.	  Among	  these	  we	  find	  the	  tetraspanins	  C9,	  CD81	  and	  CD63	  as	  well	  as	  multiple	  proteins	  from	  the	  heat	  shock	  protein-­‐70	  family	  (HSP70).	  We	  also	  find	  three	  antigens	  of	   the	   major	   histocompatibility	   complex	   I	   (MHC	   I)	   family	   and	   multiple	   proteins	  pertaining	   to	   multivesicular	   bodies,	   the	   cellular	   compartment	   where	   exosome	  biogenesis	   takes	   place.	   Finally	   we	   identify	   flotillin1	   (FLOT1),	   a	   component	   of	  membrane	  lipid	  rafts	  whose	  presence	  has	  been	  previously	  reported	  on	  extracellular	  vesicles11.	  	  	  	  Other	  than	  the	  exosomal	  markers	  common	  to	  both	  types	  of	  exosomes,	  we	  also	  see	  that	   each	   proteomic	   dataset	   contains	   cell-­‐type	   specific	   protein	  markers	  which	  we	  list	  in	  table	  3.1b.	  The	  epidermal	  growth	  factor	  receptor	  (EGFR)	  is	  identified	  in	  both	  HCC38	   and	   BT20	   exosomes,	   a	   finding	   that	   further	   validates	   immunoblots	   results	  presented	  in	  the	  following	  section	  (figure	  3.8	  and	  3.9).	  We	  also	  see	  two	  members	  of	  the	   transmembrane	   claudin	   family	   (CLDN3	   and	   CLDN4)	   present	   in	   both	   types	   of	  exosomes.	  This	  is	  particularly	  useful,	  since	  in	  the	  absence	  of	  efficient	  antibodies	  we	  previously	  were	  not	  able	  to	  confirm	  claudin	  presence	  on	  cancer	  exosomes.	  Claudins	  have	  emerged	  as	  significant	  biomarkers	  in	  breast	  cancer14	  and	  by	  consequence	  their	  presence	  in	  cancer	  exosomes	  holds	  the	  promise	  of	  diagnostic	  application.	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Alongside	  to	  common	  cancer-­‐specific	  proteins	   found	  in	  the	  two	  types	  of	  exosomes	  we	  also	  find	  tyrosine	  kinases	  specific	  to	  HCC38	  exosomes,	  MAPK	  being	  among	  them,	  as	  well	  as	  IGFBP5	  a	  growth	  factor	  antagonist	  specific	  to	  BT20	  exosomes.	  Finally	  we	  list	   the	   RAS-­‐oncoproteins	   in	   table	   3.1b	   since	   as	   discussed	   previously	   they	   are	  specific	  and	  unique	  to	  tumor-­‐derived	  exosomes.	  	  	  In	   table	   3.2	   we	   list	   proteins	   indicative	   of	   different	   cellular	   compartments	   and	  functions	   present	   in	   the	   exosomes.	   First	   comes	   a	   long	   list	   of	   metabolic	   enzymes.	  Among	   these	   GADH	   ALDOA,	   ALDOC,	   ENO1,	   FASN	   and	   MDH1	   are	   of	   common	  occurrence	  in	  a	  variety	  of	  exosomes	  and	  have	  been	  previously	  reported	  in	  exosome	  proteomic	  studies11.	  Next	  we	  list	  various	  members	  of	  the	  actin	  and	  tubulin	  protein	  familes,	   as	   representatives	   of	   the	   cell	   cytoskeleton.	   Among	   plasma	   membrane	  markers	  we	  find	  the	  transferrin	  receptor	  (TFRC)	  as	  well	  as	  a	  variety	  of	  integrins	  and	  cell	   adhesion	   molecules.	   Particularly	   the	   presence	   of	   E-­‐cadherin	   (CDH1)	   and	  epithelial	   cell	   adhesion	   molecule	   (EpCAM)	   is	   of	   diagnostic	   value	   since	   it	   can	   be	  exploited	  in	  immuno-­‐affinity	  exosome	  capturing	  technologies	  in	  order	  to	  specifically	  isolate	   tumor-­‐derived	   epithelial	   exosomes	   from	   complex	   biological	   fluids.	   These	  molecules	   are	   also	   featured	   in	   the	   immunoblots	   below	   so	   that	   once	   again	   the	  proteomic	   analysis	   confirms	   and	   validates	   these	   findings.	   Finally,	  we	   list	  multiple	  members	   of	   the	   histone	   protein	   family,	   a	   possible	   indicator	   of	   nuclear	   protein	  presence	  within	  the	  exosomes.	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Table	  3.1:	   Proteomic	   analysis	   of	  HCC38	  and	  BT20-­‐derived	   exosomes.	   a)	   List	   of	   common	  exosome	  markers	   identified	   in	  both	  proteomic	  datasets.	   b)	   List	   of	   cell-­‐type	   specific	  markers,	   demonstrating	  uniqueness	  of	  exosomes	  to	  cell	  type	  of	  origin.	  	  	  
Exosome 








CD9 CD9 molecule 4 4 
Plasma 
Membrane 
CD81 CD81 molecule 1 2 
Plasma 
Membrane 
CD63 CD63 molecule 2 2 
Plasma 
Membrane 
HLA antigens class I 
HLA-A 
major histocompatibility complex, class 




major histocompatibility complex, class 




major histocompatibility complex, class 




CHMP2A charged multivesicular body protein 2A 2 7 Cytoplasm 
CHMP4B charged multivesicular body protein 4B 1 4 Cytoplasm 
CHMP5 charged multivesicular body protein 5 1 2 Cytoplasm 
CHMP6 charged multivesicular body protein 6 1 1 Cytoplasm 
MVB12A multivesicular body subunit 12A 1 5 Cytoplasm 
CHMP1B charged multivesicular body protein 1B 2 1 
Plasma 
Membrane 
CLU clusterin 5 4 Cytoplasm 
Heat shock Protein 70 kDa 
HSPA1L heat shock 70kDa protein 1-like 13 9 Cytoplasm 
HSPA5 
heat shock 70kDa protein 5 (glucose-
regulated protein, 78kDa) 8 5 Cytoplasm 
HSPA8 heat shock 70kDa protein 8 21 20 Cytoplasm 
HSPA1A/
HSPA1B heat shock 70kDa protein 1A 12 8 Cytoplasm 
HSPA2 heat shock 70kDa protein 2 4 4 Cytoplasm 
HSPA4 heat shock 70kDa protein 4 5 2 Cytoplasm 
HSPA4L heat shock 70kDa protein 4-like 1 1 Cytoplasm 
Lipid Raft Marker 












Tyrosine Kinase Receptor 
EGFR 
epidermal growth factor 
receptor 10 17 Plasma Membrane 
Tyrosine Kinase 
PTK7 protein tyrosine kinase 7 4 7 Plasma Membrane 
NTRK2 
neurotrophic tyrosine kinase, 
receptor, type 2 1 - Plasma Membrane 
BTK 
Bruton agammaglobulinemia 
tyrosine kinase 1 - Cytoplasm 
MAPK1 
mitogen-activated protein 
kinase 1 3 - Cytoplasm 
Claudin 
CLDN3 claudin 3 2 1 Plasma Membrane 
CLDN4 claudin 4 1 1 Plasma Membrane 
Growth Factor Binding 
IGFBP5 
insulin-like growth factor 
binding protein 5 - 7 Extracellular 
Oncogene 
RAB14 
RAB14, member RAS 
oncogene family 4 4 Cytoplasm 
RRAS2 
related RAS viral (r-ras) 
oncogene homolog 2 3 4 Plasma Membrane 
RHOA 
ras homolog family member 
A 3 4 Cytoplasm 
RBBP4 
retinoblastoma binding 
protein 4 1 1 Nucleus 
RAP2B 
RAP2B, member of RAS 
oncogene family 1 1 Plasma Membrane 
RAP1A 
RAP1A, member of RAS 
oncogene family 4 5 Cytoplasm 
RAN 
RAN, member RAS 
oncogene family 4 3 Nucleus 
RALA 
v-ral simian leukemia viral 
oncogene homolog A (ras 
related) 2 7 Cytoplasm 
RAC1 
ras-related C3 botulinum 
toxin substrate 1 (rho family, 
small GTP binding protein 
Rac1) 3 3 Plasma Membrane 
RAB7A 
RAB7A, member RAS 
oncogene family 9 10 Cytoplasm 
RAB5C 
RAB5C, member RAS 
oncogene family 4 6 Cytoplasm 
RAB5B 
RAB5B, member RAS 
oncogene family 1 3 Cytoplasm 
RAB5A 
RAB5A, member RAS 
oncogene family 3 2 Cytoplasm 
RAB35 
RAB35, member RAS 
oncogene family 2 5 Cytoplasm 
RAB33B 
RAB33B, member RAS 
oncogene family 1 1 Cytoplasm 
RAB2A 
RAB2A, member RAS 
oncogene family 2 2 Cytoplasm 
RAB23 
RAB23, member RAS 
oncogene family 1 1 Cytoplasm 
RAB1A 
RAB1A, member RAS 
oncogene family 2 3 Cytoplasm 
RAB18 
RAB18, member RAS 
oncogene family 2 2 Cytoplasm 
RAB11A 
RAB11A, member RAS 
oncogene family 4 5 Cytoplasm 
NRAS 
neuroblastoma RAS viral (v-
ras) oncogene homolog 1 1 Plasma Membrane 
HRAS 
Harvey rat sarcoma viral 
oncogene homolog 4 3 Plasma Membrane 
!"# $"#
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Cellular 




Peptide Count Localization 
Cytoskeleton – Cytoplasmic Marker 
ACTBL2 actin, beta-like 2 2 2 Nucleus 
ACTB actin, beta 8 9 Cytoplasm 
ACTN1 actinin, alpha 1 31 7 Cytoplasm 
ACTN4 actinin, alpha 4 30 12 Cytoplasm 
TUBA1A tubulin, alpha 1a 15 16 Cytoplasm 
TUBA4A tubulin, alpha 4a 3 2 Cytoplasm 
TUBA4B 
tubulin, alpha 4b 
(pseudogene) 1 1 Cytoplasm 
TUBB tubulin, beta class I 4 3 Cytoplasm 
TUBB1 tubulin, beta 1 class VI 5 5 Cytoplasm 
TUBB3 tubulin, beta 3 class III 9 4 Cytoplasm 
TUBB2A tubulin, beta 2A class IIa 14 8 Cytoplasm 
TUBB4A tubulin, beta 4A class IVa 4 4 Cytoplasm 
TUBB4B tubulin, beta 4B class IVb 1 1 Cytoplasm 
Plasma Membrane Marker (Iron Transport) 
TFRC transferrin receptor 17 5 Plasma Membrane 
Cell Adhesion – Epithelial Cell Markers 
CDH1 
cadherin 1, type 1, E-
cadherin (epithelial) 2 6 Plasma Membrane 
EPCAM 
epithelial cell adhesion 
molecule 4 4 Plasma Membrane 
ICAM1 
intercellular adhesion 
molecule 1 6 4 Plasma Membrane 
ITGA2 
integrin, alpha 2 (CD49B, 
alpha 2 subunit of VLA-2 
receptor) 16 21 Plasma Membrane 
ITGA3 
integrin, alpha 3 (antigen 
CD49C, alpha 3 subunit of 
VLA-3 receptor) 23 16 Plasma Membrane 
ITGA6 integrin, alpha 6 12 18 Plasma Membrane 
ITGB1 
integrin, beta 1 
(fibronectin receptor, beta 
polypeptide, antigen 
CD29 includes MDF2, 
MSK12) 18 17 Plasma Membrane 
ITGB4 integrin, beta 4 11 20 Plasma Membrane 
ITGB5 integrin, beta 5 3 10 Plasma Membrane 
ITGB6 integrin, beta 6 2 1 Plasma Membrane 
Histone – Nuclear Marker 
H1F0 
H1 histone family, 
member 0 3 3 Nucleus 
H2AFV 
H2A histone family, 
member V 2 2 Nucleus 
H2AFY 
H2A histone family, 
member Y 2 9 Nucleus 
H2AFY2 
H2A histone family, 
member Y2 2 2 Nucleus 
HIST1H1A histone cluster 1, H1a 4 4 Nucleus 
HIST1H1B histone cluster 1, H1b 4 5 Nucleus 
HIST1H1C histone cluster 1, H1c 2 3 Nucleus 
HIST1H2AA histone cluster 1, H2aa 3 2 Nucleus 
HIST1H2BA histone cluster 1, H2ba 3 4 Nucleus 
HIST1H2BB histone cluster 1, H2bb 6 6 Nucleus 
HIST1H4A (includes 
others) histone cluster 1, H4a 12 12 Nucleus 
HIST1H4G histone cluster 1, H4g 1 1 Nucleus 
HIST2H2BE 
(includes others) histone cluster 2, H2be 2 2 Nucleus 
HIST3H3 histone cluster 3, H3 3 4 Nucleus 
Cellular 




Peptide Count Localization 
Metabolic Enzymes 
AKR1B1 
aldo-keto reductase family 
1, member B1 (aldose 
reductase) 2 4 Cytoplasm 
ALDH16A1 
aldehyde dehydrogenase 
16 family, member A1 4 4 Cytoplasm 
ALDH1A3 
aldehyde dehydrogenase 
1 family, member A3 9 1 Cytoplasm 
ALDH9A1 
aldehyde dehydrogenase 
9 family, member A1 1 3 Cytoplasm 
ALDOA 
aldolase A, fructose-
bisphosphate 17 11 Cytoplasm 
ALDOC 
aldolase C, fructose-
bisphosphate 2 1 Cytoplasm 
ASS1 
argininosuccinate 
synthase 1 1 7 Cytoplasm 
BLVRB 
biliverdin reductase B 
(flavin reductase 
(NADPH)) 1 3 Cytoplasm 
CAD 
carbamoyl-phosphate 
synthetase 2, aspartate 
transcarbamylase, and 
dihydroorotase 3 2 Cytoplasm 
CBR1 carbonyl reductase 1 3 5 Cytoplasm 
CNP 
2',3'-cyclic nucleotide 3' 
phosphodiesterase 5 9 Cytoplasm 
DARS aspartyl-tRNA synthetase 1 8 Cytoplasm 
DERA 
deoxyribose-phosphate 
aldolase (putative) 4 2 Cytoplasm 
ENO1 enolase 1, (alpha) 21 14 Cytoplasm 
EPRS 
glutamyl-prolyl-tRNA 
synthetase 6 7 Cytoplasm 
FASN fatty acid synthase 68 50 Cytoplasm 
FKBP1A 
FK506 binding protein 1A, 
12kDa 1 1 Cytoplasm 
G6PD 
glucose-6-phosphate 
dehydrogenase 5 15 Cytoplasm 
GANAB 
glucosidase, alpha; 




dehydrogenase 19 15 Cytoplasm 
GPI 
glucose-6-phosphate 




1 3 1 Cytoplasm 
IARS isoleucyl-tRNA synthetase 9 4 Cytoplasm 
IDH1 
isocitrate dehydrogenase 
1 (NADP+), soluble 3 10 Cytoplasm 
KARS lysyl-tRNA synthetase 1 4 Cytoplasm 
LDHA lactate dehydrogenase A 14 7 Cytoplasm 
LOXL2 lysyl oxidase-like 2 1 4 Extracellular Space 
MARS 
methionyl-tRNA 
synthetase 3 4 Cytoplasm 
MDH1 
malate dehydrogenase 1, 
NAD (soluble) 4 3 Cytoplasm 
ME1 
malic enzyme 1, NADP








synthetase 11 8 Cytoplasm 
NQO1 
NAD(P)H dehydrogenase, 
quinone 1 3 7 Cytoplasm 
P4HB 
prolyl 4-hydroxylase, beta 







synthetase 8 4 Cytoplasm 
PDIA6 
protein disulfide 
isomerase family A, 
member 6 1 2 Cytoplasm 
PGD 
phosphogluconate 
dehydrogenase 5 4 Cytoplasm 
PHGDH 
phosphoglycerate 








dioxygenase 3 1 2 Cytoplasm 
PPIA 
peptidylprolyl isomerase A 
(cyclophilin A) 6 9 Cytoplasm 
PPIB 
peptidylprolyl isomerase B 
(cyclophilin B) 2 10 Cytoplasm 
PYCRL 
pyrroline-5-carboxylate 
reductase-like 2 2 Cytoplasm 
RARS arginyl-tRNA synthetase 4 2 Cytoplasm 
TALDO1 transaldolase 1 3 5 Cytoplasm 
TKT transketolase 4 8 Cytoplasm 
TPI1 
triosephosphate 
isomerase 1 10 9 Cytoplasm 
UGP2 
UDP-glucose 
pyrophosphorylase 2 4 4 Cytoplasm 
!"# $"#
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Table	  3.2:	  Proteomic	  analysis	  of	  HCC38	  and	  BT20-­‐derived	  exosomes.	  a)	  List	  of	  metabolic	  enzymes	  identified	  in	  both	  proteomic	  datasets.	  b)	  List	  of	  other	  cellular	  markers	  identified	  in	  both	  proteomic	  datasets.	  	  
4.3	  Diagnostic	  Significance	  of	  Breast	  Cancer	  Derived	  Exosomes	  
	  Having	  established	  that	  exosomes	  are	  rich	  in	  protein	  content,	  a	  logical	  continuation	  of	   this	   research	   is	   to	  gear	  experiments	   toward	  obtaining	  a	  comprehensive	  protein	  profile	  for	  breast	  cancer	  exosomes	  relative	  to	  their	  cell	  lines	  of	  origin.	  The	  primary	  question	   we	   want	   to	   answer	   is	   whether	   receptor	   tyrosine-­‐kinases,	   which	   are	  routinely	   used	   to	   determine	   stage	   and	   molecular	   subtype	   of	   tumor	   biopsies,	   are	  present	  in	  breast	  cancer	  exosomes.	  There	  is	  limited	  literature	  reporting	  advances	  on	  this	   front.	   Ciravolo	   et	   al.15	   confirmed	   the	   presence	   of	   the	   HER2	   receptor	   on	  exosomes	   derived	   by	   HER2-­‐overexpressing	   breast	   cancer	   cell	   lines	   SKBR3	   and	  BT474.	  In	  addition,	  they	  showed	  that	  the	  exosome-­‐localized	  HER2	  was	  successful	  in	  binding	   Trastuzumab,	   the	  monoclonal	   antibody	   inhibitor	   of	   this	   receptor.	   A	  more	  systematic	  study	  investigating	  glioblastoma	  cell	  lines	  has	  shown	  that	  in	  addition	  to	  the	   tetraspanin	   and	  MHC	   I	  markers	   characteristic	   of	   exosomes,	   the	   glioblastoma-­‐derived	   exosomes	   also	   carried	   popular	   glioblastoma	   markers:	   EGFR,	   EGFRvIII,	  PDPN,	  PDGFR	  and	  EphA216.	  	  	  A	  secondary	  question	  up	   for	   investigation	   is	  whether	  upstream	  cytolasmic	  protein	  kinases	  are	  also	  present	  in	  breast	  cancer	  exosomes	  and	  if	  so,	  to	  what	  extent.	  Along	  the	  same	  lines,	  we	  are	  interested	  in	  characterizing	  the	  protein	  content	  in	  exosomes	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and	  seeing	  whether,	   in	  addition	  to	  cell	  membrane	  receptors,	  exosomes	  are	  able	   to	  export	  cytoplasmic	  and	  nuclear	  proteins	  in	  the	  extracellular	  space.	  	  	  In	   addition	   to	   documenting	   the	   presence	   of	   receptor	   tyrosine-­‐kinases	   in	   the	  exosomes,	   we	   are	   also	   interesting	   in	   interrogating	   the	   functionality	   of	   these	  receptors	   and	   their	   upstream	   effector	   pathways	   in	   these	   extracellular	   vesicles.	   A	  separate	   objective	   of	   ours	   is	   to	   identify	   whether	   the	   phosphorylation	   patterns	   of	  these	   proteins	   are	   conserved	   on	   the	   exosomes	  when	   the	   producing	   cell	   lines	   are	  challenged	  with	  growth	  factor	  and	  tyrosine-­‐kinase	  inhibitors.	  	  	  Finally,	   after	  documenting	   specific	   receptor	   signatures	   in	  different	   types	  of	   breast	  cancer	   exosomes,	   we	   ask	   whether	   incubation	   of	   cell	   lines	   with	   heterologous	  exosomes	  results	   in	  the	  transfer	  of	  exosome-­‐specific	  receptors	  to	  the	  recipient	  cell	  line.	   The	   experiments	   that	   are	   presented	   below	   aim	   to	   answer	   this	   multitude	   of	  questions	   by	   characterizing	   the	   content	   and	   function	   of	   breast	   cancer-­‐derived	  exosomes.	  	  	  
Methods	  
Quantitative	  Comparison	  of	  Exosomes	  to	  Cell	  Lines	  of	  Origin	  Exosome	  lysates	   for	  six	  breast	  cancer	  cell	   lines	  –MCF7,	  T47D,	  MDAMB231,	  SKBR3,	  HCC38	   and	   BT20-­‐	   were	   prepared	   as	   described	   above	   by	   resuspension	   of	   the	  exosome	   ultracentrifugation	   pellet	   in	   100ul	   MPER	   supplemented	   with	   1x	   Roche	  protease	   inhibitor.	   Cell	   lysates	   were	   prepared	   by	   scraping	   cell	   monolayers	   and	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resuspension	  of	  cells	  in	  PBS.	  The	  solution	  was	  centrifuged	  at	  400g	  for	  3min	  in	  order	  to	  pellet	  cells.	  Subsequently	  the	  cells	  were	  also	  resuspended	  in	  the	  same	  lysis	  buffer:	  MPER	  supplemented	  with	  1x	  Roche	  protease	  inhibitor.	  Both	  exosome	  and	  whole	  cell	  lysates	  were	  incubated	  on	  ice	  for	  30min	  and	  then	  centrifuged	  15min	  at	  14,000g	  to	  pellet	   insoluble	   fragments.	   The	   supernatants	   from	   the	   spin	   were	   recovered	   and	  protein	  levels	  were	  quantified	  following	  the	  protocol	  for	  a	  microBCA	  assay9.	  	  	  Following	   quantitation,	   10ug	   of	   each	   protein	   extract	   were	   supplemented	   with	  Laemmli	   buffer	   and	   denatured	   at	   95C	   for	   10min.	   Lysates	   were	   loaded	   on	   a	  polyacrylamide	   gel	   and	   separated	   by	   electrophoresis	   in	   the	   presence	   of	   MOPS	  running	   buffer.	   The	   gels	   were	   transferred	   onto	   hydrophobic	   polyvinylidene	  difluoride	   membranes	   (PVDF),	   probed	   with	   primary	   and	   secondary	   fluorescently	  tagged	  goat	  anti-­‐mouse	  Ig	  (1:5,000)	  or	  donkey	  anti-­‐rabbit	  Ig	  (1:5,000).	  Signals	  were	  detected	  using	  the	  LI-­‐COR	  Odyssey	  fluorescent	  western	  blot	  imager.	  	  
Treatment	   of	   Breast	   Cancer	   Exosomes	   with	   EGF,	   Lapatinib,	   Glucose	   and	  
Phosphatase	  Inhibitors	  For	  the	  purpose	  of	  these	  experiments	  eight	  T-­‐150	  culture	  flasks	  of	  cancer	  cells	  were	  cultured	   in	   serum-­‐free	   RPMI	   medium	   for	   48hrs.	   Following	   collection,	   the	   pooled	  supernatants	  amounting	  to	  100ml	  of	  conditioned	  medium	  (CM)	  were	  spun	  10min	  at	  300g	   to	  pellet	  whole	   cells	   followed	  by	  20min	   at	   2,000g	   to	  pellet	   large	   cell	   debris.	  The	   CMs	   were	   concentrated	   20-­‐fold	   through	   a	   3k	   filtration	   device	   centrifuged	   at	  4,000g.	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  In	   the	   experiment	   that	   examined	   EGF	   and	   Lapatinib	   activity	   on	   breast	   cancer	  exosomes,	  the	  concentrated	  CMs	  were	  divided	  into	  four	  equal	  volume	  fractions	  that	  received	   respectively	   1ml	   of	   DMEM	   supplemented	   with	   a)	   no	   treatment,	   b)	  200ng/ml	   recombinant	   EGF,	   c)	   10µM	  Lapatinib	   or	   d)	   200ng/ml	   recombinant	  EGF	  and	  10µM	  Lapatinib.	  All	  samples	  were	  incubated	  1	  hour	  at	  room	  temperature	  with	  gentle	   shaking.	   Following	   incubations,	   exosomes	  were	   pelleted	   down	   from	   all	   CM	  samples	  according	  to	  previously	  described	  differential	  ultracentrifugation	  protocol.	  The	   pelleted	   exosomes	   were	   resuspended	   in	   30µL	   Laemmli	   running	   buffer	  supplemented	   with	   Roche	   protease	   inhibitor	   and	   Sigma	   Cocktail	   2	   phosphatase	  inhibitor.	   The	   exosome	   lysates	  were	   heated	   at	   95C	   for	   10min	   and	   loaded	   on	   two	  (15µL	   each)	   polyacrylamide	   gels.	   A	   standard	   western	   blotting	   protocol	   was	  employed	   thereafter.	   Membranes	   were	   probed	   with	   anti-­‐rabbit	   EGFR,	   anti-­‐rabbit	  pEGFR	  and	  anti-­‐mouse	  beta-­‐actin	  monoclonal	  antibodies.	  Following	  quantitation	  of	  protein	  bands,	  the	  ratio	  of	  pEGFR	  to	  EGFR	  was	  plotted	  for	  all	  treatment	  conditions.	  The	   experiment	   was	   repeated	   in	   duplicate	   and	   statistical	   analysis	   calculated	  unpaired,	   two-­‐tailed,	  homoscedastic	  T-­‐tests	   comparing	  all	   treatment	   conditions	   to	  the	  untreated	  control	  condition.	  	  	  In	   the	   experiment	   that	   examined	   glucose,	   phosphatase	   inhibitor	   and	   Lapatinib	  activity	  on	  breast	  cancer	  exosomes,	  we	  began	  with	  the	  same	  process	  for	  production	  of	  100ml	  of	  conditioned	  medium,	  clarification	  by	  centrifugation	  followed	  by	  20-­‐fold	  concentration.	   Next,	   the	   concentrated	   CMs	   were	   divided	   in	   to	   four	   equal	   volume	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fractions	  that	  received	  respectively	  a)	  1ml	  of	  PBS	  (no	  treatment)	  b)	  10µM	  Lapatinib	  in1ml	  of	  PBS,	  c)	  1ml	  of	  glucose/orthovanadate	  buffer	  d)	  10µM	  Lapatinib	   in	  1ml	  of	  glucose/orthovanadate	   buffer.	   The	   glucose/orthovanadate	   buffer	   consisted	   of	  25mM	   glucose,	   100mM	   NaCl,	   1mM	   CaCl2,	   1mM	   MgCl2,	   50mM	   Hepes	   pH7.5	   and	  100mM	  orthovanadate	  activated	  at	  90C	  for	  5min.	  All	  samples	  were	  incubated	  1	  hour	  at	   room	   temperature	   with	   gentle	   shaking.	   Following	   incubations,	   exosomes	   were	  pelleted	   down	   from	   all	   CM	   samples	   according	   to	   previously	   described	   differential	  ultracentrifugation	   protocol.	   The	   pelleted	   exosomes	   were	   resuspended	   in	   30µL	  Laemmli	   running	   buffer	   supplemented	   with	   Roche	   protease	   inhibitor	   and	   Sigma	  Cocktail	  2	  phosphatase	  inhibitor.	  The	  exosome	  lysates	  were	  heated	  at	  95C	  for	  10min	  and	   loaded	   on	   two	   (15µL	   each)	   polyacrylamide	   gels.	   A	   standard	  western	   blotting	  protocol	  was	  employed	  thereafter.	  Membranes	  were	  probed	  with	  anti-­‐rabbit	  EGFR,	  anti-­‐rabbit	   pEGFR,	   anti-­‐rabbit	   AKT,	   anti-­‐rabbit	   pAKT	   and	   anti-­‐mouse	   beta-­‐actin	  monoclonal	  antibodies.	  Following	  quantitation	  of	  protein	  bands,	  the	  ratios	  of	  pEGFR	  to	   EGFR	   as	   well	   as	   pAKT	   to	   AKT	   were	   plotted	   for	   all	   treatment	   conditions.	   The	  experiment	   was	   repeated	   in	   triplicate	   for	   HCC38	   exosomes	   and	   quatruplicate	   for	  BT20	   exosomes	   and	   statistical	   analysis	   calculated	   unpaired,	   two-­‐tailed,	  homoscedastic	  T-­‐tests	  comparing	  all	  treatment	  conditions	  to	  the	  untreated	  control	  condition.	  	  	  
Collection	  of	  Exosomes	  from	  EGF	  and/or	  Lapatinib	  Treated	  Cells	  For	   the	  purpose	  of	   this	  experiment	  eight	  T-­‐150	  culture	   flasks	  of	   cancer	  cells	  were	  seeded	  and	  allowed	  to	  reach	  80%	  confluence.	  The	  cells	  were	  then	  serum	  starved	  in	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serum-­‐free	  RPMI	  culture	  overnight.	  The	  next	  day	  the	  media	  was	  replaced	  with	  fresh	  serum-­‐free	  RPMI	  supplemented	  with	  a)	  no	  treatment,	  b)	  100ng/ml	  EGF	  and	  1:1000	  phosphatase	   inhibitor,	   c)	   100ng/ml	   EGF,	   1:1000	   phosphatase	   inhibitor	   and	   10µM	  Lapatinib	   and	   d)	   10µM	   Lapatinib.	   Each	   treatment	   condition	   was	   applied	   in	   two	  flasks	  of	   cells.	  The	   cells	  were	   incubated	  with	   treatment	   for	  24hrs,	   after	  which	   the	  supernatants	   were	   collected	   for	   each	   condition	   and	   exosomes	   were	   pelleted	  following	   according	   to	   previously	   described	   differential	   ultracentrifugation	  protocol.	  The	  pelleted	  exosomes	  were	  resuspended	  in	  30µL	  Laemmli	  running	  buffer	  supplemented	   with	   Roche	   protease	   inhibitor	   and	   Sigma	   Cocktail	   2	   phosphatase	  inhibitor.	   The	   exosome	   lysates	  were	   heated	   at	   95C	   for	   10min	   and	   loaded	   on	   two	  (15µL	   each)	   polyacrylamide	   gels.	   A	   standard	   western	   blotting	   protocol	   was	  employed	   thereafter.	   Membranes	   were	   probed	   with	   anti-­‐rabbit	   EGFR,	   anti-­‐rabbit	  pEGFR,	   anti-­‐rabbit	   AKT,	   anti-­‐rabbit	   pAKT	   and	   anti-­‐mouse	   beta-­‐actin	   monoclonal	  antibodies.	  Following	  quantitation	  of	  protein	  bands,	  the	  ratios	  of	  pEGFR	  to	  EGFR	  as	  well	  as	  pAKT	  to	  AKT	  was	  plotted	  for	  all	  treatment	  conditions.	  	  	  In	  order	  to	  perform	  the	  corresponding	  in-­‐cell	  control	  experiment,	  cancer	  cells	  were	  seeded	  in	  6-­‐well	  plates	  and	  allowed	  to	  reach	  80%	  confluence.	  The	  same	  protocol	  as	  above	  was	  followed.	  After	  treatment	  we	  waited	  3	  hrs	  and	  proceeded	  to	  lyse	  the	  cells	  with	  2x	  Laemmli	  buffer.	  The	  cell	  lysates	  were	  heated	  at	  95C	  for	  10min	  and	  15µL	  of	  each	   condition	   were	   loaded	   on	   polyacrylamide	   gels.	   A	   standard	   western	   blotting	  protocol	  was	  employed	  thereafter.	  Membranes	  were	  probed	  with	  anti-­‐rabbit	  EGFR,	  anti-­‐rabbit	   pEGFR,	   anti-­‐rabbit	   AKT,	   anti-­‐rabbit	   pAKT	   and	   anti-­‐mouse	   beta-­‐actin	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monoclonal	  antibodies.	  Following	  quantitation	  of	  protein	  bands,	  the	  ratios	  of	  pEGFR	  to	  EGFR	  as	  well	  as	  pAKT	  to	  AKT	  were	  plotted	  for	  all	  treatment	  conditions.	  	  
	  
Receptor	   Transference	   from	   Receptor-­Positive	   Exosomes	   to	   Receptor-­Negative	  
Cell	  Lines	  Donor	   cell	   lines	   MCF7	   and	   T47D	   were	   seeded	   at	   80%	   confluence	   in	   eight	   T-­‐150	  culture	   flasks.	   Supernatants	   were	   collected	   after	   48hrs	   of	   culture	   in	   serum-­‐free	  RPMI	  and	  exosomes	  were	  purified	  employing	  the	  to	  the	  previously	  described	  serial	  ultracentrifugation	  protocol.	  Exosome	  pellets	  were	  resuspended	  in	  PBS	  and	  stored	  at	   4C.	   Recipient	   cell	   lines	   MDAMB231	   and	   SKBR3	   were	   seeded	   at	   a	   density	   of	  100,000	   cells/well	   in	   6-­‐well	   plates	   and	   allowed	   to	   adhere	   to	   the	   culture	   plate	  overnight.	  Then	   the	  media	  was	   switched	   to	   serum	   free	  RPMI	  and	   cell	  monolayers	  were	  serum	  starved	   for	  24hrs.	  We	   then	  proceeded	   to	  add	  half	   the	  volume	  of	  each	  exosomes	   preparation	   to	   each	   cell	   line,	   while	   the	   untreated	   control	   received	   an	  equal	   volume	   of	   blank	   PBS.	   The	   cells	  were	   incubated	  with	   the	   exosomes	   for	   6hrs	  after	   which	   the	   supernatants	   were	   discarded	   and	   the	   monolayers	   were	   washed	  twice	  in	  PBS	  to	  remove	  any	  unbound	  vesicles.	  Next	  the	  monolayers	  were	  lysed	  using	  100µL	   2x	   Laemmli	   buffer.	   Finally	   15µL	   of	   each	   sample	   were	   heated	   at	   95C	   for	  10min,	   then	   loaded	   in	  a	   standard	  polyacrylamide	  gel.	  A	  standard	  western	  blotting	  protocol	  was	  employed	  thereafter.	  Membranes	  were	  probed	  with	  anti-­‐rabbit	  CDH1,	  anti-­‐rabbit	   EpCAM	   and	   anti-­‐mouse	   beta-­‐actin	   monoclonal	   antibodies.	   Following	  quantitation	  of	  protein	  bands,	  the	  ratios	  of	  CDH1	  to	  beta-­‐actin	  as	  well	  as	  EpCAM	  to	  beta-­‐actin	  were	  plotted	  for	  all	  treatment	  conditions.	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Results	  
Quantitative	  Comparison	  of	  Exosomes	  to	  Cell	  Lines	  of	  Origin	  The	   first	   set	   of	   results	   aims	   to	   compare	   exosomes	   to	   their	   cell	   lines	   of	   origin	   by	  loading	   equal	   amounts	   of	   both	   lysates	   on	   polyacrylamide	   gels	   and	   blotting	   for	   a	  variety	  of	  cell	  membrane	  proteins.	  The	  ensuing	  western	  blots	  are	  displayed	  in	  figure	  3.8	  and	  feature	  eight	  cell	  surface	  receptors.	  The	  majority	  of	  receptors	  tested	  are	  of	  diagnostic	   and	   therapeutic	   importance	   in	   breast	   cancer:	   the	   epidermal	   growth	  factor	   receptors	   1	   (EGFR)	   as	   well	   as	   2	   (HER2),	   the	   hepatocyte	   growth	   factor	  receptor	   (MET),	   the	   insulin-­‐like	   growth	   factor	   receptor	   (IGF1R),	   the	   major	  histocompatibility	   complex	   I	   and	   finally	   cadherin-­‐1	   (CDH1).	   The	   first	   four	   are	  receptor	   tyrosine	   kinases	   that	   are	   clinical	   targets	   for	   monoclonal	   antibody	  therapies.	  The	   last	  one,	   cadherin-­‐I	  or	  E-­‐cadherin,	   is	  an	  epithelial	   cell-­‐cell	  adhesion	  glycoprotein.	  The	  loss	  of	  E-­‐cadherin	  has	  been	  implicated	  in	  cancer	  progression	  and	  metastasis.	   Absence	   of	   E-­‐cadherin	   in	   breast	   tumor	   clinical	   histology	   sections	  indicates	  an	  invasive	  cancer	  phenotype.	  In	  addition	  to	  these	  we	  also	  probed	  for	  the	  epithelial	   cell-­‐adhesion	   molecule	   (EpCAM)	   and	   proto-­‐oncogene	   tyrosine-­‐protein	  kinase	  SRC.	  We	  probed	   for	  EpCAM	  since	   it	   is	  a	  common	  molecule	  used	   in	  affinity-­‐capture	   diagnostic	   technologies	   that	   aim	   to	   purify	   circulating	   cells	   of	   epithelial	  origin	  from	  blood	  samples.	  We	  probed	  for	  SRC	  because	  in	  contrast	  to	  EGFR	  and	  HER,	  it	   is	  a	  non-­‐receptor	  tyrosine	  kinase	  and	  wanted	  to	  establish	  if	  the	  protein	  receptor	  TRKs	  patterns	  observed	  in	  exosomes	  	  also	  extend	  to	  non-­‐receptor	  TRKs.	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On	  figure	  3.8	  we	  observe	  that	  when	  a	  protein	  is	  featured	  in	  the	  whole	  cell	  lysates,	  it	  can	   also	   be	   found	   in	   the	   corresponding	   exosomes.	   This	   fact	   alone	   establishes	  exosomes	  as	  a	  strong	  diagnostic	  molecule	  in	  breast	  cancer.	  	  	  On	  figure	  3.9	  we	  quantitatively	  compare	  the	  western	  blot	  findings	  by	  normalizing	  all	  cell	  lysates	  to	  the	  maximum	  fluorescent	  intensity	  value	  in	  each	  receptor	  group.	  We	  repeat	   this	   process	   for	   the	   corresponding	   exosomes.	   The	   question	   we	   pose	   is	  whether	  exosomes	  accurately	  reflect	  the	  cell	  line	  that	  is	  overexpressing	  the	  receptor	  in	  each	  group.	  We	  find	  that	  exosomes	  accurately	  predict	  that	  SKBR3	  cells	  are	  HER2	  over-­‐expressers	   and	   that	   BT20	   cells	   are	   EGFR	   over-­‐expressers.	   We	   also	   see	   that	  exosomes	  reflect	  the	  fact	  that	  MCF7	  cells	  are	  IGF1R	  over-­‐expressers	  and	  that	  T47D	  cells	  have	  the	  highest	  amount	  of	  CDH1.	  In	  addition,	  we	  find	  that	  exosomes	  in	  most	  cases	  accurately	   reflect	   the	   lowest	  expressers	   in	   the	  group.	  MDAMB231	  exosomes	  are	   negative	   for	   CDH1,	   as	   are	  MDAMB231	   cells.	   Similarly	  MDAMB231	   and	  HCC38	  cells	  are	  negative	  for	  IGF1R	  much	  like	  the	  corresponding	  cells.	  In	  the	  middle	  of	  the	  expression	  spectrum	  we	  see	  some	  fluctuations	  in	  the	  exosome	  pattern	  as	  compared	  to	  the	  cell	  lysate	  profile	  of	  expression.	  When	  differences	  in	  expression	  levels	  become	  small	   between	   two	   cell	   lines,	   exosomes	   predictions	   blur.	   This	   is	   evident	   in	   IGF1R	  receptor,	   where	   cell	   lysates	   show	   that	   BT20	   cells	   contain	  more	   IGF1R	   that	   T47D	  cells,	  yet	  exosomes	  indicate	  the	  opposite.	  	  	  	  Upon	  closer	  inspection	  of	  the	  western	  blot	  images	  on	  figure	  3.8	  we	  are	  able	  to	  note	  subtleties	  on	  the	  state	  of	  the	  blotted	  proteins	  in	  the	  exosomes	  versus	  the	  cell	  lysates.	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Notably,	  MET	  cell	   lysates	   feature	  a	  secondary	  band	  at	  170kDa	  that	  corresponds	  to	  pro-­‐MET,	  most	  visible	   in	   the	  high	  MET	  expresser	  cell	   lines	  BT20	  and	  MDAMB231.	  	  The	  band	   is	  absent	   from	  the	  exosomal	  MET	  version,	   in	  both	  cases.	   	   In	  contrast,	   in	  MCF7	  cells	  the	  pro-­‐IGF1R	  subunit	  of	  200kDa	  weight	  can	  be	  found	  in	  MCF7-­‐derived	  exosomes	  but	  is	  absent	  in	  the	  whole	  cell	  lysate.	  	  	  We	   also	   see	   that	   while	   some	   receptors	   are	   found	   in	   exosomes	   in	   comparable	  quantities	  to	  their	  cellular	  amounts,	  others	  are	  significantly	  enriched	  or	  depleted	  in	  the	   exosomes.	   Specifically	   EpCAM	   is	   significantly	   enriched	   in	   all	   exosomes	   as	  compared	  to	  the	  cell	  lines	  of	  origin.	  While	  we	  have	  no	  biological	  explanation	  for	  this	  finding,	  it	  is	  nevertheless	  convenient	  from	  a	  diagnostic	  perspective.	  As	  discussed	  in	  the	  introductory	  chapter,	  EpCAM	  is	  the	  primary	  molecule	  used	  to	  affinity-­‐purify	  first	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  circulating	   tumor	  cells	   and	  more	   recently	  exosomes	   from	  blood	  samples.	   Its	  over-­‐representation	  in	  these	  extracellular	  vesicles	  ensures	  that	  the	  exosomes	  will	  not	  go	  undetected	   in	   the	   patient’s	   circulation.	   One	   shortcoming	   of	   these	   diagnostic	  technologies	   is	   that	   breast	   cancer	   cell	   lines	   further	   along	   the	   epithelial-­‐mesenchymal	   transition	   down-­‐regulate	   or	   switch	   off	   EpCAM	   expression.	   These	  tumors	  are	   represented	   in	  our	   in	   vitro	  model	  by	   the	  EpCAM-­‐negative	  MDAMB231	  cells.	  One	  possible	  remedy	  to	  this	  limitations	  would	  be	  to	  affinity-­‐purify	  circulating	  exosomes	  based	  on	  two	  receptors:	  EpCAM	  and	  EGFR.	  	  	  In	   addition	   to	   developing	   informed	   purification	   strategies	   for	   blood	   biopsies,	   this	  cursory	   screen	   of	   exosome	   membrane	   proteins	   reveals	   that	   while	   only	   two	  receptors	  are	  sufficient	  to	  purify	  exosomes,	  three	  receptors	  is	  the	  minimum	  amount	  necessary	   to	   define	   the	  molecular	   subtype	   of	   a	   particular	   breast	   cancer	   from	   the	  circulating	   exosomes.	   These	   receptors	   are	   EGFR,	   HER2	   and	   EpCAM.	   Indeed	   EGFR	  high/EpCAM	  high	  exosomes	  indicate	  Basal	  cells.	  EGFR	  high/	  EpCAM	  low	  exosomes	  indicates	   the	   special	   category	   of	   invasive	   Basal	   B	   breast	   cancer	   with	   epithelial	  marker	   downregulation.	   The	   EGFR	   low/EpCAM	   high	   phenotype	   indicates	   luminal	  cells.	  And	  finally	  EGFR	  high/EpCAM	  high/HER2	  high	  reflects	  the	  special	  category	  of	  HER2	  overexpressing	  tumors.	  	  	  	  	  
	   145	  
	  





































































	   146	  
Nevertheless,	   some	   kinases	   such	   as	   AKT	   and	   p38	   MAPK	   appear	   to	   be	   more	  consistently	  expressed	  across	  all	   types	  of	  breast	  cancer	  exosomes.	  The	  mechanism	  by	  which	  some	  cytoplasmic	  proteins	  are	  represented	  in	  the	  exosomes	  while	  others	  are	  not	  is	  unknown	  at	  this	  point.	  Therefore	  intracellular	  protein	  presence	  will	  have	  to	  be	  determined	  in	  a	  case-­‐by-­‐case	  basis	  in	  a	  clinical	  setting	  	  On	  figure	  3.11	  we	  plot	  the	  ratio	  of	  quantified	  protein	  level	  of	  the	  exosomes	  over	  the	  cell	   lysates	   in	   order	   to	   examine	   enrichment	   and	   depletion	   patterns.	   Figure	   3.11a	  features	  the	  protein	  levels	  of	  basal	  exosomes	  (MDAMB231,	  HCC38	  and	  BT20)	  while	  figure	   3.11b	   features	   the	   protein	   levels	   of	   luminal	   exosomes	   (SKBR3,	   MCF7	   and	  T47D).	   One	   salient	   feature	   of	   this	   analysis	   is	   that	   luminal	   cells	   have	   higher	  enrichment	  patterns	  across	  most	  proteins.	  Specifically	  in	  the	  intracellular	  proteins,	  basal	  exosomes	  display	  depletion	  of	  beta-­‐actin	  and	  AKT	  while	  luminal	  exosomes	  are	  mostly	   enriched	   in	   these	   proteins.	   Even	   though	   all	   exosomes	   have	   detectable	  amounts	  of	  p38	  MAPK,	  the	  protein	  is	  depleted	  in	  exosomes	  when	  compared	  to	  cell	  levels.	  Overall	   the	  most	  depletion	   is	  observed	   in	   intracellular	  proteins,	  while	  most	  membrane	   proteins,	   with	   the	   exception	   of	   the	  MET	   receptor,	   are	   enriched	   in	   the	  vesicles.	  This	  once	  again	  highlights	   these	  vesicles	  as	  robust	  extracellular	  reporters	  of	   membrane	   proteins.	   We	   specifically	   observe	   that	   exosomes	   are	   enriched	   in	  EpCAM,	   SRC	   and	   MHCI	   membrane	   receptors,	   from	   10-­‐fold	   to	   400-­‐fold	   in	   the	  extreme	   case	   of	   EpCAM.	   One	   possible	   interpretation	   for	   this	   is	   that	   while	   some	  proteins	   might	   be	   passively	   transferred	   in	   the	   exosomes	   during	   their	   biogenesis,	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others	  might	  be	  selectively	  inserted	  based	  on	  an	  active	  mechanism	  of	  enrichment	  or	  depletion.	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Figure	   3.11:	   Fold-­‐enrichment	   pattern	   of	   cell	   membrane	   and	   intracellular	   proteins	   in	   exosomes,	  comparatively	  to	  whole	  cell	  lysates.	  a)	  Basal	  cell	  line	  profiles	  of	  protein	  enrichment	  in	  the	  exosomes	  for	  cell	  types	  MDAMB231,	  HCC38	  and	  BT20.	  b)	  Luminal	  cell	  line	  profiles	  of	  protein	  enrichment	  in	  the	  exosomes	  for	  cell	  types	  SKBR3,	  MCF7	  and	  T47D.	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the	  exosomes	  of	  BT20	  and	  HCC38	  cancer	  cell	  lines.	  An	  ensuing	  question	  is	  whether	  exosomes	  can	  convert	  extravesicular	  glucose	  to	  ATP	  and	  if	  so,	  are	  exosomes	  able	  to	  use	  ATP	  in	  order	  to	  phosphorylate	  the	  EGFR	  receptor.	  In	  this	  section	  we	  therefore	  examine	  exosomal	  EGFR	  more	  closely	   to	  determine	  whether	   the	   receptor	   remains	  functional	   on	   the	   extracellular	   vesicles.	   For	   this	   study	  we	   employ	   exosomes	   from	  two	  cell	  lines:	  HCC38,	  an	  EGFR	  expresser	  and	  BT20,	  an	  EGFR	  over-­‐expresser.	  	  The	  results	  are	  summarized	   in	   figures	  3.12	   for	  BT20-­‐derived	  exosomes	  and	   figure	  3.13	  for	  HCC38-­‐derived	  exosomes.	  In	  panels	  3.12a	  and	  3.13a	  we	  incubate	  exosomes	  in	   the	   presence	   of	   glucose	   with	   EGF	   and/or	   Lapatinib	   treatment.	   One	   striking	  feature	   is	   that	   both	   types	   of	   exosomes	   have	   detectable	   baseline	   amounts	   of	  phosphorylated	  EGFR.	  However,	  the	  phosphorylation	  does	  not	  statistically	  increase	  due	   to	   EGF	   treatment,	   nor	   does	   it	   decrease	   in	   the	   presence	   of	   EGFR/HER2	   dual	  inhibitor	   Lapatinib.	   We	   conclude	   that	   in	   both	   cases,	   the	   exosomal	   EGFR	   is	   not	  functional	  in	  that	  it	  is	  not	  able	  to	  phosphorylate	  or	  de-­‐phosphorylate	  in	  response	  to	  extravesicular	  stimulants.	  We	  want	  to	  note	  however	  that	  this	  was	  an	  activity	  study	  rather	  than	  a	  binding	  study.	   It	   is	  still	  entirely	  possible	   that	   the	  exosomes	  can	  bind	  EGF	  and/or	  Lapatinib.	  This	  was	  a	  phenomenon	  we	  did	  not	   specifically	   look	  at	  but	  there	   are	   reports	   in	   the	   literature	   that	   document	   binding	   ability	   of	   exosomes	   to	  various	   receptor	   TRK	   ligands.	   Instead	   our	   objective	   was	   to	   determine	   functional	  response	   of	   exosomes	   to	   these	   ligands	   and	   in	   that	   respect	   we	   conclude	   that	   the	  EGFR	  receptor	  is	  not	  functional	  on	  the	  exosomes.	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In	   panels	   3.12b	   and	   3.13b	   we	   take	   a	   step	   back	   and	   incubate	   exosomes	   in	   the	  presence	  and	  absence	  of	  glucose	  in	  the	  extravesicular	  medium.	  In	  addition,	  instead	  of	   the	   EGF	   biological	   ligand	   we	   attempt	   to	   non-­‐specifically	   increase	   the	   baseline	  EGFR	   phosphorylation	   by	   treating	   exosomes	   with	   orthovanadate	   phosphatase	  inhibitor.	   Lapatinib	   inhibitor	   is	   added	   in	   the	   presence	   or	   absence	   of	   glucose	   and	  phosphatase	   inhibitors.	   Finally,	   in	   addition	   to	   monitoring	   the	   phosphorylation	   of	  EGFR	   we	   also	   document	   the	   phosphorylation	   of	   the	   upstream	   kinase	   AKT.	   Even	  though	  we	  observe	  mild	   fluctuations	   in	  pEGFR	  and	  pAKT	  neither	   type	  of	  exosome	  displays	  statistically	  significant	  change	  in	  response	  to	  the	  various	  treatments.	  Once	  again	  we	  conclude	  that	  exosomal	  EGFR	  is	  present	  but	  not	  functional.	  Specifically	  the	  failure	   of	   exosomes	   to	   ‘sense’	   a	   difference	   in	   glucose-­‐free	   versus	   glucose-­‐rich	  extravesicular	  buffer	  implicates	  a	  lack	  of	  intact	  glycolytic	  mechanism	  as	  the	  etiology	  behind	  EGFR	  functional	  failure.	  	  	  	  
	   151	  
	  







Glucose     
Vanadate
-     +      -       +
-     -       +      +
-     -       +      +
Lapatinib  
Glucose     
Vanadate
-     +      -       +
-     -       +      +














Glucose     
Vanadate
-       +       -       +
-        -       +      +
-        -       +      +
ns
-       +       -       +
-        -       +      +
-        -       +      +
ns
Lapatinib  
































































































	   152	  
	  








Glucose     
Vanadate
-     +      -       +
-     -       +      +
-     -       +      +
Lapatinib  
Glucose     
Vanadate
-     +      -       +
-     -       +      +





































Glucose     
Vanadate
-       +       -       +
-        -       +      +
-        -       +      +
ns
Lapatinib  
Glucose     
Vanadate
-       +       -       +
-        -       +      +











































































	   153	  
Collection	  of	  Exosomes	  from	  EGF	  and/or	  Lapatinib	  Treated	  Cells	  Having	   established	   that	   exosomal	  EGFR	  does	  not	   retain	  phosphorylation	   function,	  we	   now	   re-­‐formulate	   our	   original	   hypothesis	   and	   query	   whether	   the	  phosphorylation	  level	  of	  EGFR	  and	  upstream	  AKT	  kinase	  on	  the	  exosomes	  can	  carry	  information	  regarding	  the	  phosphorylation	  state	  of	  the	  exosome-­‐producing	  cells.	  In	  order	  to	  answer	  this	  question	  we	  treat	  serum-­‐starved	  cell	  monolayers	  with	  EGF	  and	  Lapatinib	   separately	  as	  well	   as	   simultaneously.	  We	  allow	  24hrs	   to	  pass	  before	  we	  collect	   and	   purify	   exosomes	   from	   the	   culture	   supernatants.	   In	   parallel	   to	   this	  experiment	  we	  also	  perform	  the	  corresponding	  in-­‐cell	  control	  by	  treating	  cells	  with	  EGF	  and/or	  Lapatinib	  and	  collecting	   the	  cell	   lysates.	  Once	  again	  we	  perform	  these	  experiements	  with	  two	  types	  of	  cells	  and	  resulting	  exosomes:	  HCC38	  and	  BT20.	  	  	  
Figure	  3.14	  displays	  results	  for	  BT20	  cells,	  while	  figure	  3.15	  summarizes	  HCC38	  cell	  results.	   Panels	   3.14a	   and	   3.15a	   show	   the	   extent	   of	   cellular	   EGFR	   and	   AKT	  phosphorylation	  in	  response	  to	  EGF	  and	  Lapatinib	  treatment.	  We	  observe	  a	  10-­‐fold	  rise	  of	  pEGFR	  in	  response	  to	  EGF	  stimulation.	  This	  response	  is	  completely	  mitigated	  my	  Lapatinib	  treatment	  in	  both	  cell	  types.	  We	  also	  observe	  a	  more	  moderate	  pattern	  when	  it	  comes	  to	  upstream	  AKT	  phosphorylation	  in	  response	  to	  EGF	  treatment.	  In	  BT20	  cells	  pAKT	  approximately	  doubles	  during	  EGF	  treatment,	  while	  in	  HCC38	  cells	  it	  retains	  baseline	  levels.	  Lapatinib	  has	  a	  more	  pronounced	  effect	  on	  pAKT,	  since	  it	  decreases	  it	  below	  baseline	  levels	  in	  both	  cases.	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Panels	  3.14b	  and	  3.15b	  display	  the	  experiments	  where	  we	  are	  attempting	  to	  readout	  phosphorylation	  of	  AKT	  and	  EGFR	  on	  exosomes	  isolated	  from	  EGF	  and/or	  Lapatinib	  treated	  cells.	  Phospho-­‐EGFR	  in	  both	  types	  of	  exosomes	  behaves	  similarly	  to	  the	  in-­‐cell	   controls.	   The	   phosphorylation	   rises	   in	   response	   to	   EGF	   treatment,	   while	  Lapatinib	  returns	  pEGFR	  to	  baseline	  levels.	  However,	  in	  contrast	  to	  in	  cell-­‐controls,	  pEGFR	   in	   BT20	   exosomes	   only	   rises	   up	   two-­‐fold	   more	   than	   the	   baseline	   control	  when	  in	  the	  cell	  the	  phosphorylation	  response	  to	  the	  same	  treatment	  goes	  up	  more	  than	   10-­‐fold.	   The	   potency	   of	   the	   information	   is	   somewhat	   mitigated	   in	   these	  exosomes.	   On	   the	   contrary,	   HCC38	   exosomes	   display	   a	   7-­‐fold	   rise	   in	  phosphorylation	  in	  response	  to	  EGF	  treatment,	  which	  is	  close	  to	  the	  in-­‐cell	  control	  amount.	  In	  both	  types	  of	  exosomes	  pAKT	  displays	  a	  similar	  rise-­‐and-­‐fall	  pattern	  as	  in	  the	  cells,	  yet	  once	  again	  the	  fold-­‐induction	  is	  weaker	  than	  in	  the	  cells.	  	  	  Further	   replicates	   are	   currently	   underway	   that	   will	   establish	   the	   statistical	  reproducibility	   of	   these	   results.	   However,	   this	   early	   finding	   suggests	   that	   breast	  cancer	   exosomes	   can	  mirror	   not	   only	   receptors	   from	   their	   cell	   lines	   of	   origin	   but	  furthermore	  the	  phosphorylation	  status	  of	  those	  receptors.	  Clinically,	  this	  feature	  of	  exosomes	   can	   be	   exploited	   as	   a	   real-­‐time	  dynamic	   read	   out	   of	   tumor	   response	   to	  TRK	  inhibitor	  drug	  treatments.	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Receptor	   Transference	   from	   Receptor-­Positive	   Exosomes	   to	   Receptor-­Negative	  
Cell	  Lines	  In	   chapter	   2	   we	   presented	   time	   lapse	   imaging	   data	   showing	   the	   endocytosis	   of	  fluorescently-­‐labeled	  exosomes	  by	  a	  heterologous	  cancer	  cell	   line.	  This	  data	  raised	  the	   question	   of	   whether	   exosomes	   are	   able	   to	   transfer	   biological	  material,	   in	   the	  form	  of	  microRNAs	  or	  proteins,	  into	  the	  recipient	  cell	  lines.	  In	  this	  section	  we	  devise	  a	   simple	   experimental	   assay	   in	   order	   to	   answer	   this	   question,	   as	   far	   as	   protein	  transfer	  goes.	  We	  realized	  that	  we	  had	  to	  make	  a	  strategic	  choice	  when	  it	  came	  to	  which	   protein	   to	   use	   as	   a	   reporter	   of	   exosome-­‐mediated	   transfer.	   We	   needed	   to	  select	  a	  protein	  that	  is	  abundant	  in	  the	  exosomes,	  yet	  not	  expressed	  in	  the	  recipient	  cell	   lines	   so	   that	   a	   small	   amount	   of	   exosome-­‐transplanted	   protein	  will	   be	   readily	  detectable	  in	  the	  recipient	  cell	  lysates.	  For	  this	  purpose	  we	  refer	  back	  to	  figure	  3.8	  and	  select	  CDH1	  and	  EpCAM-­‐positive	  exosomes	  derived	  from	  MCF7	  and	  T47D	  cells.	  For	  the	  recipient	  cell	  lines	  we	  select	  MDAMB231	  cells	  since	  they	  are	  both	  CDH1	  and	  EpCAM-­‐negative,	   as	   well	   as	   SKBR3	   cells	   which	   as	   CDH1-­‐negative	   and	   EpCAM	  positive.	  	  Figure	  3.16	  summarizes	   the	   results	  of	   this	  experiment.	  We	  see	   that	  MCF7-­‐derived	  exosomes	  are	  not	  significantly	  efficient	  at	  transferring	  CDH1	  or	  EpCAM	  in	  either	  cell	  line.	   On	   the	   contrary,	   T47D	   exosomes	   induce	   a	   5-­‐fold	   increase	   in	   the	   amount	   of	  EpCAM	   present	   in	   SKBR3	   cells	   and	   a	   two-­‐fold	   increase	   in	   MDAMB231	   EpCAM.	  Furthermore,	  T47D	  exosomes	  are	  successful	  at	  transferring	  a	  detectable	  6-­‐fold	  band	  of	  CDH1	  in	  SKBR3	  cells,	  and	  a	  corresponding	  4-­‐fold	  CDH1	  band	  in	  MDAMB231	  cells.	  
	   158	  
Perhaps	  the	  efficiency	  of	  T47D	  exosomes	  in	  protein	  transfer	  stems	  from	  the	  fact	  that	  these	  exosomes	  show	  higher	   levels	  of	  protein	  enrichment,	   in	  comparison	   to	  MCF7	  exosomes	  (figure	  3.11).	  	  	  Further	   experimental	   replicates	   are	  needed	   to	  validate	   this	   result,	   yet	   this	   finding	  sheds	  some	  light	  into	  the	  biological	  role	  of	  exosomes.	  Future	  studies	  should	  center	  around	  the	  characterization	  of	  this	  transfer	  phenomenon	  by	  immunohistochemistry	  in	  order	   to	  unveil	   the	   localization	  of	   the	   transferred	  adhesion	  molecules.	  Are	   they	  transferred	   within	   the	   cytoplasm	   of	   the	   recipient	   cells	   or	   do	   they	   assume	   a	  functional	  role	  on	  the	  cell	  membrane	  and	  initiate	  changes	  in	  the	  cellular	  phenotype.	  Another	   issue	   that	   remains	   to	   be	  qualified	   is	   the	  precise	   timescale	   of	   the	   transfer	  phenomenon.	  When	  does	   transfer	  begin,	  when	  does	   it	  peak	  and	   is	   the	  presence	  of	  the	  transferred	  proteins	  transient	  or	  permanent	  in	  the	  recipient	  cells.	  Future	  studies	  geared	   toward	   biological	   activity	   of	   breast	   cancer	   exosomes	   will	   center	   around	  these	  critical	  questions.	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5.1	  Indentifying	  pro-­apoptotic	  factors	  in	  breast	  cancer	  conditioned	  media	  In	  chapter	  2	  we	  showed	  that	   the	  conditioned	  media	  (CM)	  of	   triple	  negative	  breast	  cancer	  cell	  lines	  was	  toxic	  to	  breast	  cancer	  cells.	  Among	  the	  triple	  negative	  cell	  lines,	  HCC38	  and	  BT20-­‐derived	  CMs	  that	  were	  particularly	  pro-­‐apoptotic	  and	  resulted	  in	  high	   apoptotic	   cell	   count	   on	   the	   majority	   of	   responder	   cell	   lines	   tested.	   We	  consequently	   embarked	   in	   further	  biochemical	   characterization	  of	   those	   two	  CMs.	  We	  showed	  that	  the	  apoptotic	  effect	  can	  be	  concentrated,	  heated	  to	  95°C	  and	  frozen	  in	   liquid	   nitrogen.	   In	   contrast,	   a	   dilution	   series	   of	   CM	   HCC38	   showed	   that	   the	  apoptotic	  effect	   cannot	  be	  diluted.	  Furthermore,	  we	  established	   that	   the	  apoptotic	  effect	   is	   retained	   in	   the	   soluble	   supernatant	   of	   the	   ultracentrifugation	   spin	   that	  pellets	  membranous	  particles	  present	  in	  the	  CMs.	  	  	  Although	   interesting,	   this	   line	   of	   investigation	   presented	   significant	   challenges.	  There	  was	  batch-­‐to-­‐batch	  variability	  in	  the	  apoptotic	  potency	  of	  conditioned	  media	  that	  complicated	  the	  process	  of	  obtaining	  multiple	  biological	  replicates	  of	  the	  same	  experiment.	  In	  addition,	  as	  demonstrated	  by	  live	  cell	  timelapse	  movies	  presented	  in	  chapter	  1,	  the	  apoptotic	  effect	  derived	  from	  incubation	  of	  target	  cell	   lines	  with	  the	  cytotoxic	   CMs	   set	   in	   at	   about	   30hrs	   of	   culture.	   This	  made	   experiments	   of	   further	  characterization	   of	   the	   apoptotic	   effect	   significantly	   time	   consuming.	   For	   these	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reasons	  we	  eventually	  changed	  course	  and	  turned	  to	  different	  approaches	  in	  order	  to	   elucidate	   the	   protein	   content	   of	   the	   CMs	   and	   generate	   leads,	   that	   is	   candidate	  proteins	  responsible	  for	  the	  apoptotic	  effect.	  	  In	   chapter	  3	  we	  used	   transcriptomic	   as	  well	   as	   proteomic	   approaches	   in	   order	   to	  mine	  the	  secretome	  of	  HCC38	  and	  BT20	  cells	  for	  pro-­‐apoptotic	  factors.	  Each	  of	  these	  approaches	   had	   some	   advantages	   as	   well	   as	   caveats	   associated	   with	   it.	   The	  transcriptional	  profiles	  of	  all	  18	  out	  of	  the	  20	  breast	  cancer	  cell	  lines	  were	  publicly	  available	   for	   this	   cancer	   cell	   library.	   Therefore	   we	   were	   able	   to	   correlate	   the	  transcriptome	  of	  18	  cell	  lines	  to	  the	  phenotypic	  data	  matrix	  presented	  in	  chapter	  1.	  The	  obvious	  disadvantage	  of	  using	  transcriptional	  data	  to	  predict	  secreted	  protein	  profiles	  is	  that	  numerous	  biological	  events	  can	  alter	  the	  expression	  of	  a	  final	  protein	  product	   after	   transcription.	   For	   this	   reason	   we	   followed	   up	   this	   effort	   with	  proteomic	  analysis	  of	  BT20	  and	  HCC38-­‐derived	  conditioned	  media.	  We	   looked	   for	  pro-­‐apoptotic	  hits	  in	  the	  protein	  pool	  that	  is	  common	  to	  both	  CMs,	  as	  well	  as	  among	  the	  proteins	   that	  where	   found	   to	  be	  unique	   for	  each	  media.	  As	  mentioned	  earlier,	  fractionation	  of	  the	  CM	  and	  re-­‐testing	  of	  fractions	  for	  apoptotic	  activity	  had	  revealed	  that	  CM-­‐induced	  apoptosis	   is	  retained	  in	  the	  particulate-­‐free	  fraction	  of	  the	  media.	  In	   order	   to	   compress	   the	   list	   of	   proteomically-­‐identified	   apoptotic	   hits,	   we	   also	  compared	   the	   proteome	   of	   CM-­‐derived	   exosomes	   to	   that	   of	   the	   full	   CMs	   and	  examined	   the	   pool	   of	   CM-­‐unique	   proteins	   for	   molecules	   with	   known	   apoptotic	  activity.	  We	  took	  this	  analysis	  one	  step	  further	  and	  looked	  for	  hit	  overlap	  between	  the	   two	   lists,	   CM	   HCC38	   unique	   proteins	   and	   CM	   BT20	   unique	   proteins.	   As	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predicted,	   this	   approach	   resulted	   in	   a	   significantly	   shorter	   list	   of	   hits	   awaiting	  validation.	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extracellular	  proteins	  while	  only	  a	  small	  minority	  of	  extracellular	  proteins	  is	  found	  free-­‐floating	   in	   the	   soluble	   CM	   fractions.	   Another	   finding	  was	   that	   the	   soluble	   CM	  fraction	   features	   cytokines	  and	  growth-­‐promoting	   factors	   (such	  as	  attractin	  ATRN	  and	   hepatocyte	   growth	   factor	   HDGF)	   in	   addition	   to	   pro-­‐apoptotic	   molecules.	   A	  question	   that	  arises	   is	  whether	   these	  pro-­‐growth	  cell	   stimulants	  act	   competitively	  against	   the	   pro-­‐apoptotic	   factors	   or	   whether	   they	   actually	   act	   as	   co-­‐factors	  amplifying	  the	  apoptotic	  activity	  of	  pro-­‐death	  molecules.	  Validation	  of	  these	  hits	   is	  the	   next	   rational	   step	   that	  would	   answer	   remaining	   questions	   and	   unveil	   specific	  molecular	  mechanisms	  responsible	  for	  apoptotic	  activity.	  	  In	   the	   future,	   fractionation	   of	   the	   active	   conditioned	   media	   by	   high-­‐performance	  liquid	   chromatography	   could	   further	   condense	   the	   list	   of	   candidate	   apoptotic	  molecules.	  Some	  caveats	  associated	  with	  this	  approach	  are	  that	  we	  risk	  diluting	  the	  apoptotic	  activity	  beyond	  our	  assay’s	  detection	  limit.	  Furthermore,	  in	  the	  case	  a	  co-­‐factor	   is	   required	   in	   order	   to	   achieve	   the	   apoptotic	   effect,	   chromatographic	  separation	   of	   the	   CMs	   risks	   yielding	   no	   active	   fractions.	   Nevertheless,	   liquid	  chromatography	  constitutes	  the	  golden	  standard	  for	  biochemical	  purification	  and	  is	  therefore	  worth	  pursuing	  in	  the	  context	  of	  this	  study.	  	  	  A	  less	  labor-­‐intensive	  approach	  that	  also	  holds	  the	  potential	  of	  condensing	  the	  list	  of	  apoptotic	  hits	  is	  to	  extend	  the	  proteomic	  analysis	  to	  encompass	  conditioned	  media	  from	  cell	   lines	  that	  scored	  negative	  for	  apoptosis	   in	  our	  original	  20x20	  screen.	  We	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expect	   that	   the	   comparison	   of	   these	   proteomes	   to	   the	   toxic	   CM	   proteomes	   will	  eliminate	  the	  vast	  majority	  of	  our	  current	  apoptotic	  hits.	  	  	  In	  order	  to	  further	  validate	  apoptotic	  hits	  for	  activity	  in	  cells,	  a	  variety	  of	  methods	  can	   be	   employed.	   Neutralizing	   antibodies	   can	   be	   purchased	   to	   silence	   a	   pro-­‐apoptotic	   protein	   in	   the	   CMs,	   or	   to	   block	   a	   particular	   receptor	   on	   the	   target	   cell	  lines.	  Alternatively,	   if	  the	  protein	  is	  commercially	  available	  in	  recombinant	  form,	  it	  can	   be	   tested	   directly	   in	   solution	   for	   apoptotic	   activity.	   RNA	   interference	   is	   also	  commonly	  used	  in	  order	  to	  transiently	  knock	  out	  target	  genes	  in	  either	  the	  producer	  or	  receiver	  cell	  line.	  The	  choice	  of	  method	  will	  be	  dependent	  on	  the	  specific	  protein	  hit	  and	  the	  amount	  of	  reagents	  commercially	  available	  for	  that	  particular	  protein.	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5.2	  Evaluating	   the	  effectiveness	  and	   functionality	  of	  breast	   cancer	  exosomes	  
as	  diagnostic	  material	  In	   chapters	   2	   and	   3	   we	   repeatedly	   collected	   breast	   cancer	   culture	   medium	   and	  attempted	   to	   tease	  out	   its	  protein	  contents	   in	  search	  of	  pro-­‐apoptotic	   factors.	  One	  unexpected	  finding	  was	  that	  in	  addition	  to	  soluble	  proteins,	  conditioned	  media	  also	  featured	   a	   considerable	   amount	   of	   nuclear,	   cytoplasmic	   and	   plasma	   membrane	  proteins	   neatly	   compiled	   and	   exported	   in	   the	   extracellular	   space	   in	   the	   form	   of	  extracellular	   microvesicles	   known	   as	   exosomes.	   In	   chapter	   4	   we	   turned	   our	  attention	  to	  these	  vesicles	  and	  embarked	  in	  a	  series	  of	  studies	  aimed	  to	  characterize	  them.	  	  Proteomic	   studies	   showed	   an	   abundance	   of	   cytoskeletal	   proteins,	   RAB	   GTP-­‐ases,	  and	   glycolytic	   enzymes	   present	   in	   the	   exosomes	   of	   HCC38	   and	   BT20	   cells.	   More	  predictably,	  we	  also	  found	  numerous	  exosome	  markers,	  integrins	  and	  cell-­‐adhesion	  molecules	   present	   in	   the	   vesicles.	   A	   series	   of	   western	   blots	   targeted	   towards	  receptor	   tyrosine	   kinases	   as	   well	   as	   upstream	   intracellular	   kinases	   revealed	   that	  exosomes	  quite	  accurately	  reflect	  the	  receptors	  of	  the	  cell	  line	  they	  originated	  from.	  Intracellular	  kinase	  enrichment	  patterns	  are	  more	  varied	  and	  unpredictable	  among	  exosomes	   derived	   from	   different	   cell	   lines,	   but	   in	   our	   screen	   encompassing	   six	  breast	  cancer	  cell	  lines	  spanning	  the	  spectrum	  from	  luminal	  to	  basal	  A	  and	  basal	  B,	  we	   found	   p38	   MAPK	   to	   be	   consistently	   detectable	   among	   all	   exosomes	   and	   AKT	  kinase	  to	  be	  detectable	  in	  five	  out	  of	  the	  six	  exosome	  types.	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Next	   we	   asked	   whether	   the	   exosome	   version	   of	   the	   TRK	   receptor	   EGFR	   retains	  functionality,	  i.e.	  the	  ability	  to	  add	  or	  subtract	  a	  phosphate	  group	  when	  exposed	  to	  EGF	  or	  Lapatinib	  respectively.	  We	  found	  the	  answer	  to	  this	  question	  to	  be	  negative.	  Specifically	   we	   were	   unable	   to	   readout	   changes	   in	   phosphorylation	   pattern	   of	  exosomal	   EGFR	   when	   treating	   exosomes	   with	   biological	   ligand,	   non-­‐specific	  phosphatase	   inhibitor	   or	   Lapatinib	   inhibitor	   either	   in	   the	   presence	   or	   absence	   of	  extravesicular	   glucose.	  We	   conclude	   that	  despite	   the	  wealth	  of	   glycolytic	   enzymes	  present	   in	   the	  exosomes,	   these	  anuclear	  vesicles	  do	  not	   retain	   an	   intact	   glycolytic	  pathway	   and	   are	   unable	   to	   convert	   extravesicular	   glucose	   to	   ATP	   in	   order	   to	  complete	  the	  phosphorylation	  process.	  	  	  We	   were	   however	   able	   to	   detect	   baseline	   phosphorylation	   levels	   of	   EGFR	   and	  upstream	  AKT	   kinase	   in	   cancer-­‐derived	   exosomes	   and	   curiosity	   as	   to	  what	   is	   the	  origin	  of	   this	  phosphorylation	  pattern	   led	  us	   to	   formulate	  an	  alternate	  hypothesis.	  We	  hypothesized	  that	  if	  exosomes	  are	  unable	  to	  phosphorylate	  EGFR	  once	  secreted	  by	   the	   producer	   cell	   line,	   they	  must	   then	   incorporate	   phospho-­‐EGFR	   during	   their	  biogenesis	  process	  within	  the	  producer	  cells.	  If	  this	  was	  indeed	  the	  case,	  we	  should	  be	   able	   to	   regulate	   phosho-­‐EGFR	   and	   phosphor-­‐AKT	   levels	   by	   challenging	   the	  producer	   cells	   with	   biological	   ligand	   EGF	   and/or	   Lapatinib	   and	   consequently	  observe	   the	   rise	   and	   fall	   of	   pEGFR	   and	   pAKT	   on	   the	   resulting	   exosomes.	  Experiments	  confirmed	  this	  alternate	  hypothesis	  as	  valid.	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A	  final	  study	  on	  exosome	  biology	  examined	  the	  transfer	  of	  membrane	  cell	  adhesion	  molecules	   from	  EpCAM	  and	  CDH1-­‐positive	  exosomes	   to	  cell	   types	   that	  are	  EpCAM	  and	   CDH1-­‐negative.	   We	   found	   that	   T47D-­‐derived	   exosomes	   were	   successful	   at	  transferring	  both	  adhesion	  molecules	  to	  recipient	  cell	  lines	  MDAMB231	  and	  SKBR3.	  This	   was	   a	   pilot	   functional	   study	   and	   more	   experiments	   are	   needed	   in	   order	   to	  characterize	   the	   time-­‐scale	   of	   the	   transfer	   event	   as	  well	   as	   the	   localization	   of	   the	  transferred	  molecules	  on	  the	  recipient	  cell	  lines.	  	  	  In	  terms	  of	  clinical	  relevance,	  the	  implications	  of	  these	  findings	  are	  far-­‐reaching.	  We	  showed	   that	   breast-­‐cancer	   derived	   exosomes	   reflect	   not	   only	   the	   receptors	   from	  their	  originating	  cell	  lines,	  but	  also	  the	  phosphorylation	  status	  of	  these	  receptors.	  As	  such,	   breast	   cancer	   exosomes	   hold	   the	   promise	   of	   becoming	   real-­‐time	   dynamic	  diagnostic	  material	   that	  can	  convey	   information	  regarding	  TRK	   inhibitor	   response	  of	  a	  tumor,	  right	  at	  the	  time	  of	  drug	  treatment.	  	  In	   terms	   of	   affinity-­‐capture	   methods	   aimed	   at	   purifying	   breast	   cancer	   exosomes	  from	  complex	  biological	   fluids	  such	  as	  blood	  or	  malignant	  ascites,	  we	  showed	  that	  the	  majority	  of	  breast-­‐cancer	  derived	  exosome	  are	  highly	  enriched	  in	  the	  epithelial	  cell	   adhesion	   molecule	   EpCAM.	   Therefore	   EpCAM	   constitutes	   a	   good	   first-­‐past	  capture	  molecule	  that	  will	  select	  specifically	  for	  epithelial	  tumor-­‐derived	  vesicles	  in	  a	   clinical	   setting.	  We	   showed	   however	   that	   a	  minority	   of	   breast	   cancer	   cells	   will	  downregulate	   or	   cease	   expression	   of	   epithelial	  markers.	   In	   these	   cases	   EGFR	   is	   a	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preferable	   molecule	   for	   affinity-­‐capture	   methods	   since	   it	   is	   expressed	   at	   varying	  levels	  by	  all	  breast	  cancer	  exosomes	  we	  tested.	  	  	  In	  terms	  of	  molecular	  typing	  of	  tumors	  using	  breast-­‐cancer	  derived	  exosomes,	  this	  liquid	   biopsy	  method	   has	   an	   obvious	   hurdle	   to	   overcome:	   exosomes	   are	   anuclear	  units	  that	  lack	  the	  hormone	  receptors	  (estrogen	  and	  progesterone)	  typically	  used	  to	  classify	  luminal	  hormone	  receptor	  positive	  tumors.	  However	  we	  showed	  that	  three	  membrane	  markers	   are	   sufficient	   to	   classify	   all	   molecular	   types	   of	   breast	   cancer	  cells	   tested.	   Luminal	   tumor	   classification	   in	   exosomes	   can	   be	   interpreted	   as	   an	  EpCAM	  high/EGFR	  low	  phenotype.	  HER2	  positive	  tumor	  classification	  in	  exosomes	  can	   be	   interpreted	   as	   a	   HER2	   high/EGFR	   high	   phenotype,	   while	   triple	   negative	  classification	  will	  correspond	  to	  an	  EGFR	  high/EpCAM	  low/HER2	  low	  phenotype.	  	  	  Finally	   our	   study	   showing	   adhesion	   molecule	   transfer	   from	   exosomes	   to	  heterologous	   cells	   hints	   at	   roles	   exosomes	   potentially	   play	   during	   primary	   tumor	  development,	  the	  metastatic	  cascade	  and	  the	  homing	  of	  tumor	  cells	  in	  the	  metastatic	  niche.	   EpCAM	   and	   CDH1	   are	  molecules	   conducive	   to	   an	   epithelial,	   less	   aggressive	  phenotype.	  Therefore,	  the	  successful	  transfer	  of	  functional	  adhesion	  proteins	  within	  aggressive	   EpCAM	   and	   CDH1-­‐negative	   breast	   cancer	   cell	   lines	   opens	   novel	  therapeutic	   avenues.	   Studies	   in	   the	   field	   of	   biomedical	   engineering	   of	   cancer	  therapeutic	  vectors	  are	  presently	  exploring	  the	  delivery	  of	  cell	  adhesion	  molecules	  as	   a	   means	   of	   ‘re-­‐programming’	   a	   tumor	   to	   assume	   a	   less	   metastatic,	   more	  epithelial-­‐like	   phenotype.	   Exploring	   the	   efficiency	   and	  mechanistic	   underpinnings	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Appendix	  
	  
Measuring	  apoptosis	  in	  tissue	  culture	  cells	  
	  During	   the	  course	  of	   this	   research	  project	   I	  experimented	  with	  a	  variety	  of	  assays	  for	  measuring	  cellular	  apoptosis.	  In	  contrast	  to	  other	  cell-­‐based	  measurements	  such	  as	   proliferation,	   measuring	   apoptosis	   presents	   some	   challenges.	   Apoptotic	   cells	  round	  up	  and	  eventually	  forgo	  attachment	  to	  the	  tissue	  culture	  plate,	  which	  makes	  it	  likely	   to	   loose	   these	   cells	  during	  plate	  washes	  and	  by	   consequence	  underestimate	  the	   apoptotic	   cell	   count.	   Another	   confounding	   factor	   that	   I	   ran	   into	   is	   that	   the	  specific	  phenotype	  associated	  with	  conditioned-­‐media	  induced	  apoptosis	  held	  some	  similarity	   to	   the	  phenotype	  of	  dividing	   cells.	   CM-­‐induced	  apoptotic	   cells	   round	  up	  much	   like	   cells	   about	   to	   undergo	   cell	   division.	   However,	   rather	   than	   dividing	   the	  apoptotic	   cells	  will	   eventually	  bleb	  and	  die.	  This	  prevented	  me	   from	  being	  able	   to	  read	   out	   apoptosis	   simply	   by	   glancing	   at	   cell	   plates	   under	   the	   microscope	   and	  required	   me	   to	   employ	   an	   assay	   that	   specifically	   probes	   for	   molecular	   apoptotic	  events	   in	  order	  to	  measure	  apoptotic	  cells.	  Below	  I	  summarize	  the	  assays	  used	  for	  this	  purpose	  throughout	  this	  study.	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Cleaved	  PARP	  Immunofluorescence	  Full-­‐length	   poly(ADP-­‐ribose)	   polymerase	   	   PARP	   is	   a	   116kDa	   nuclear	   protein	  involved	   in	   the	   repair	   of	   DNA,	   in	   differentiation	   and	   in	   chromatin	   structure	  formation.	  During	  apoptosis	  this	  protein	  is	  cleaved	  by	  caspase-­‐3,	  and	  possibly	  other	  caspases,	   into	  an	  89kDa	   fragment.	  Staining	  of	  cell	  monolayers	  with	  a	  p89	  cleaved-­‐PARP	   antibody	   after	   fixation	   and	   permeabilization	   reveals	   apoptotic	   cells.	   The	  obvious	  drawback	  of	  this	  method	  is	  that	  the	  fixation	  process	  eliminates	  all	  floating	  apoptotic	  cells	  that	  are	  the	  result	  of	  early	  events	  of	  apoptosis.	  Therefore	  the	  method	  captures	   only	   the	   late	   apoptotic	   events,	   i.e.	   the	   cells	   that	   are	   still	   adhered	   to	   the	  culture	   plate	   at	   the	   time	   of	   fixation.	   The	   reason	   I	   used	   this	   particular	   assay	   to	  acquire	  the	  20x20	  conditioned	  media	  screen	  data	  presented	  in	  the	  second	  chapter,	  is	   that	   it	   allows	  multiplexing	  with	   other	   readouts.	   In	   our	   case	   I	  was	   able	   to	   use	   a	  proliferative	  reporter	  in	  addition	  to	  the	  cleaved-­‐PARP	  apoptotic	  reporter.	  	  
Cleaved	  PARP	  western	  blot	  A	  variation	  of	  the	  previous	  assay	  is	  the	  cleaved	  PARP	  western	  blot.	  This	  is	  a	  rather	  time-­‐consuming	   way	   of	   measuring	   cellular	   apoptosis.	   Yet	   the	   advantage	   of	   a	  western	  blot	   is	  that	   it	  can	  be	  multiplexed	  with	  a	  plethora	  of	  antibodies	  in	  order	  to	  readout	  a	  wealth	  of	  molecular	  information	  pertinent	  to	  the	  apoptotic	  phenotype.	  In	  order	  to	  minimize	  cell	  losses	  in	  this	  method,	  the	  cell	  culture	  supernatant	  is	  collected	  and	  centrifuged	  to	  pellet	  any	  floating	  apoptotic	  cells.	  These	  cells	  are	  then	  lysed	  along	  with	   the	   tissue	   culture	   monolayers	   and	   the	   cell	   lysate	   is	   used	   to	   run	   a	   standard	  western	   blot	   protocol.	   Nitrocellulose	   membranes	   are	   eventually	   blotted	   with	   the	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116kDa	  full-­‐length	  PAPR	  antibody,	   in	  order	  to	  visualize	  the	  amount	  of	  intact	  PARP	  as	  well	  as	  that	  of	  the	  cleaved	  89kDa	  fragment.	  	  	  	  
Caspase	  Glo	  Luminescence1	  The	  Caspase-­‐Glo	  luminescent	  assay	  measures	  caspase-­‐3	  and	  -­‐7	  activities.	  The	  assay	  provides	   a	   luminogenic	   caspase-­‐3/7	   substrate,	   which	   contains	   the	   tetrapeptide	  sequence	  DEVD,	   in	  a	  reagent	  optimized	   for	  caspase	  activity,	   luciferase	  activity	  and	  cell	   lysis.	   Adding	   a	   single	   Caspase-­‐Glo	   reagent	   in	   an	   “add-­‐mix-­‐measure”	   format	  results	  in	  cell	  lysis,	  followed	  by	  caspase	  cleavage	  of	  the	  substrate	  and	  generation	  of	  a	  “glow-­‐type”	   luminescent	   signal,	   produced	   by	   luciferase.	   The	   assay	   readout	   is	  quantitative	   as	   luminescence	   is	   proportional	   to	   the	   amount	   of	   caspase	   activity	  present.	   The	   great	   advantage	   of	   this	   method	   is	   the	   speed	   and	   ease	   of	   use	   of	   the	  reagent.	  On	  the	  other	  hand,	  this	  assay	  is	  a	  population	  ensemble	  measurement	  that	  sacrifices	  sensitivity.	  	  
M30	  Cytodeath	  ELISA2	  This	   assay	   measures	   a	   fragment	   of	   the	   intermediate	   filament	   protein	   keratin	   18	  (K18)	  that	  gets	  cleaved	  by	  caspases	  during	  the	  apoptotic	  process.	  	  The	  advantage	  of	  the	  method	  is	  that	  it	  captures	  both	  the	  extracellular	  ccK18	  that	  becomes	  released	  in	  the	  culture	  medium	  during	  secondary	  necrosis	  of	  the	  apoptotic	  cell	  bodies	  as	  well	  as	  the	  intracellular	  ccK18,	  which	  is	  an	  early	  event	  of	  apoptosis.	  Due	  to	  this	  advantage,	  the	  assay	  constitutes	  an	  extremely	  sensitive	  reporter	  of	  apoptosis.	  One	  limitation	  of	  the	  assay	  however	   is	   that	   it	   is	  only	  applicable	   to	  cells	  of	  epithelial	  phenotype	   that	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express	  keratin	  18.	  Even	  in	  cancer	  cell	   lines	  derived	  from	  epithelial	   tissues,	   that	   is	  not	   always	   the	   case	   as	   cell	   lines	   further	   along	   the	   epithelial-­‐to-­‐mesenchymal	  transition	  are	  prone	  to	  ceasing	  expression	  of	  epithelial	  protein	  markers.	  	  	  
Nucview	  Live	  Cell	  Apoptotic	  Reporter3	  NucView	   488	   Caspase-­‐3	   substrate	   consists	   of	   a	   fluorogenic	   DNA	   dye	   and	   a	   DEVD	  substrate	   moiety	   specific	   for	   caspase-­‐3.	   The	   substrate,	   which	   is	   initially	   not	  fluorescent	  and	  nonfunctional	  as	  a	  DNA	  dye,	  crosses	  the	  cell	  membrane	  to	  enter	  the	  cytoplasm,	  where	   it	   is	   cleaved	   by	   caspase-­‐3	   to	   form	   a	   high-­‐affinity	   DNA	   dye.	   The	  released	  DNA	  dye	  migrates	  to	  the	  cell	  nucleus	  to	  stain	  the	  nucleus	  with	  bright	  green	  fluorescence.	   The	   obvious	   advantage	   of	   this	   reagent	   is	   that,	  when	   combined	  with	  timelapse	   imaging	  of	   live	  cells,	   it	   informs	  the	  viewer	  on	   the	   timescale	  of	  apoptotic	  onset.	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